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A B S T R A C T
Background
A range of health workforce strategies are needed to address health service demands in low-, middle- and high-income countries.
Non-medical prescribing involves nurses, pharmacists, allied health professionals, and physician assistants substituting for doctors in a
prescribing role, and this is one approach to improve access to medicines.
Objectives
To assess clinical, patient-reported, and resource use outcomes of non-medical prescribing for managing acute and chronic health
conditions in primary and secondary care settings compared with medical prescribing (usual care).
Search methods
We searched databases including CENTRAL, MEDLINE, Embase, and five other databases on 19 July 2016. We also searched the
grey literature and handsearched bibliographies of relevant papers and publications.
Selection criteria
Randomised controlled trials (RCTs), cluster-RCTs, controlled before-and-after (CBA) studies (with at least two intervention and two
control sites) and interrupted time series analysis (with at least three observations before and after the intervention) comparing: 1. non-
medical prescribing versus medical prescribing in acute care; 2. non-medical prescribing versus medical prescribing in chronic care; 3.
non-medical prescribing versus medical prescribing in secondary care; 4 non-medical prescribing versus medical prescribing in primary
care; 5. comparisons between different non-medical prescriber groups; and 6. non-medical healthcare providers with formal prescribing
training versus those without formal prescribing training.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. Two review authors independently reviewed studies for inclusion,
extracted data, and assessed study quality with discrepancies resolved by discussion. Two review authors independently assessed risk of
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bias for the included studies according to EPOC criteria. We undertook meta-analyses using the fixed-effect model where studies were
examining the same treatment effect and to account for small sample sizes. We compared outcomes to a random-effects model where
clinical or statistical heterogeneity existed.
Main results
We included 46 studies (37,337 participants); non-medical prescribing was undertaken by nurses in 26 studies and pharmacists in 20
studies. In 45 studies non-medical prescribing as a component of care was compared with usual care medical prescribing. A further
study compared nurse prescribing supported by guidelines with usual nurse prescribing care. No studies were found with non-medical
prescribing being undertaken by other health professionals. The education requirement for non-medical prescribing varied with country
and location.
A meta-analysis of surrogate markers of chronic disease (systolic blood pressure, glycated haemoglobin, and low-density lipoprotein)
showed positive intervention group effects. There was a moderate-certainty of evidence for studies of blood pressure at 12 months
(mean difference (MD) -5.31 mmHg, 95% confidence interval (CI) -6.46 to -4.16; 12 studies, 4229 participants) and low-density
lipoprotein (MD -0.21, 95% CI -0.29 to -0.14; 7 studies, 1469 participants); we downgraded the certainty of evidence from high due
to considerations of serious inconsistency (considerable heterogeneity), multifaceted interventions, and variable prescribing autonomy.
A high-certainty of evidence existed for comparative studies of glycated haemoglobin management at 12 months (MD -0.62, 95% CI -
0.85 to -0.38; 6 studies, 775 participants). While there appeared little difference in medication adherence across studies, a meta-analysis
of continuous outcome data from four studies showed an effect favouring patient adherence in the non-medical prescribing group (MD
0.15, 95% CI 0.00 to 0.30; 4 studies, 700 participants). We downgraded the certainty of evidence for adherence to moderate due to
the serious risk of performance bias. While little difference was seen in patient-related adverse events between treatment groups, we
downgraded the certainty of evidence to low due to indirectness, as the range of adverse events may not be related to the intervention
and selective reporting failed to adequately report adverse events in many studies.
Patients were generally satisfied with non-medical prescriber care (14 studies, 7514 participants). We downgraded the certainty of
evidence from high to moderate due to indirectness, in that satisfaction with the prescribing component of care was only addressed in
one study, and there was variability of satisfaction measures with little use of validated tools. A meta-analysis of health-related quality
of life scores (SF-12 and SF-36) found a difference favouring usual care for the physical component score (MD 1.17, 95% CI 0.16 to
2.17), but not the mental component score (MD 0.58, 95% CI -0.40 to 1.55). However, the quality of life measurement may more
appropriately reflect composite care rather than the prescribing component of care, and for this reason we downgraded the certainty of
evidence to moderate due to indirectness of the measure of effect. A wide variety of resource use measures were reported across studies
with little difference between groups for hospitalisations, emergency department visits, and outpatient visits. In the majority of studies
reporting medication use, non-medical prescribers prescribed more drugs, intensified drug doses, and used a greater variety of drugs
compared to usual care medical prescribers.
The risk of bias across studies was generally low for selection bias (random sequence generation), detection bias (blinding of outcome
assessment), attrition bias (incomplete outcome data), and reporting bias (selective reporting). There was an unclear risk of selection
bias (allocation concealment) and for other biases. A high risk of performance bias (blinding of participants and personnel) existed.
Authors’ conclusions
The findings suggest that non-medical prescribers, practising with varying but high levels of prescribing autonomy, in a range of
settings, were as effective as usual care medical prescribers. Non-medical prescribers can deliver comparable outcomes for systolic blood
pressure, glycated haemoglobin, low-density lipoprotein, medication adherence, patient satisfaction, and health-related quality of life.
It was difficult to determine the impact of non-medical prescribing compared to medical prescribing for adverse events and resource use
outcomes due to the inconsistency and variability in reporting across studies. Future efforts should be directed towards more rigorous
studies that can clearly identify the clinical, patient-reported, resource use, and economic outcomes of non-medical prescribing, in both
high-income and low-income countries.
P L A I N L A N G U A G E S U M M A R Y
Prescribing roles for health professionals other than doctors
What is the aim of this review?
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The aim of this Cochrane review was to find out if prescribing by health professionals other than doctors delivers comparable outcomes
to prescribing by doctors. Cochrane researchers collected and analysed all relevant studies to answer this question and found 46 studies.
Key messages
With appropriate training and support, nurses and pharmacists are able to prescribe medicines as part of managing a range of conditions
to achieve comparable health management outcomes to doctors. The majority of studies focus on chronic disease management in
higher-income counties where there is generally a moderate-certainty of evidence supporting similar outcomes for themarkers of disease
in high blood pressure, diabetes, and high cholesterol. Further high-quality studies are needed in poorer countries and to better quantify
differences in prescribing outcomes for adverse events, and to determine health economic outcomes. Further studies could also focus
more specifically on the prescribing component of care.
What was studied in the review?
A number of countries allow health professionals other than doctors to prescribe medicines. This shift in roles is thought to provide
improved and timely access to medicines for consumers where there are shortages of doctors or the health system is facing pressures
in coping with the burden of disease. In addition, this task shift has been supported by a number of governments as a way to more
appropriately use the skills of health professionals, such as nurses and pharmacists, in the care of patients. We compared the outcomes
of any healthcare workers who were prescribing with a high degree of autonomy with medical prescribers in the hospital or community
setting in low-, middle- and high-income countries.
What are the main results of the review?
This review found 45 studies where nurses and pharmacists with high levels of prescribing autonomy were compared with usual care
medical prescribers. A further study compared nurse prescribing with guideline support with usual nurse prescribing care. No studies
were found with other health professionals or lay prescribers. Four nurse prescribing studies were undertaken in the low- and middle-
income settings of Colombia, South Africa, Uganda, and Thailand. The remainder of studies were undertaken in high-incomeWestern
countries. Forty-two studies were based in a community setting, two studies were located in hospitals, one study in the workplace, and
one study in an aged care facility. Prescribing was but one part of many health-related interventions, particularly in the management
of chronic disease.
The review found that the outcomes for non-medical prescribers were comparable to medical prescribers for: high blood pressure
(moderate-certainty of evidence); diabetes control (high-certainty of evidence); high cholesterol (moderate-certainty of evidence);
adverse events (low-certainty of evidence); patients adhering to their medication regimens (moderate-certainty of evidence); patient
satisfaction with care (moderate-certainty of evidence); and health-related quality of life (moderate-certainty of evidence).
Pharmacists and nurses with varying levels of undergraduate, postgraduate, and specific on-the-job training related to the disease or
condition were able to deliver comparable prescribing outcomes to doctors. Non-medical prescribers frequently had medical support
available to facilitate a collaborative practice model.
How up-to-date is this review?
The review authors searched for studies that had been published up to 19th July 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Non-medical prescribing compared to medical prescribing for acute and chronic disease management in primary and secondary care
Patient or population: pat ients with acute and chronic disease
Settings: secondary care and ambulatory/ primary care in low-, m iddle- and high-income count ies
Intervention: non-medical prescribing
Comparison: medical prescribing
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
M edical prescribing Non-medical prescrib-
ing
Systolic blood pressure
(mmHg) at 12 months
The mean systolic
blood pressure in the
control group ranged
f rom 124 mmHg to 149
mmHg
The mean systolic
blood pressure in the in-
tervent ion group was 5.
31 mmHg lower (-6.46
lower to -4.16 lower)
- 4229
(12 RCTs)
⊕⊕⊕©
M oderate
1,2,3
Random-ef fects analy-
sis: MD -5.91 mmHg
lower (95% CI -7.71
lower to -4.10 lower)
Glycated haemoglobin
(HbA1c, %) at 12
months
The mean change in
glycated haemoglobin
in the control group
ranged f rom -0.90% to
9.7%
The mean change in gly-
cated haemoglobin in
the intervent ion group
was 0.62% lower (-0.85
lower to -0.38 lower)
- 775
(6 RCTs)
⊕⊕⊕⊕
High2,3
Random-ef fects analy-
sis:
MD -0.62 (95% CI -0.85
to -0.38)
Low-density lipoprotein
(mmol/ L) at 12 months
The mean low-density
lipoprotein in the con-
trol group ranged f rom
-0.26 to 3.41 mmol/ L
The mean low-density
lipoprotein in the inter-
vent ion group was 0.
21 mmol/ L lower (-0.29
lower to -0.14 lower)
- 1469
(7 RCTs)
⊕⊕⊕©
M oderate 1,2,3
Random-ef fects analy-
sis: MD -0.30 (95% CI -
0.62 to 0.02)
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Adherence (cont inu-
ous)
6 months follow-up
The mean adherence
(cont inuous) in the con-
trol group was 0.79
The mean adherence in
the intervent ion group
was 0.15 higher (0.00
higher to 0.30 higher)
- 700
(4 RCTs)
⊕⊕⊕©
M oderate4,5
Patient sat isfact ion Patient sat isfact ion was reported in 14 stud-
ies (Table 4). The majority of surveys were ei-
ther not referenced or developed locally. Vali-
dated quest ionnaires assessing overall non-med-
ical pract it ioner sat isfact ion with care were re-
ported in six studies rather than pat ient sat isfac-
t ion with prescribing. An except ion was the study
by Bruhn 2013, which found for the prescrib-
ing intervent ion, pat ients were generally posit ive
about the pharmacist prescribing service, 85%
(39/ 46) were totally sat isf ied, while 9% (4/ 44)
would have preferred to see their GP
Not est imable 7514
(14 RCTs)
⊕⊕⊕©
M oderate8,9
Adverse events There was lit t le or no dif ference in adverse events
between treatment groups in nine studies. Two
studies reported higher rates of adverse events in
the usual care group. It was dif f icult to determ ine
ef fects in the remaining studies because lim ited
data were reported
Not est imable 18,400
(18 RCTs)
⊕⊕©©
Low6,7
Health-related quality
of lif e measured with
SF-12/ 36
The mean health-re-
lated quality of lif e in
the control group was 0
The mean health-re-
lated quality of lif e in
the intervent ion group:
physical component
was 1.17 higher (0.16
to 2.17)
mental component was
0.58 higher (-0.40 to 1.
55)
- 4631
(8 RCTs)
⊕⊕⊕©
M oderate10
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; GP: general pract it ioner; M D: mean dif ference; RCT : randomised controlled trial.
GRADE Working Group grades of evidence
High-certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate-certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low-certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low-certainty: We are very uncertain about the est imate.
1Downgraded one level due to serious inconsistency (considerable heterogeneity was found).
2Mult if aceted intervent ions.
3Variable prescribing autonomy.
4Downgraded one level due to serious risk of bias (high risk of performance bias).
5Variable report ing measures of adherence.
6Downgraded one level due to indirectness (range of adverse events; may not be related to the intervent ion).
7Downgraded one level due to select ive outcome report ing (adverse events not reported in many studies).
8Downgraded one level due to indirectness (prescribing component not adequately assessed across studies).
9Variability in sat isfact ion measures.
10Downgraded one level due to indirectness (prescribing component ef fect on quality of lif e dif f icult to determ ine).
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B A C K G R O U N D
Description of the healthcare challenge
A range of health workforce strategies are needed to address issues
of health service access and efficiency. In low-, middle- and high-
income countries, the increasing demand for health services arises
from an ageing population and the resultant increasing burden of
chronic disease (Bhanbhro 2011; Duckett 2005; Phillips 2008;
WHO 2012).
Increased health demands can be met in part by task substitution
within the health workforce. One health workforce strategy for
task substitution is to permit prescribing by healthcare providers
other than medical doctors. Non-medical prescribers may include
nurses, pharmacists, allied health professionals, and physician as-
sistants. In some low- and middle-income countries, lay health
workers have been used to distribute medications with preventive
or curative intent, including contraceptives, iron or vitamin sup-
plements, vaccinations, and agents for tuberculosis management
(Glenton 2013).
Extending a health provider’s scope of practice, including the right
to prescribe, has been supported in a number of countries as a
means of benefiting patient care by the effective use of health pro-
fessionals’ skills, improving patient access to timely care, improv-
ing patient choice, and enhancing teamwork and the better use of
resources (Department of Health 1999; Ellis 2006; Hooker 2006;
Stewart 2010).
The devolution of prescribing rights in high-income countries has
continued from a historical base in the United States of America
(USA) in the 1970s through to more recent government-led re-
forms in the United Kingdom (UK), Canada, the Netherlands,
New Zealand, and Australia. While the definition of prescribing
may vary between countries, for the purpose of our review, pre-
scribing was defined as: “an iterative process involving the steps
of information gathering, clinical decision making, communica-
tion and evaluation which results in the initiation, continuation or
cessation of a medicine” (Health Workforce Australia 2013). The
term ’medical prescribing’ refers to prescribing by medically qual-
ified doctors. The supply of non-prescription (over-the-counter)
medicines by pharmacists or pharmacy assistants working in com-
munity pharmacies is excluded from our definition of prescribing,
as is the supply of medicines by lay health workers.
The term ’non-medical prescribing’ originates from the UK,
where it is defined as: “prescribing by specially trained nurses, op-
tometrists, pharmacists, physiotherapists, podiatrists, and radiog-
raphers, working within their clinical competence as either inde-
pendent or supplementary prescribers” (NPC 2012).
Supplementary prescribing which was introduced in the UK in
2003, is defined as ’a voluntary partnership between an indepen-
dent prescriber (a doctor or dentist) and a supplementary pre-
scriber (e.g. nurse, optometrist, pharmacist, physiotherapist, chi-
ropodist/podiatrist, or radiographer) to implement an agreed pa-
tient-specific clinical management plan with the patient’s agree-
ment’ (Department of Health 2003). Non-medical prescribing
rights were extended in 2006 with the introduction of indepen-
dent prescribing. The UK Department of Health defines inde-
pendent prescribing as ’prescribing by a practitioner (e.g. doctor,
dentist, nurse, pharmacist, optometrist) responsible and account-
able for the assessment of patients with undiagnosed or diagnosed
conditions, and for decisions about the clinical management re-
quired, including prescribing’. Independent prescribing is one el-
ement of the clinical management of a patient and occurs in part-
nership with the patient. It requires an initial patient assessment,
interpretation of that assessment, a decision on safe and appro-
priate therapy, and a process for ongoing monitoring. The inde-
pendent prescriber is responsible and accountable for at least this
element of a patient’s care (Department of Health 2006). Inde-
pendent prescribing does not require a clinical management plan.
From 1May 2006, nurse and pharmacist independent prescribers
who completed the appropriate training could prescribe, with a
few exceptions, any licensed medicine for any medical condition
within their competence. In 2009, independent prescribing rights
were extended to include unlicensed medicines. While prescrib-
ing of controlled drugs was restricted, this limitation was removed
through legislative change in April 2012 (Home Office 2012).
In the USA, devolution of prescribing authority varies from state
to state. Collaborative Practice Agreements in 46 States allow a
pharmacist to partner with a physician to manage a number of
patient services, including medication management (Law 2013;
Thomas 2006). Physician assistants and nurse practitioners were
introduced in 1967 to support medical care. These practitioners
undertake a range of clinical functions, including prescribing (
Hooker 2006).
Within Canada, a pharmacist’s scope of prescribing practice varies
between the provinces from independently prescribing to adapting
(modifying) or continuing prescriptions (Law 2012).
A collaborative prescribing model has emerged as the preferred
model of practice within New Zealand and Australia. Collabora-
tive prescribing is undertaken within a multidisciplinary team and
can include the continuum of prescribing from transcription of
orders (with or without medical signature), prescribing specified
drugs and doses by protocol, prescribing by clinical management
plan (allowing choice of drugs and doses) to independent prescrib-
ing, where a prescribing consultation with a medical practitioner
is not required (Weeks 2008; Wheeler 2012).
The Health Professionals Prescribing Pathway developed by
Health Workforce Australia (HWA) includes five steps to safely
and competently prescribe, and covers: education and training,
recognition by the profession’s national registering board, autho-
risation to prescribe by legislation, prescribing within the scope
of practice, and maintaining and enhancing competence to pre-
scribe. The prescribingmodels suggested byHWAemphasise team
communication and are divided into autonomous prescribing,
prescribing under supervision, and prescribing via a structured
7Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
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prescribing arrangement (HWA 2013). The reforms started by
HWA have been transferred to a working group of the Australian
Health Practitioner Regulation Agency. As part of the reform pro-
cess, health agencies in Australia, Canada, New Zealand, and the
UK have developed prescribing competency frameworks for non-
medical health professionals (NPC 2012; NPS 2012; Pharmacy
Council NZ 2013; Yuksel 2008).
Description of the intervention
For the purpose of our review the term ’non-medical prescrib-
ing’ was used to cover prescribing of medicines by a broad range
of healthcare providers other than medical doctors, prescribing
in primary or secondary care. No limitation was set on the type
of non-medical healthcare provider undertaking prescribing. Fre-
quently, non-medical prescribing is done in collaboration or part-
nership with doctors, and within this practice there are different
models of prescribing practice. However, for this review the non-
medical prescriber was required to have a high degree of auton-
omy in their prescribing practice. We excluded studies reporting
prescribing practices requiring medical review, consultation, and
approval requiring a medical signature on medication orders. Our
review focused on prescribing, which as per our definition is much
broader than issuing a prescription.
The role of non-medical prescribers in secondary care settings
may involve supporting acute or chronic care by prescribing in a
timely way medication on admission, discharge, or where there
is a specialist need, e.g. total parenteral nutrition. Specialist out-
patient clinics managed by non-medical health professionals may
exist in either the primary or secondary care setting, e.g. for the
management of hypertension, lipids, diabetes, and pain. In pri-
mary care settings, prescribing may be undertaken for acute or
chronic conditions by nurses or other healthcare providers caring
for patients in their homes or through involvement with general
practice teams, community health centres, mental health teams,
or community pharmacies.
How the intervention might work
Non-medical prescribing has developed as an accepted healthcare
practice in a number of countries to improve access to healthcare,
to better use the skills of doctors who can focus on more acute pa-
tient needs, to better use the skills of pharmacists, nurses and other
health providers, to potentially reduce costs for achieving at least
equivalent, if not better health outcomes for consumers, and to
retain health workers by increasing job satisfaction (Department
of Health 1999; Tonna 2007). While qualitative studies support
non-medical prescribing from a patient and practitioner perspec-
tive, robust evidence is still required for clinical, patient-reported,
and resource use outcomes. It is noted that where non-medical
prescribers are practising in collaborative teams, it may be diffi-
cult to apportion the impact of the non-medical prescribing com-
ponent to the primary and secondary outcomes of this review.
Wider adoption of non-medical prescribing practice in high-in-
come countries frequently faces local regulatory hurdles and op-
position from the medical community which has raised concerns
about professional autonomy, patient safety, the diagnostic com-
petency of non-medical prescribers, and costs (Cooper 2008). Evi-
dence that patient outcomes arising from non-medical prescribing
are as effective as those from medical prescribing would provide a
basis for policy-makers to support wider implementation of this
practice.
Why it is important to do this review
It is important for health practitioners and policy-makers to un-
derstand the evidence existing for non-medical prescribing in or-
der to address access or health workforce needs. This information
will also guide future decision making with regards to implement-
ing or expanding non-medical prescribing.
Potential beneficiaries of the findings include:
1. policy-makers seeking to use workforce resources more
efficiently;
2. policy-makers seeking to meet a clinical need;
3. consumers seeking greater choice and easier access to
medicines;
4. non-medical health professionals seeking to better utilise
their skills and/or extend their scope of practice; and
5. medical staff seeking to focus on patients with the greatest
medical need.
Despite a gradual rolling out of reforms, the evidence for the po-
tential benefits of non-medical prescribing from well-controlled
trials involving a wide range of health professionals requires iden-
tification, synthesis, and evaluation. Several narrative reviews of
the non-medical prescribing literature have been undertaken (Kay
2004; Tonna 2007), and the British government commissioned
two evaluations covering supplementary and independent pre-
scribing (Bissell 2008; Latter 2010).
A Cochrane Review on substitution of doctors by suitably trained
nurses in primary care found that trained nurses can produce as
high a quality of care and as good health outcomes with no appre-
ciable difference between doctors and nurses in resource utilisation
outcomes associated with prescribing (Laurant 2005). The review
was limited to nurses in the primary care setting as first contact or
ongoing care for undifferentiated patients.
A further Cochrane Review found a single RCT of pharmacist-
managed drug therapy (Nkansah 2010), including the prescrib-
ing of drugs versus physician medication management (Hawkins
1979). However, we assessed the study to be of low-quality, leav-
ing open the question of whether the delivery of patient-targeted
services by pharmacists improves patient outcomes compared to
other health professionals.
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TheDriscoll 2015 Cochrane Review of nurse-led titration of drug
therapy for people with heart failure, found that participants in
the nurse-led group were less likely to be admitted to hospital or
to die. More participants reached the maximum drug dose in the
nurse-led titration group compared to titration of doses by primary
care physicians. The certainty of evidence that nurse-led titration
reduced hospitalisations was graded as high and the certainty of
evidence regarding the proportion of participants reaching opti-
mal dose was graded as low. However, in the majority of studies
the influence of medical supervision on nurse-dose titration (pre-
scribing) was unclear.
Against this background, we systematically identified, reviewed,
and updated the evidence from controlled studies and uncon-
trolled studies on the clinical, patient-reported and resource use
outcomes of non-medical prescribing in primary and secondary
care settings. This review considered any adverse effects of non-
medical prescribing which may be clinical (e.g. deterioration in
care or incidence of adverse drugs reactions), patient-reported (e.g.
decreased satisfaction), or resource-related (e.g. increased treat-
ment costs).
The review covered healthcare providers undertaking non-medical
prescribing, spanning primary and secondary care settings, and
considered acute and chronic prescribing situations.
O B J E C T I V E S
To assess the clinical, patient-reported, and resource use outcomes
of non-medical prescribing for managing acute and chronic health
conditions in primary and secondary care settings compared with
medical prescribing (usual care).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies of patients or health professionals or health-
care settings using the definitions of designs outlined in the
Cochrane Effective Practice and Organisation of Care (EPOC)
Group checklist (Cochrane EPOC Group 2013a). We included
randomised controlled trials (RCTs) and cluster-RCTs, one con-
trolled trial where investigators had allocated participants to the
different groups that were being compared using a method that
is not random, but where at least two groups with interventions
were followed, and one controlled before-and-after (CBA) study
with at least two intervention sites and two control sites. We did
not find either interrupted time series (ITS) studies nor qualita-
tive studies linked to quantitative studies using qualitative analysis
methods.
Types of participants
Healthcare providers who are not medical doctors, undertaking
prescribing including, nurses, optometrists, pharmacists, physi-
cian assistants, and other allied health professionals or categories
not specificallymentioned whose rolesmeet our definition of non-
medical prescribing.
Setting
We included studies based in any primary or secondary care setting
where non-medical prescribing occurred.
Types of interventions
We included studies involving health providers other thanmedical
doctors undertaking prescribing according to our definition of
prescribing. We excluded studies limited to the supply function
of pharmacists, including over-the-counter products and studies
involving the supply function of lay health workers.
We included the following six comparisons for non-medical pre-
scribing.
1. Non-medical prescribing versus medical prescribing in
acute care.
2. Non-medical prescribing versus medical prescribing in
chronic care.
3. Non-medical prescribing versus medical prescribing in
secondary care.
4. Non-medical prescribing versus medical prescribing in
primary care.
5. Comparisons between different non-medical prescriber
groups.
6. Non-medical healthcare providers with formal prescribing
training versus those without formal prescribing training.
Types of outcome measures
The studies included in the review reported a wide variety of out-
come measures. We only included studies with objective measures
of patient clinical outcomes. Non-inferiority was regarded as a
positive outcome where a non-medical prescribing outcome was
at least as good as the comparator. We excluded studies with only
a qualitative component in order to maintain the clinical focus of
the review.
Primary outcomes
Clinical outcomes
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Patient outcomes
We used standard outcome measures covering health and well-be-
ing, including physiological measures of treatment such as systolic
blood pressure, glycated haemoglobin, and low-density lipopro-
tein. Outcomes were divided into dichotomous and continuous
outcomes.
We also considered the following outcomes.
1. Proportion of prescribers, medical and non-medical,
appropriately adhering to practice guidelines.
2. Proportion of patients demonstrating medication
adherence.
3. Proportion of patients and items appropriately prescribed
or deprescribed.
4. Patient satisfaction, where measured by a validated tool as
part of an effectiveness study.
5. Non-medical prescriber versus medical prescriber waiting
time to care.
6. Non-medical prescribers adversely affecting the health
outcomes of patients through medication errors, prescribing
errors, adverse events, wrong diagnoses or treatment, increased
hospitalisations, or representations for medical care.
Secondary outcomes
Patient-reported outcomes
We considered patient-reported outcomes without clinician inter-
pretation of their knowledge requirements, daily functioning, and
health-related quality of life.
Non-medical prescriber outcomes
Where present, we also reported non-medical prescriber outcomes
of job satisfaction, skills utilisation, education needs, andworkload
effects.
Resource use outcomes
1. Medical time saved by non-medical prescribers.
2. Non-medical prescriber versus medical prescriber
prescription volume and cost, patient out-of-pocket expenses,
service costs, and deprescribing rate and cost.
3. Increased resource use for providing the intervention and
for providing subsequent care such as hospitalisations,
emergency department visits, and outpatient visits.
Search methods for identification of studies
Electronic searches
We searched the following databases.
1. Cochrane Central Register of Controlled Trials
(CENTRAL, including the Effective Practice and Organisation
of Care (EPOC) Group Specialised Register; 2016, Issue 6), in
the Cochrane Library (Wiley).
2. Cochrane Methodology Register, the Cochrane Library;
2012, Issue 3 (Wiley).
3. Cochrane Database of Systematic Reviews (CDSR), the
Cochrane Library; 2016, Issue 7.
4. Database of Abstracts and Reviews of Effects (DARE), the
Cochrane Library; 2015, Issue 2 (Wiley).
5. Health Technology Assessment Database, the Cochrane
Library; 2016, Issue 2 (Wiley).
6. NHS Economic Evaluation Database, the Cochrane
Library; 2015, Issue 2 (Wiley).
7. MEDLINE (1946 to 19 July 2016), (Epub Ahead of Print,
In-Process & Other Non-Indexed Citations, Ovid
MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 19 July
2016) (OvidSP).
8. Embase (OvidSP) (1980 to 18 July 2016).
9. PsycINFO (OVID) (1806 to July Week 2, 2016).
10. Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (EBSCOhost) (1980 to 19 July 2016).
The MEDLINE search strategy as illustrated in Appendix 1 was
developed by the Cochrane Effective Practice and Organisation of
Care (EPOC) Group Information Specialist in consultation with
the authors. We translated it for other databases using appropri-
ate syntax and vocabulary for those databases. We employed the
Cochrane Highly Sensitive Search Strategy (sensitivity- and pre-
cision-maximizing version, 2008 revision) to identify randomised
trials, and the Cochrane EPOCGroupmethodology filter to iden-
tify non-randomised studies. We managed search results using
reference management software and removed duplicates before
screeningwas undertaken.We also searched theCochrane Database
of Systematic Reviews (CDSR) and the Database of Abstracts of
Reviews of Effects (DARE) for related systematic reviews.
Searching other resources
Grey literature
We conducted a grey literature search to identify studies not in-
dexed in the databases listed above.We used the following sources.
1. OpenGrey (www.opengrey.eu).
2. Grey Literature Report by the New York Academy of
Medicine (www.greylit.org).
3. Agency for Healthcare Research and Quality (AHRQ) (
www.ahrq.gov).
Trial registries
We searched the following registries.
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1. The Word Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP) search portal (
apps.who.int/trialsearch).
2. ClinicalTrials.gov (clinicaltrials.gov).
The corresponding search terms and numbers of results are re-
ported.
Other resources
1. We screened individual journals and conference
proceedings (via handsearching).
2. We reviewed reference lists of all included studies, relevant
systematic reviews; reference lists of other publications.
3. We contacted authors of relevant studies or reviews when
necessary to clarify reported published information or to seek
unpublished results or data.
4. We contacted researchers with expertise relevant to the
review topic/EPOC interventions.
5. We conducted cited reference searches for all included
studies in citations indices.
Data collection and analysis
Selection of studies
We merged the search results through the use of a reference man-
agement software and removed duplicate records. Two review au-
thors (GW, JG) then independently assessed the titles and ab-
stracts of the search results to evaluate their potential eligibility,
and discussed the relevance of articles to the topic. The two review
authors were not responsible for the selection of studies they were
involved in or associated with. Neutral members of the review
team were responsible for assessing the eligibility of each study for
inclusion in the review. We retrieved the full-text of all remaining
relevant papers and the two review authors assessed these full-text
articles independently, based on the review’s inclusion criteria.
We included a ’Characteristics of excluded studies’ table in the
review. This table included studies that appear to meet the inclu-
sion criteria but were eventually excluded, and we reported the
reasons for exclusion (e.g. not a RCT, only one intervention and/
or control site for a CBA study, absence of non-medical prescriber
autonomy). If there was uncertainty or disagreement, consensus
was reached by discussion with other review authors. We corre-
sponded with authors of included studies if necessary to obtain
further information in order to assess compliance with eligibility
and confirm data.Within the review, wemapped the flow of infor-
mation of identified, included, and excluded studies by depicting
them in a PRISMA flow diagram (Moher 2009) (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
Weadapted a standard data extraction formbased on theCochrane
EPOCGroup’s data collection checklist (Cochrane EPOCGroup
2013a). We designed and assessed the form to suitably extract
data on the characteristics of each study, including study design,
study participants, the interventions and comparators, outcomes
and follow-up periods, funding source, and interest declarations.
Four review authors (GW, JG, DS, KM) independently extracted
study characteristics and the outcome data outlined above. We
checked the data against each other. If there was uncertainty or
disagreement, we reached consensus by discussion or in the pres-
ence of an adjudicating third review author, if necessary. We con-
tacted study authors to obtain any missing information. If a study
was reported in more than one publication, we extracted the data
from all publications into separate data collection forms before
combining them.
Assessment of risk of bias in included studies
Two review authors (GW, JG) independently assessed the risk
of bias of included studies, with any disagreements resolved by
consensuswith a third review author (KM).We used theCochrane
EPOC Group nine-point criteria for RCTs, non-RCTs, and CBA
studies (Cochrane EPOC Group 2015).
1. Allocation sequence generation.
2. Allocation concealment.
3. Baseline outcome measurements.
4. Baseline characteristics.
5. Incomplete outcome data.
6. Knowledge of allocated interventions.
7. Protection against contamination.
8. Selective outcome reporting.
9. Other risks of bias.
We did not find any ITS studies, but we will assess future studies
using the seven standard Cochrane EPOC Group criteria for ITS
studies (Cochrane EPOC Group 2015).
1. Intervention independent of other changes.
2. Prespecified effect shape.
3. Intervention unlikely to affect data collection.
4. Blinding.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We rated each component and categorised it in a ’Risk of bias’
table as ’low risk’, ’unclear risk’, or ’high risk’, as described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We documented for each included study a summary as-
sessment of the risk of bias.
Measures of treatment effect
We recorded and reported measures of effect in the same way
investigators reported them. We performed all analyses using
Cochrane’s statistical software, Review Manager 5 (RevMan
2014), and recorded data in the form of a table included in
the Cochrane EPOCGroup’s data extraction template (Cochrane
EPOCGroup2013b). For continuous variables, we reportedmean
differences (MDs) with 95% confidence intervals (CIs) between
the intervention and comparison groups. We used a standard-
ised mean difference (SMD) with 95% CI for the same continu-
ous variable measured with different scales. For dichotomous out-
comes, we calculated the risk difference (RD) with 95% CI. We
planned to calculate the risk ratio (RR), again with 95% CI.
Unit of analysis issues
We assessed whether an appropriate adjustment had been made
for clustering in RCTs and CBA studies to avoid unit of analysis
errors. If there were insufficient data for re-analysis, we attempted
to correct such errors by contacting study authors to obtain ad-
ditional data. Determining the intracluster correlation coefficient
from additional data or like studies allows adjustment of clustering
by inflating the standard error. Where re-analysis was not possible
we reported the point estimate without a standard error or CI and
the P value was annotated ’re-analysed’.
Dealing with missing data
We applied the ’Risk of bias’ criteria to exclude studies with a
high risk of missing data, as they pose serious threats to validity
(Higgins 2011). Where appropriate, we contacted study authors
for further information. If this was not possible, we reported the
number of participants lost to follow-up. Imputing missing data
was only considered when continuous outcomes were reported
without measures of variance. We followed the principles of in-
tention-to-treat analysis as far as possible.
Assessment of heterogeneity
We found that the range of healthcare settings, differing non-med-
ical prescribers, differing clinical conditions being managed, and
variation in study designs lead to clinical, methodological, and
statistical heterogeneity. Assessment of these differences informed
the analysis and determined whether results could be statistically
combined in a meta-analysis. The review team made this decision
on a consensus basis. We assessed statistical heterogeneity by using
the Chi2 test to assess if differences in results are compatible with
chance alone using P < 0.10. We quantified statistical heterogene-
ity using the I2 statistic, as appropriate. We determined that het-
erogeneity might not be important between 0% and 40%, 30% to
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60% represented moderate heterogeneity, 50% to 90% substan-
tial heterogeneity, and 75% to 100% considerable heterogeneity
(Higgins 2011).
Assessment of reporting biases
We assessed the risk of publication bias based on the information
in the ’Risk of bias’ tables and constructed funnel plots for the
outcomes of systolic blood pressure and low-density lipoprotein.
Data synthesis
We used a structured synthesis approach to analyses. After consid-
eration of the small-study effects of many included studies we used
a fixed-effect model for meta-analysis and compared outcomes
with a random-effects model. For quantitative synthesis we used
Review Manager 5 for statistical analysis (RevMan 2014). Where
we could not combine data for a meta-analysis due to inconsis-
tency of reporting measures, or when it was not applicable to use
the average effect across studies of an intervention, we reported
in this plain language summaries as appropriate. We included key
data elements such as explanatory factors, results, effects, and cer-
tainty of evidence in a table for each category of interventions.
Summary of findings
Weused a ’Summary of findings’ table andGRADEproGDT soft-
ware to record results, outcomes, and outcome risks in our struc-
tured synthesis (GRADEpro GDT 2014). In addition, we used
the five GRADE study considerations (study limitations, consis-
tency of effort, imprecision, indirectness, and publication bias) to
assess the certainty of the body of evidence and summarise our
confidence in the effects of the interventions by outcome across
studies (Atkins 2004). We included the following outcomes in the
’Summary of findings’ table: systolic blood pressure, glycated hae-
moglobin, low-density lipoprotein, medication adherence, patient
satisfaction, adverse events, and health-related quality of life. We
justified all decisions to down- or upgrade the certainty of evi-
dence using footnotes, and we made comments to aid the reader’s
understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
Differences in healthcare settings, non-medical prescriber types,
clinical conditions being managed, and study designs informed
the assessments of methodological and statistical heterogeneity.
Explanatory variables or effect modifiers which may have influ-
enced the size of intervention effects included the level of pre-
scriber education, study location, patient condition being treated,
and adherence to therapy and practice guidelines. The degree of
non-medical prescribing autonomy within and across subgroups
may have explained differences in outcomes and limited the ap-
plicability of findings.
For consistency across studies, we presented data as subgroups for
the clinical outcomes of systolic blood pressure, glycated haemo-
globin, and low-density lipoprotein at six and 12 months. We pre-
sented quality of life measures (SF-36 and SF-12) as subgroups of
physical component and mental component scores.
In considering the type of intervention, we did not undertake
a meta-analysis comparing algorithm prescribing to more au-
tonomous prescribing on clinical outcomes due to considerable
heterogeneity.
There were insufficient studies to compare outcomes from differ-
ent non-medical prescriber settings e.g. secondary care versus pri-
mary care.
Variability in education standards made it difficult to compare
non-medical prescriber subgroups.
Sensitivity analysis
We undertook a sensitivity analysis comparing meta-analyses out-
comes using fixed-effect and random-effects analyses for the three
clinical surrogate markers of disease: systolic blood pressure; gly-
cated haemoglobin; and low-density lipoprotein (Table 1). The
effect modifier of clustering in RCTs on systolic blood pressure
at six months was tested by removing these trials from the meta-
analysis (Margolis 2013 at six months; Khunti 2007 andMargolis
2013 at 12 months; Analysis 1.2; Analysis 1.3). We did not un-
dertake a sensitivity analysis excluding unclear or high risk of bias
studies due to the similar risk of bias elements existing within the
outcome categories.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
The database search yielded 13,220 titles. We found 51 addi-
tional studies through handsearching. After removing duplicates,
we screened 9335 studies and reviewed 162 full-text articles. We
excluded 112 studies that did not meet the inclusion criteria
and recorded our reasons for exclusion. We included 46 studies
(37,337 participants). Of these, 44 were randomised controlled
trials (RCTs), including six cluster-RCTs (Fairall 2008; Heisler
2012; Khunti 2007; Margolis 2013; Moher 2001; Pagaiya 2005),
one controlled trial (Denver 2003), and one controlled before-
and-after (CBA) study (Thompson 1984). Three studies are await-
ing classification (Barton 2013;Neilson 2015; Tsuyuki 2014), and
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one study is ongoing (Mikuls 2015). Refer to Figure 1 for PRISMA
diagram.
Included studies
Non-medical prescribing studies were included where the health
professional (other than a medical practitioner) undertook a high
level of autonomous prescribing. This included medication initi-
ation, dosage change, or cessation of medication (with or without
guidance from established protocols and guidelines).
Participants
Non-medical prescribing versus medical prescribing was practised
by nurses in 26 studies with 28,621 participants (Ansari 2003;
Aubert 1998; Barr Taylor 2003; Becker 2005; DeBusk 1994;
Denver 2003; Einhorn 1978; Fairall 2008; Fischer 2012; Hill
2003; Houweling 2009; Houweling 2011; Ishani 2011; Khunti
2007; Klingberg-Allvin 2015; Kuethe 2011; Litaker 2003; Logan
1979; MacMahon Tone 2009; Moher 2001; New 2003; Pagaiya
2005; Rudd 2004; Spitzer 1974; Tobe 2006; Wallymahmed
2011), and by pharmacists in 20 studies with 8716 participants
(Bruhn 2013; Chenella 1983; Choe 2005; Cohen 2011; Ellis
2000; Finley 2003; Heisler 2012; Hirsch 2014; Hunt 2008; Jaber
1996; Magid 2013; Margolis 2013; Marotti 2011; McAlister
2014; Taveira 2010; Taveira 2011; Thompson 1984; Tsuyuki
2015; Tsuyuki 2016; Vivian 2002).
The health professionals delivering the interventions were phar-
macists or nurses with varying degrees of formal or informal train-
ing. We did not find any studies where other non-medical health
professionals, such as physician assistants undertook prescribing
roles. Nurse prescribing was undertaken in the majority of studies
by reference to algorithms. While nurses exercised independence
in prescribing by algorithm, physicians were usually available for
consultation for issues beyond the scope of the algorithm, or for
more complex cases or for periodic review.
Pharmacist prescribing was generally undertaken in a more au-
tonomous way, with more reliance on clinical judgement and
guidelines rather than restrictive algorithms. This broader practice
scope was supported through collaborative practice agreements in
the USA and independent or supplementary prescribing in the
UK. In addition to their defined prescribing autonomy, non-med-
ical prescribers in several studies had limits placed on additional
prescribing, and required medical prescribing or approval for dose
acceleration (Tobe 2006), management of conditions outside the
focus of care (Finley 2003; Litaker 2003; New2003; Taveira 2011;
Vivian 2002), and initiation of new drugs (Barr Taylor 2003;
DeBusk 1994; New 2003; Rudd 2004).
Excluding the cluster-RCTs, nine studies had less than 100 pa-
tients, seven studies had more than 100 and less than 200 pa-
tients, 16 studies had more than 200 and less than 500 patients,
five studies had between 500 to 800 patients, and three studies
included over 1000 patients. There were six cluster-RCTs: Fairall
2008, 31 clinics, cohort one 9252 patients, cohort two 6231 pa-
tients; Heisler 2012, 16 primary care teams at five medical cen-
tres, 4100 patients; Khunti 2007, 20 primary care practices, 1316
patients; Margolis 2013, 16 primary care clinics, 450 patients;
Moher 2001, 21 general practices, 1906 patients; Pagaiya 2005,
18 nurse-led health centres, 3960 patients.
Setting
Four nurse prescribing studies (14,921 participants) were un-
dertaken in low- and middle-income settings within Colombia,
South Africa, Uganda, and Thailand (Einhorn 1978; Fairall 2008;
Klingberg-Allvin 2015; Pagaiya 2005). The remainder of studies
were undertaken in the high-income countries, of Australia (1),
Canada (6), Ireland (1), Netherlands (3), UK (6), and USA (25).
Forty-two studies were based in ambulatory care settings, includ-
ing primary care clinics, medical centres, general practices, com-
munity pharmacies, and hospital outpatient clinics. Two studies
were located in secondary care settings (Chenella 1983; Marotti
2011). One study was set in the workplace (Logan 1979), and one
in an aged care setting (Thompson 1984).
Interventions
Pharmacist and nurse interventions were often multifaceted, with
prescribing being one element of a complex management ap-
proach. For example, in diabetes care, patient education, self-care,
diet, exercise, and follow-up were factors influencing outcomes, as
well as the prescribing of medications.
Outcomes
The majority of studies involved the management of one or more
chronic diseases (heart failure, hypertension, diabetes, dyslipi-
daemias) and risk factors for disease recurrence such as stroke
(McAlister 2014), and acute myocardial infarction or heart fail-
ure (DeBusk 1994; Khunti 2007). Studies outside of these areas
included the management of chronic pain (Bruhn 2013), fam-
ily planning (Einhorn 1978), HIV treatment (Fairall 2008), in-
complete abortion (Klingberg-Allvin 2015), depression (Finley
2003), and asthma in children, whichwas the only paediatric study
(Kuethe 2011).
Non-medical clinician collaborative care approaches with physi-
cians (Litaker 2003), or community health workers (Becker 2005;
Hill 2003), and interventions with telemonitoring (Magid 2013;
Margolis 2013), added to the complexity of determining specific
non-medical prescribing outcomes.
The following 21 studies had a more direct relationship between
non-medical prescribing and the outcome markers of the disease
or condition: Ansari 2003 (heart failure); Bruhn 2013 (chronic
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pain); Chenella 1983 (anticoagulation); Denver 2003 (blood pres-
sure); Fairall 2008 (HIV medications); Hirsch 2014 (blood pres-
sure); Houweling 2009 and Houweling 2011 (glycaemia, blood
pressure, lipids); Hunt 2008 (blood pressure); Ishani 2011 (gly-
caemia, blood pressure, lipids); Jaber 1996 (glycaemia, blood pres-
sure, lipids); Klingberg-Allvin 2015 (incomplete abortion); Logan
1979 (blood pressure); MacMahon Tone 2009 (glycaemia, blood
pressure, lipids); McAlister 2014 (blood pressure, lipids); Marotti
2011 (regular medications); Thompson 1984 (medications in the
geriatric setting); Tsuyuki 2015 (blood pressure); Tsuyuki 2016
(glycaemia, blood pressure, lipids); Vivian 2002 (blood pressure);
and Wallymahmed 2011 (glycaemia, blood pressure, lipids).
Excluded studies
We excluded studies if the study design did not meet the EPOC
criteria for a RCT, controlled clinical trial, CBA or ITS. We ex-
cluded studies where we judged that the non-medical health pro-
fessional did not have a significant degree of autonomy in their
prescribing practice, and prescribing requiredmedical review, con-
sultation, or authorisation.
Risk of bias in included studies
The risk of bias assessment for included studies is presented in the
’Risk of bias’ tables, under each study in the section Characteristics
of included studies. The risk of bias results are presented in a
graphical form in Figure 2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Thirty-three of 46 studies (72%) adequately described the random
sequence generation and we considered them to be at low risk of
bias. Allocation concealment was undertaken in 13 studies (28%),
unclear in 31 studies (67%) and with no concealment in two
studies (Margolis 2013; Thompson 1984).
Blinding
Blinding of both participants and personnel could not be achieved
through the study design in 44 of the 46 included studies. In the
Chenella 1983 study it was unclear whether patients would be
aware that the pharmacist had undertaken anticoagulation dose
determinations, and in the Pagaiya 2005 study, whether the inter-
vention group nurses had undertaken additional training and were
using guidelines. Objective clinical outcomes in studies requiring
laboratorymeasures such as glycated haemoglobin and low-density
lipoprotein were coded as blinded outcome assessment. In seven
studies, blinded assessment of blood pressure was undertaken (Hill
2003; Hunt 2008; Logan 1979; Magid 2013; McAlister 2014;
Moher 2001; Rudd 2004). Where blood pressure assessment was
not clear or undertaken by study investigators, we judged this to
be an unclear outcome assessment. Ansari 2003 used an indepen-
dent research assistant to assess β-blocker use in heart failure.
Incomplete outcome data
Loss to follow-up of 20%ormore in either the intervention or con-
trol arms occurred in 14 studies (Aubert 1998; Becker 2005; Bruhn
2013; Choe 2005; Einhorn 1978; Finley 2003; Heisler 2012;
Hirsch 2014; Hunt 2008; Ishani 2011; Jaber 1996; McAlister
2014; Moher 2001; New 2003).
Selective reporting
The funnel plots of systolic blood pressure revealed a degree of
asymmetry, demonstrating a possible publication bias from an
absence of published negative intervention studies. The funnel
plot of low-density lipoprotein studies was asymmetrical, with
heterogeneity a consideration.
Other potential sources of bias
The majority of studies had a degree of confounding either by the
multifactorial intervention (which made it difficult to distinguish
the influence of non-medical prescribing on outcomes) or by un-
clear prescribing autonomy or medical influence. The six cluster-
RCTs appropriately accounted for the cluster design.
Effects of interventions
See: Summary of findings for the main comparison Non-
medical prescribing compared tomedical prescribing for acute and
chronic disease management in primary and secondary care
See: Summary of findings for the main comparison for the main
comparisons; systolic blood pressure, glycated haemoglobin, low-
density lipoprotein, adherence, adverse events, patient satisfaction,
and quality of life.
We had planned to analyse the six comparisons listed in the Types
of interventions section, however we only found studies for the
following two comparisons: non-medical prescribing in acute care
(secondary care); and non-medical prescribing in chronic care (pri-
mary/ambulatory care).
Non-medical prescribing in acute care (secondary
care)
Primary Outcomes
Studies involving non-medical prescribing interventions were of-
ten characterised by degrees of confounding, including the pres-
ence of multiple interventions, patient comorbidities, study dura-
tion, differing levels of non-medical prescriber training, and un-
clear influences from medical prescribers. However, while recog-
nising these complexities and limitations, care involving non-med-
ical prescribers resulted in improvements or similar effectiveness
to usual care for a range of clinical outcomes and surrogate disease
markers.
We found two studies (438 participants) where non-medical pre-
scribing was practised in an acute/secondary care setting (Chenella
1983; Marotti 2011).
1. Systolic blood pressure
Outcome not reported.
2. Glycated haemoglobin
Outcome not reported.
3. Low-density lipoprotein
Outcome not reported.
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4. Proportion of prescribers, medical and non-medical,
appropriately adhering to practice guidelines
Pharmacist prescribers adjusted anticoagulant therapy, as well as
an experienced physician, in the independent management of an-
ticoagulation therapy for inpatients. There were no significant dif-
ferences between groups formean heparin and warfarin doses, par-
tial thromboplastin time, days to reach therapeutic levels, or mean
prescribed and simulated heparin doses (Chenella 1983; Table 2).
5. Proportion of patients demonstrating medication adherence
Outcome not reported.
6. Proportion of patients and items appropriately prescribed
or deprescribed
Preoperative medication history taking and prescribing by a phar-
macist improved the accuracy of medication documentation and
significantly reduced missed doses of regular medication for elec-
tive surgical patients. The marginal mean number of missed doses
per patient was 3.21 (95% confidence interval (CI) 2.89 to 3.52)
in the control group, which was significantly reduced in the phar-
macist prescribing group 1.07 (95% CI 0.90 to 1.25; P = 0.002)
(Marotti 2011; Table 2).
7. Patient satisfaction, where measured by a validated tool as
part of an effectiveness study
Outcome not reported.
8. Non-medical prescriber versus medical prescriber waiting
time to care
Outcome not reported.
9. Non-medical prescribers adversely affecting the health
outcomes of patients through medication errors, prescribing
errors, adverse events, wrong diagnoses or treatment,
increased hospitalisations, or representations for medical care
Chenella 1983 reported no patients had major bleeding but four
patients in the pharmacist prescriber group had minor bleeding
(one patient had a bleeding facial laceration on admission but
a normal prothrombin time). One patient in the physician pre-
scriber group died, after receiving heparin and warfarin for a stroke
in evolution, but there was no evidence of bleeding.
Secondary Outcomes
Patient-reported outcomes
1. Health-related quality of life
Outcome not reported.
Non-medical prescriber outcomes
1. Job satisfaction, skills utilisation, education needs, and
workload effects
Outcome not reported.
Resource-use outcomes
1. Medical time saved by non-medical prescribers
Outcome not reported.
2. Non-medical prescriber versus medical prescriber
prescription volume and cost, patient out-of-pocket expenses,
service costs, deprescribing rate, and cost
There was little or no difference in amount of anticoagulant drugs
prescribed by pharmacists compared to a physician (Chenella
1983; Table 2).
3. Increased resource use for providing the intervention and
for providing subsequent care such as hospitalisations,
emergency department visits, and outpatient visits.
Outcome not reported.
Non-medical prescribing in chronic care
(primary/ambulatory care)
We included 40 studies in this comparison. We included am-
bulatory care clinics for chronic disease management located
with secondary care hospitals in this subgroup (Denver 2003;
Houweling 2009; Jaber 1996; Kuethe 2011; MacMahon Tone
2009; McAlister 2014; New 2003). Two studies were under-
taken in the community pharmacy setting (Tsuyuki 2015; Tsuyuki
2016,).
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Meta-analyses were undertaken for systolic blood pressure, gly-
cated haemoglobin, and low-density lipoprotein using the fixed-ef-
fectmethod for outcomes at six and 12months (Figure 3; Figure 4;
Figure 5). These studies were skewed toward either nurse or phar-
macist prescribers, namely, systolic blood pressure at six months
(3 nurse studies, 8 pharmacist studies), systolic blood pressure at
12 months (10 nurse studies, 2 pharmacist studies), glycated hae-
moglobin at six months (1 nurse study, 2 pharmacist studies) gly-
cated haemoglobin at 12 months (6 nurse studies, 0 pharmacist
studies), low-density lipoprotein at six months (4 nurse studies,
2 pharmacist studies), low-density lipoprotein at 12 months (7
nurse studies, 0 pharmacist studies).
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Figure 3. Forest plot of comparison: 1 Non-medical prescribing group versus usual care, Outcome: 1.2
Systolic blood pressure mmHg.
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Figure 4. Forest plot of comparison: 1 Non-medical prescribing group versus usual care, Outcome: 1.1
HbA1c (%).
Figure 5. Forest plot of comparison: 1 Non-medical prescribing group versus usual care, Outcome: 1.3 Low-
density lipoprotein (LDL) mmol/L.
Moderate or considerable heterogeneity was evident in all sub-
groups apart from the glycated haemoglobin 12-month subgroup
for which heterogeneity might not be important given an I2 =
0%. While the degree of heterogeneity provides a caution, stud-
ies which contained non-medical prescribing as an intervention
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component showed improvement in three surrogate markers of
disease; systolic blood pressure, glycated haemoglobin, and low-
density lipoprotein.
A single study compared pharmacist case management versus the
active control of nurse-led case management and feedback to pri-
mary care physicians for medication adjustment in the secondary
prevention after minor stroke (McAlister 2014). Improvements in
both systolic blood pressure and low-density lipoprotein guide-
line targets were observed in both the pharmacist group (43.4%)
and nurse-led group (30.9%) after six months (absolute difference
12.5%, P = 0.03). Multivariable analyses confirmed the greater
attainment of targets in the pharmacist group (adjusted odds ratio
(OR) 2.31, 95% CI 1.29 to 4.2; P = 0.005, adjusted for age, co-
morbidities, sex, smoking status, and waist circumference). Both
groups had similar reductions in systolic blood pressure during the
trial and the overall result was driven by a higher proportion of pa-
tients meeting low-density lipoprotein targets in the pharmacist-
led group versus the nurse-led group (51.1% versus 33.8%, P =
0.003).
Primary Outcomes
1. Systolic blood pressure
Eleven ambulatory care studies (2076 participants) reporting sys-
tolic blood pressure at six months showed amean difference (MD)
favouring the non-medical prescribing group compared to usual
care of -6.76 mmHg (95% CI -8.24 to -5.27; Analysis 1.1), but
there was considerable heterogeneity (I2 = 82%, overall effect P <
0.00001) (Cohen 2011; Denver 2003; Hirsch 2014; Houweling
2009; Magid 2013; Margolis 2013; McAlister 2014; Rudd 2004;
Taveira 2011; Tsuyuki 2015; Vivian 2002). At 12 months, 12 am-
bulatory care studies (4229 participants) showed a MD favour-
ing the non-medical prescribing group of -5.31 mmHg (95% CI
-6.46 to -4.16; Analysis 1.1) with moderate heterogeneity (I2 =
50%, overall effect P < 0.00001) (Aubert 1998; Barr Taylor 2003;
Becker 2005; Hill 2003; Houweling 2009; Hunt 2008; Khunti
2007; MacMahon Tone 2009; Margolis 2013; New 2003; Tobe
2006;Wallymahmed 2011). The test for subgroup differences was
not significant (I2 = 56.3%, P= 0.13) (Figure 3).
The systolic blood pressure effect estimate at six months for the
fixed-effect model was MD -6.76 mmHg, 95% CI -8.24 to -
5.27 compared to the random-effects estimate (MD -7.34mmHg,
95% CI -11.09 to -3.60). At 12 months the respective compari-
son was MD -5.31 mmHg, 95% CI -6.46 to -4.16 versus MD -
5.91 mmHg, 95% CI -7.71 to -4.10 (Table 1). There was a mod-
erate-certainty of evidence (Summary of findings for the main
comparison).
Excluding the cluster-RCT at six months (Margolis 2013), the
effect estimate was MD -6.13 mmHg, 95% CI -7.83 to -4.44; 10
studies, 1628 participants (Analysis 1.1.3). Excluding the cluster-
RCTs at 12 months (Khunti 2007; Margolis 2013), the effect
estimatewasMD-4.84mmHg, 95%CI -6.29 to -3.39; 10 studies,
2627 participants (Analysis 1.1.4).
The subgroup analysis of four studies (695 participants) where
non-medical prescribers demonstrated a higher level of prescrib-
ing autonomy in the control of systolic blood pressure showed:
fixed-effect MD -2.98 mmHg, 95% CI -5.36 to -0.59; P = 0.01,
compared with a random-effects model MD -6.78 mmHg, 95%
CI -15.38 to 1.81; P = 0.12, with considerable heterogeneity I2 =
90% (Analysis 1.1.5; Figure 3).
2. Glycated haemoglobin
For glycated haemoglobin, three ambulatory care studies at six
months demonstrated a MD favouring the non-medical prescrib-
ing group of -0.42% (95% CI -0.75 to -0.09; 271 participants;
Analysis 1.2) withmoderate heterogeneity (I2 = 44%, overall effect
P < 0.01) (Cohen 2011; Houweling 2009; Taveira 2011). At 12
months, six ambulatory care studies managing glycated haemoglo-
bin showed aMD favouring the non-medical prescribing group of
-0.62% (95% CI -0.85 to -0.38; 775 participants) with minimal
heterogeneity (I2 = 0%, overall effect P < 0.00001; Analysis 1.2)
(Aubert 1998; Barr Taylor 2003; Houweling 2009; Litaker 2003;
MacMahon Tone 2009; Wallymahmed 2011). The test for sub-
group differences was not significant (I2 = 0%, P = 0.35; Figure
4). For fixed-effect versus random-effects estimates refer to Table
1. There was a high-certainty of evidence (Summary of findings
for the main comparison; Table 1).
3. Low-density lipoprotein
Six ambulatory care studies (1213 participants) for low-density
lipoprotein management at six months showed a MD favouring
the non-medical prescribing group of -0.25 mmol/L (95% CI -
0.34 to -0.17), but these studies demonstrated considerable hetero-
geneity (I2 = 88%, overall effect P < 0.00001; Analysis 1.3) (Cohen
2011; DeBusk 1994; Hirsch 2014; Houweling 2009; McAlister
2014; Taveira 2011). At 12 months the MD favouring the non-
medical prescribing group in seven ambulatory care studies was
-0.21 mmol/L (95% CI -0.29 to -0.14; 7 studies, 1469 partici-
pants; Analysis 1.3). The studies demonstrated considerable het-
erogeneity (I2 = 93%; overall effect P < 0.00001) (Aubert 1998;
Barr Taylor 2003; Becker 2005; DeBusk 1994; Houweling 2009;
MacMahon Tone 2009; Wallymahmed 2011). The test for sub-
group differences was not significant (I2 = 0%, P = 0.53; Figure 5).
There was moderate-certainty of evidence (Summary of findings
for the main comparison; Table 1).
Further exploration of the high heterogeneity in the six-month
low-density lipoprotein study was undertaken by examining the
differences in pharmacist and nurse prescribing. It was found that
heterogeneitymight not be important in the four pharmacist stud-
ies (629 participants) (MD -0.09, 95% CI -0.20 to 0.02; I2= 0%;
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Analysis 1.4), which did not yield a significantly different over-
all effect (P = 0.1). Considerable heterogeneity existed in the two
nursing studies (584 participants) (MD -0.52, 95% CI -0.67 to
-0.38; I2 = 94%; Analysis 1.4), with a significant overall effect
(P < 0.00001). The test for overall effect for both subgroups had
considerable heterogeneity and was significant (I2 = 88%, P <
0.00001). The subgroup differences showed very high heterogene-
ity and were significant (I2 = 95.6%, P < 0.00001). For fixed-effect
versus random-effects estimates refer to Table 1.
4. Proportion of prescribers, medical and non-medical,
appropriately adhering to practice guidelines
Adherence to practice guidelines was difficult to quantify across
studies. Intervention group prescribing was usually aimed at treat-
ing a target based on approved therapeutic guidelines. Usual care
prescribing may have been based on supplied guidelines, educa-
tion, or an assumed knowledge of current guidelines.
5. Proportion of patients demonstrating medication
adherence (Analysis 1.5 and 1.6)
Medication adherence was assessed in 10 studies using a number of
approaches including Morisky Medication Adherence Scale, med-
ication possession ratio, patient report, pill count, electronic drug
event monitoring, and pharmacy medication refill information
(Table 3). Medication adherence was reported as high in interven-
tion and usual care groups across studies. There was probably little
or nodifference between groups in six studies (Bruhn 2013;Cohen
2011; Finley 2003; Hunt 2008; Magid 2013; Vivian 2002), and
an improved outcome favouring the intervention group in two
studies (Logan 1979; Rudd 2004). The study by Margolis 2013
found an improved outcome favouring the intervention group
at six months, but no difference between groups at 12 and 18
months. Medication adherence outcomes could not be assessed in
the study by Hirsch 2014.
A meta-analysis was undertaken for four studies (Cohen 2011;
Finley 2003; Magid 2013; Rudd 2004), with adherence data cap-
tured as continuous variables with an outcome probably favouring
the intervention group, standardised mean difference (SMD) 0.15
(95% CI 0.00 to 0.30; 700 participants, overall effect P = 0.05)
and moderate heterogeneity I² = 38% (Analysis 1.5). Four studies
(935 participants) with dichotomous adherence data (Hunt 2008;
Logan 1979; Margolis 2013; Vivian 2002), showed little adher-
ence difference (risk difference (RD) 0.06, 95% CI -0.00 to 0.12;
P = 0.05) and moderate heterogeneity I2 = 67% (Analysis 1.6).
There was a moderate-certainty of evidence (Summary of findings
for the main comparison; Table 1).
6. Proportion of patients and items appropriately prescribed
or deprescribed
In the aged care setting the pharmacist prescribed 2.2 fewer drugs
per patient than medical colleagues, comparing before-and-after
study periods (Thompson 1984). Tsuyuki 2015 reported com-
munity pharmacist prescribers discontinued 76 antihypertensive
drugs in 181 intervention group patients compared to 15 antihy-
pertensive drugs being discontinued in 67 usual care group pa-
tients.
7. Patient satisfaction, where measured by a validated tool as
part of an effectiveness study
Patient satisfaction was reported in 14 studies (7514 participants)
(Table 4). Validated tools assessing the overall satisfaction with
care were included in six studies, namely, diabetes care (Houweling
2009; Houweling 2011), hypertension care (Hunt 2008), clinical
pharmacist care (Hirsch 2014), and general care (Litaker 2003;
Margolis 2013). The majority of satisfaction surveys were not ref-
erenced or were locally developed. Some aspects important in the
prescribingprocesswere covered in overall satisfaction assessments,
e.g. the quantity and quality of contact (Finley 2003; Houweling
2011; Margolis 2013). The locally developed satisfaction survey
by Bruhn 2013 focused on the prescribing intervention. Patients
were generally positive about the pharmacist prescribing service,
85% (39/46) were totally satisfied, while 9% (4/44) would have
preferred to see their general practitioner (GP). Overall, there was
a moderate-certainty of evidence (Summary of findings for the
main comparison; Table 1). Studies looking at medical provider
satisfaction with non-medical prescribers were limited in number
and scope (Barr Taylor 2003; Bruhn 2013), but generally positive.
8. Non-medical prescriber versus medical prescriber waiting
time to care
Outcome not reported.
9. Non-medical prescribers adversely affecting the health
outcomes of patients through medication errors, prescribing
errors, adverse effects, wrong diagnoses or treatment,
increased hospitalisations, or representations for medical care
Adverse events were reported in 18 of the 46 studies (18,400 par-
ticipants) (Table 5). There was probably little or no difference in
adverse events between the intervention and usual care groups in
nine studies (Ansari 2003; Aubert 1998; Fairall 2008; Ishani 2011;
Klingberg-Allvin 2015; Kuethe 2011; Spitzer 1974; Taveira 2011;
Tobe 2006), with a probable increase in adverse events in the usual
care group in two studies (New 2003; Thompson 1984). We are
uncertain whether the intervention has an effect on adverse events
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in the remaining studies due to limited data reporting. The rela-
tionship between increased medication use in intervention groups
and adverse events remains uncertain. Overall, there was a low-
certainty of evidence between the intervention and adverse events
(Summary of findings for the main comparison; Table 1).
10. Other surrogate outcome markers
Studies of surrogate outcome markers not included in the meta-
analyses reported either probable improvements favouring the in-
tervention over usual care (Choe 2005; Ellis 2000; Fischer 2012;
Logan 1979); little difference in outcome (Houweling 2011;
Moher 2001); or uncertainty of outcome, with surrogate markers
showing a combination of probable improvements or little differ-
ence in outcomes (Heisler 2012; Ishani 2011; Taveira 2010; Table
2).
Secondary outcomes
Patient-reported outcomes
1. Health-related quality of life
Quality of life measures reflected general non-medical prescriber
care compared to usual care. We combined physical and mental
component scores for the Short Form-12 (SF-12) and Short Form-
36 (SF-36) in a meta-analysis. Eight studies (2385 participants)
were included in the physical component meta-analysis (Bruhn
2013; Cohen 2011; Houweling 2011; Hunt 2008; Khunti 2007;
Litaker 2003; Margolis 2013; Vivian 2002); six studies (2246
participants) contributed to the mental component meta-analy-
sis (Cohen 2011; Houweling 2011; Hunt 2008; Khunti 2007;
Litaker 2003; Margolis 2013). The physical subgroups showed a
small effect (MD 1.17, 95% CI 0.16 to 2.17, P = 0.02) favouring
intervention, with low heterogeneity, I² = 17% (Analysis 1.7). The
mental component subgroup did not show an effect difference (P
= 0.25) with aMD of 0.58 (95% CI -0.40 to 1.55) with moderate
heterogeneity, I² = 66% (Analysis 1.7). There was no significant
difference between the subgroups (P = 0.41) where heterogeneity
might not be a factor, I2 = 0%.
Across studies, various quality of life measures generally demon-
strated little difference between intervention and control groups
(Table 6). There was a moderate-certainty of evidence (Summary
of findings for the main comparison; Table 1).
Non-medical prescriber outcomes
1. Job satisfaction, skills utilisation, education needs, and
workload effects
Outcome not reported.
Resource use outcomes
1. Medical time saved by non-medical prescribers
Outcome not reported.
2. Non-medical prescriber versus medical prescriber
prescription volume and cost, patient out-of-pocket expenses,
service costs, deprescribing rate, and cost
Medication use, including medication amount, medication type,
medication dosing, medication frequency, and medication cost
was higher in 14 non-medical prescribing groups (7092 par-
ticipants) compared to usual care (Ansari 2003; Cohen 2011;
Denver 2003; Heisler 2012; Houweling 2009; Hunt 2008; Logan
1979;MacMahon Tone 2009;Magid 2013;Margolis 2013; Rudd
2004;Taveira 2010;Taveira 2011;Tsuyuki 2015). Little difference
in medication use was reported in two studies (Chenella 1983;
Vivian 2002) (137 participants), and a variable outcome was re-
ported in six studies (7924 participants) (Einhorn 1978; Hirsch
2014;McAlister 2014;Moher 2001; Pagaiya 2005;Wallymahmed
2011). (Table 7).
Costs relating to prescription volume, patient out-of-pocket ex-
penses, and deprescribing rate were not reported.
3. Increased resource use for providing the intervention and
for providing subsequent care such as hospitalisations,
emergency department visits, and outpatient visits
Twenty-five studies (22,590 participants) reported resource use,
including hospital admissions, emergency department visits, out-
patient visits, primary care visits, physician visits, pharmacists’ vis-
its, examinations, and staff and laboratory costs (Table 7). Due to
the heterogeneity of resource use across studies and the measures
used to record resource use,meta-analysis was confined to a limited
number of studies of emergency department visits (RD 0.01, 95%
CI -0.02 to 0.03) and hospitalisation (RD -0.01, 95% CI -0.03
to 0.01) comparing the non-medical prescribing group to usual
care. There was no statistical difference between study groups for
these parameters (P = 0.52 and P = 0.51, respectively) in the meta-
analysis (Analysis 1.8). There appeared to be little difference in
25Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
hospitalisations, emergency department visits, and outpatient vis-
its between intervention versus control groups across the studies.
Non-medical prescribing in other settings
Two studies were undertaken in other settings. Logan 1979 de-
scribed a study of bloodpressure control by nurses in theworkplace
compared to usual medical care. Patients in the nurse group were
more likely to be put on antihypertensive medications (94.7%
versus 62.7%, P < 0.001), to reach blood pressure goals in the first
six months (48.5 versus 27.5%, P < 0.001) and to take drugs pre-
scribed (67.6 versus 49.1%, P < 0.005). Thompson 1984 reported
on pharmacist prescribing in a geriatric setting. The clinical phar-
macist group probably had a lower number of deaths (P = 0.05), a
higher number of patients being discharged to lower levels of care
(P = 0.03) and a lower average number of drugs per patient (P =
0.04) (Table 2).
Four studies were undertaken in low- and middle-income country
settings. Einhorn 1978 evaluated nurse management versus usual
doctor care of family planning and prescribing oral contraceptives.
While differences in patient management occurred, the outcomes
of continuing oral contraceptive use and preventing pregnancy
were probably not different. As outlined, Fairall 2008 evaluated
task shifting of antiretroviral therapy from doctors to primary care
nurses. The intervention improved survival slightly in patients not
yet taking antiretrovirals with CD4 counts of 201 to 350 cells
per µL but resulted in little difference in patients with higher cell
counts. There was little or no difference in viral load suppression
between patient groups for patients already taking antiretrovirals
at enrolment. Klingberg-Allvin 2015 compared treatment of in-
complete abortion with misoprostol by physicians and midwives
at district level in Uganda and found the diagnosis and treatment
of incomplete abortion by midwives equally safe and effective as
when provided by physicians. In the study by Pagaiya 2005, educa-
tional intervention with guidelines for nurses probably improved
antibiotic prescribing for acute respiratory tract infections and the
prescribing of diazepam. There was probably no difference in the
prescribing of antibiotics for diarrhoea, and it is uncertain whether
diabetes care improved because the certainty of evidence is low.
D I S C U S S I O N
Summary of main results
The overall findings suggest that non-medical prescribing prac-
tised with varying but high degrees of autonomy and with collab-
orative support, can deliver comparable outcomes to usual med-
ical care prescribing. However, these results must be interpreted
with a degree of caution, recognising the variation in non-medical
prescribing practice reported within studies and the complex in-
terplay of factors affecting outcomes. There are a limited number
of well-designed randomised controlled trials (RCTs) evaluating
the specific prescribing outcomes of non-medical prescribers.
Meta-analyses examining surrogate markers of disease with the
fixed-effect method demonstrated interventions with a non-med-
ical prescribing component decreased systolic blood pressure at six
months by -6.76 mmHg, and at 12 months by -5.31 mmHg. The
fixed-effect estimates gave a more conservative estimate of effect
than the random-effects estimate for systolic blood pressure ( -
7.34 mmHg and -5.91 mmHg, respectively). There was little dif-
ference between fixed- and random-effects outcomes for glycated
haemoglobin at six months (-0.42% versus -0.45%, respectively)
and at 12 months (-0.62% versus -0.62%, respectively). Reduc-
tions in low-density lipoprotein demonstrated variable results us-
ing fixed- and random-effects at six months (-0.25 mmol/L ver-
sus -0.13 mmol/L, respectively), and 12 months (-0.21 mmol/
L versus -0.30 mmol/L, respectively). However, all studies apart
from those assessing glycated haemoglobin at 12 months demon-
strated moderate to considerable heterogeneity. Removal of the
two cluster-RCTs for systolic blood pressure reduced the fixed-
effect difference by 0.63 mmHg at six months and 0.47 mmHg
at 12 months.
Clinical findings of interventions with non-medical prescribing
components outside themeta-analyses showed equivalence or ben-
efit compared to usual care (Table 2). Medication adherence was
measured in less than a quarter (22%) of studies. Where adher-
ence was measured, there was either no difference between study
groups or a small improvement in intervention groups. More reg-
ular contact by the non-medical prescriber with intervention pa-
tients compared to usual care may be a confounding factor. For ex-
ample, in the telemonitoring of blood pressure study by Margolis
2013, which demonstrated improved medication adherence at six
months, there was regular telephone support from the interven-
tion pharmacist every two weeks until blood pressure control was
sustained for six weeks. Contact then reduced to monthly contact
for six months which may account for little or no difference in
medication adherence at 12 and 18 months. A meta-analysis of
four studies with continuous adherence data favoured the non-
medical prescriber group with minimal heterogeneity.
In studies reporting adverse events, there was either little differ-
ence between intervention and usual care groups or insufficient
information to determine if differences occurred. In two studies,
more deaths were reported in the usual care group versus the in-
tervention group (New 2003; Thompson 1984).
The meta-analysis of the combined quality of life measures (SF-12
and SF-36 scores at 12 months) showed an overall improvement
favouring the intervention. A variety of other quality of life mea-
sures (used in the remaining studies and not included in the meta-
analysis) generally demonstrated little difference between the in-
tervention and usual care groups. In assessing quality of life ef-
fects, consideration must be given to the effect of the multifaceted
nature of many interventions beyond the non-medical prescribing
component.
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Patient satisfaction data were reported in 14/46 (30%) of studies
and focused on the care patients received from the non-medical
health professional as a whole, with little specific comparative ev-
idence of satisfaction with the prescribing element of care. Bruhn
2013 obtained a high patient satisfaction rating of 85% (39/46)
with the pharmacist service involving prescribing and education in
the management of chronic pain. Two studies included results of
small samples of medical provider satisfaction with non-medical
providers, which were generally positive, but they raised respec-
tive concerns about time commitments to intervention patients
and the cost-effectiveness of non-medical prescribers (Barr Taylor
2003; Bruhn 2013).
A wide variety of measures of resource use were reported in 37/46
(80%) of studies. In the majority of studies reporting medication
use, non-medical prescribers initiated and prescribed more drugs,
titrated drugs to a higher dose, and used a greater variety of drugs
than usual care medical prescribers in treating chronic disease. In
the aged care setting, the pharmacist prescribed fewer drugs than
medical colleagues (Thompson 1984). There was little difference
in hospitalisations, emergency department visits, and outpatient
visits between intervention versus usual care groups across the
studies.
Non-medical prescribers had varying levels of prescriber training,
determined by country or setting, and no studies were found com-
paring different levels of non-medical prescriber training and out-
comes.
Overall completeness and applicability of
evidence
The majority of studies were from high-income countries with
the greater proportion, 25 of 46 studies emanating from the USA.
While the results of this review are more applicable in West-
ern countries, the four studies involving non-medical prescribing
nurses in low- and middle-income countries demonstrated safe
and effective outcomes compared to usual care, and provide an
opportunity for further study in the application of non-medical
prescribing. It is unclear why more studies meeting inclusion cri-
teria did not originate from the UK where legislative change and
formal training requirements have allowed independent prescrib-
ing by nurses and pharmacists since 2006. Chronic disease man-
agement was the focus of most studies with only two studies un-
dertaken in the acute inpatient secondary care setting (Chenella
1983; Marotti 2011).
No studies reported comparisons between non-medical prescribers
in both arms of the study.
In only 19 studies could a more defined non-medical prescribing
role with less confounding elements provide a clearer effect on
outcomes. Pharmacists were judged to have more autonomy in
their prescribing roles than nurses, who relied more heavily on al-
gorithms to adjust medications. The degree of prescribing auton-
omy within study designs was guided by local legislative controls
and healthcare organisation policies and practices.
Formal training as a requirement to prescribe was limited. Inde-
pendent pharmacist prescribers in the Bruhn 2013 UK study were
required to complete a course of approved study and have regis-
tration with the General Pharmaceutical Council as independent
prescribers. In Alberta Canada, pharmacists in the Tsuyuki studies
were required to undergo an assessment process when applying for
the authorisation to prescribe (Tsuyuki 2015; Tsuyuki 2016). In
other studies, prescribing permissions were granted through col-
laborative practice agreements for pharmacists in the USA, and
varying degrees of specific on-the-job training for the disease or
condition of focus. Prescribers frequently had advanced practice
qualifications, for example, in diabetes management, and a num-
ber of years of experience in ambulatory chronic disease care. Pre-
scribing of oral contraceptives was within the remit of family plan-
ning nurses in Bogota, Colombia (Einhorn 1978). Local training
was provided to nurses in South Africa covering antiretroviral drug
prescribing, drug effects and side-effects, and the use of algorith-
mic clinical practice guidelines (Fairall 2008).Midwives inUganda
underwent a five-day training programme covering incomplete
abortion and treatmentwithmisoprostol (Klingberg-Allvin2015).
Nurses in health centres in Thailand prescribed antibiotics for
children and diazepam for adults without additional education
and guideline support, which was the focus of the study (Pagaiya
2005).
The heterogeneity of educational requirements for non-medical
prescribers across studies did not allow a pooled assessment of
outcomes, but within individual studies the education level did
not appear to influence the outcome.
Local trial protocols, which included additional collaborativemed-
ical support for the non-medical prescriber, were aimed at ensur-
ing safe practice.
Most excluded studies were before-and-after studies and there re-
mains a need for further large, well-controlled trials, where the
prescribing component can be clearly associated with an outcome,
and the degree of prescribing autonomy is clearly defined.
Mikuls 2015 is an ongoing study (see Characteristics of ongoing
studies). We are waiting for further information from one study
that is reported as an abstract (Tsuyuki 2014). We have placed
this study in Characteristics of studies awaiting classification and
we will incorporate this study in a future review update. Two fur-
ther studies, assessing economic impacts, are awaiting assessment
(Barton 2013; Neilson 2015). We made the pragmatic decision
that these two studies will be incorporated in the update of this
review, so as to avoid delaying the publication of the current ver-
sion of this review.
Quality of the evidence
We evaluated the certainty of the body of evidence for seven out-
comes according to the GRADE system.
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We graded the certainty of evidence for systolic blood pressure
at 12 months as moderate due to considerations of serious in-
consistency (finding considerable heterogeneity), the multifaceted
nature of interventions, and variable prescribing autonomy. We
found high levels of certainty of evidence for the outcome of gly-
cated haemoglobin at 12 months. There were low levels of cer-
tainty of evidence for low-density lipoprotein due to serious in-
consistency (finding considerable heterogeneity), multifaceted in-
terventions, and variable prescribing autonomy. We graded medi-
cation adherence at moderate-certainty of evidence due to serious
risk of bias (high risk of performance bias) and variable adherence
reporting measures. We graded the certainty of evidence around
adverse event reporting as low due to indirectness, as the range of
adverse eventsmay not be related to the intervention, and selective
outcome reporting with adverse events not being reported inmany
studies. We graded the certainty of evidence for patient satisfac-
tion as moderate due to indirectness in measuring the prescribing
component of care, the variability of measures used, and the con-
sideration that some measures were not validated. We graded the
health-related quality of life measures as moderate, considering
that within the quality of life outcomes it is difficult to distinguish
the contribution non-medical prescribing made to the outcome
versus the other components of care.
The certainty of the body of evidence provides support that there
is probably no difference in outcomes between non-medical and
medical prescribers. Specific outcomes may be improved by non-
medical prescribers working within collaborative care arrange-
ments in a range of settings.
Potential biases in the review process
Differing terminologies for non-medical prescribing across coun-
tries may have limited the number of studies found. In addition,
we made judgements on the degree of prescribing autonomy for
non-medical prescribers in included studies.
Agreements and disagreements with other
studies or reviews
The findings of this review are generally consistent with the find-
ings of other reviews. Meta-analyses of studies involving phar-
macist and nurse-led care may include studies involving medica-
tion management, medication reconciliation, medication educa-
tion, treatment monitoring, treatment support, and lifestyle ad-
vice.Medication management is a broad term thatmay ormay not
include a prescribing component. Subgroup analysis of studies in-
volving either independent prescribing, prescribing or dosage ad-
justment by protocol or algorithm have demonstrated benefit over
usual care. Findings of improvements in clinical markers and het-
erogeneity accord with our findings. In a meta-analysis, Santschi
2014 reported pharmacist interventions improved blood pressure
compared to usual care, but due to the large heterogeneity be-
tween studies the effect size varied widely, and it was difficult to
determine the most effective intervention. A range of pharmacist
interventions were found to reduce systolic blood pressure, but
possibly not diastolic blood pressure (Machado 2007). A limita-
tion for both studies was the quality of the studies included in the
analyses. In a systematic review of the effects of nurse prescribing,
Gielen 2014 reviewed 35 studies including 10 RCTs and one con-
trolled clinical trial. All but five studies had a high risk of bias, but
tentative conclusions were that nurses prescribed in a similar way
to doctors with few differences in health outcomes, quality of care,
and patient satisfaction. Clark 2010 found nurse-led interventions
required an algorithm to improve blood pressure control com-
pared to usual care, and there was some evidence of improved out-
comes by nurse prescribers outside the UK. In reviewing 72 RCTs
of interventions to control blood pressure in patients with hyper-
tension, Glynn 2010 included 12 studies of nurse-led or pharma-
cist-led care to improve blood pressure control. While the results
were significantly heterogeneous, the effects were favourable and
warranted further investigation in larger trials. The Hypertension
Detection and Follow-Up study was cited for providing evidence
of the importance of a multifaceted intervention in blood pressure
control, which consisted of an organised system of regular review
and vigorous antihypertensive drug therapy (Hypertension 1979).
In chronic disease management, nurses successfully titrated med-
ications by protocol for diabetes, hypertension, and hyperlipi-
daemia within a team approach.There were limited descriptions
of the interventions and protocols used for studies in the meta-
analysis (Shaw 2014). Greer 2016 found pharmacist-led chronic
disease management was similar to usual care for resource use, and
may improve goals for glycaemia, blood pressure, and cholesterol,
but there is uncertainty whether clinical outcomes are improved.
In a review of the effects of pharmacist-provided non-dispensing
services on patient outcomes, health service utilisation, and costs
in low- andmiddle-income countries, Pande 2013 reported on the
outcomes of pharmacist interventions that involved counselling,
education, and advice. There were small improvements in clinical
outcomes (blood pressure, blood glucose, lipids, peak expiratory
flow) and quality of life scores, however, the certainty of the evi-
dence was graded as low. Health service utilisation andmedication
costs were reduced, but again the certainty of the evidence was
graded as low. In a review of the effect of outpatient pharmacists’
non-dispensing roles on patient outcomes and prescribing pat-
terns, Nkansah 2010 found that most of the 43 studies included
in their review supported the role of pharmacists in medication/
therapeutic management as one of a number of interventions to
improve clinical outcomes.
It is often difficult to distinguish the specific outcomes of non-
medical prescribing in reported studies and reviews, and the degree
of influence on prescribing by physicians where team care arrange-
ments exist. Driscoll 2015, in a review of nurse-led titration of
drug therapy for people with heart failure, found that participants
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in the nurse-led group were less likely to be admitted to hospital
or to die. More participants reached the maximum drug dose in
the nurse-led group compared to titration of doses by primary care
physicians. However we assessed a high level of autonomy in pre-
scribing in only one of the seven reported studies (Ansari 2003).
In a review of substitution of doctors by nurses in primary care,
Laurant 2005 found that the quality of care and health outcomes
are similar for nurses and doctors, but it is not known if nurse
substitutiondecreases doctors’ workload.Nurses tended to provide
more health advice and achieve higher levels of patient satisfaction
compared to doctors. Nurses’ higher use of resources, for example,
ordering more tests, may offset savings in lower salary costs.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Non-medical prescribers practising in a variety of settings and
with varying but high levels of prescribing autonomy, can achieve
comparable outcomes in the management of chronic disease and
preventive healthcare. Non-medical prescribers can deliver com-
parable outcomes for systolic blood pressure, glycated haemoglo-
bin, low-density lipoprotein, medication adherence, patient satis-
faction, and general quality of life. The certainty of evidence in
studies reporting adverse events and resource use make it difficult
to determine the impact of non-medical prescribing compared to
medical prescribing for these outcome measures. Pharmacists and
nurses are able to deliver comparable prescribing outcomes with
varying levels of undergraduate, postgraduate, and specific on-
the-job training. Non-medical prescribers frequently have med-
ical support available, if needed, and where these circumstances
exist, a collaborative approach appears the preferredmodel of care.
Non-medical prescribers across a range of different settings in low-
, medium- and high-income countries may be able to meet the
growing burden of chronic disease, or where doctor shortages or
scarce health resources exist.
Implications for research
It is frequently difficult within collaborative care models to dis-
tinguish specific outcomes that can be related to the non-medical
prescribing component of care. There is a need for trials to more
effectively control the variables around non-medical prescribing
to truly determine its effect compared to usual medical prescribing
care. Outcomes should be clearly defined, studies should facilitate
meta-analysis, and more effectively quantify adverse prescribing
events. Further studies on patient satisfaction using validated tools
are required to identify satisfaction with the prescribing compo-
nent of care. There weremany parameters of resource use in the in-
cluded studies, with few studies capturing comparative drug costs
of non-medical prescribing versus usual care medical prescribing.
The cost of doctors’ time saved and whether this time is transferred
to more acute patient care should be quantified in future studies.
Therefore, there is a need for cost-effectiveness analysis of a range
of non-medical prescribing interventions. Well-controlled studies
are also required in the acute secondary care setting to establish
the effect of non-medical prescribing roles on medical workload,
resource use, patient flow, and safety. Due to the limited number
of studies in low- and middle-income countries, further well-con-
trolled trials are required in such settings.
A C K N OW L E D G E M E N T S
Within the Cochrane Effective Practice and Organisation of Care
(EPOC) Group, we would like to thank Paul Millar, Information
Specialist, for assistance in developing the search strategy; Gillian
Leng (Contact Editor); Clare Dooley (Assistant Managing Edi-
tor); Emma Tavender (Managing Editor); Luke Vale (Economics
Editor), Kristoffer Yunpeng Ding (Statistical Editor), and Arash
Rashidian (Editor). In addition, we thank Neal Maskey (Peer Ref-
eree), and Heather Maxwell (Copy-Editor).
R E F E R E N C E S
References to studies included in this review
Ansari 2003 {published data only}
Ansari M, Shlipak MG, Heidenreich PA, Van Ostaeyen
D, Pohl EC, Browner WS, et al. Improving guideline
adherence. A randomized trial evaluating strategies to
increase β-blocker use in heart failure. Circulation 2003;
107(22):2799–804. [4455458]
Aubert 1998 {published data only}
Aubert RE, Herman WH, Waters J, Moore W, Sutton
D, Peterson BL, et al. Nurse case management to
improve glycaemic control in diabetic patients in a health
maintenance organisation. Annals of Internal Medicine
1998;29:605–12. [4455460]
Barr Taylor 2003 {published data only}
Barr Taylor C, Houston Miller N, Reilly KR, Greenwald
G, Cunning D, Deeter A, et al. Evaluation of a nurse-care
management system to improve outcomes in patients with
complicated diabetes. Diabetes Care 2003;26:1058–63.
[4455462]
Becker 2005 {published data only}
Becker DM, Yanek LR, Johnson WR, Garrett D, Moy
TF, Reynolds SS, et al. Impact of a community-based
29Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
multiple risk factor intervention on cardiovascular risk in
black families with a history of premature coronary disease.
Circulation 2005;111:1298–304. [4455464]
Bruhn 2013 {published data only}
Bruhn H, Bond CM, Elliott AM, Hannaford PC, Lee AJ,
McNamee P, et al. Pharmacist-led management of chronic
pain in primary care: Results from a randomised controlled
exploratory trial. BMJ Open 2013;3:2013. [4455466]
Chenella 1983 {published data only}
Chenella FC, Klotz TA, Gill MA, Kern JW, McGhan WF,
Paulson YJ, et al. Comparison of physician and pharmacist
management of anticoagulant therapy of inpatients.
American Journal of Hospital Pharmacy 1983;40:1642–5.
[4455468]
Choe 2005 {published data only}
Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL,
Vijan S. Proactive case management of high-risk patients
with type 2 diabetes mellitus by a clinical pharmacist: a
randomized controlled trial. American Journal of Managed
Care 2005;11:253–60. [4455470]
Cohen 2011 {published data only}
Cohen LB, Taveira TH, Khatana SA, Dooley AG, Pirraglia
PA, Wu WC. Pharmacist-led shared medical appointments
for multiple cardiovascular risk reduction in patients with
type 2 diabetes. Diabetes Educator 2011;37:801–12.
[4455472]
DeBusk 1994 {published data only}
DeBusk RF, Houston Miller N, Superko R, Dennis CA,
Thomas RJ, Lew HT, et al. A case-management system for
coronary risk factor modification after acute myocardial
infarction. Annals of Internal Medicine 1994;120:721–9.
[4455474]
Denver 2003 {published data only}
Denver EA, Barnard M, Woolfson RG, Earle KA.
Management of uncontrolled hypertension in a nurse-
led clinic compared with conventional care for patients
with type 2 diabetes. Diabetes Care 2003;26:2256–60.
[4455476]
Einhorn 1978 {published data only}
Einhorn RF, Trias M. Differences between physicians and
nurses in providing family planning services: Findings from
a Bogota clinic. Studies in Family Planning 1978;9(2):35–8.
[4455478]
Ellis 2000 {published data only}
Ellis SL, Carter BL, Malone DC, Billups SJ, Okano
GJ, Valuck RJ, et al. Clinical and economic impact of
ambulatory care clinical pharmacists in management of
dyslipidemia in older adults: The IMPROVE Study.
Pharmacotherapy 2000;20(12):1508–16. [4455480]
Fairall 2008 {published data only}
Fairall L, Bachmann MO, Lombard C, Timmerman
V, Uebel K, Zwarenstein M, et al. Task shifting of
antiretroviral treatment from doctors to primary-care nurses
in South Africa (STRETCH): a pragmatic, parallel, cluster-
randomised trial. Lancet 2012;380:889–98. [4455482]
Finley 2003 {published data only}
Finley PR, Rens HR, Pont JT, Gess SL, Louie C, Bull SA,
et al. Impact of a collaborative care model on depression
in a primary care setting: a randomized controlled trial.
Pharmacotherapy 2003;23:1175–85. [4455484]
Fischer 2012 {published data only}
Fischer HH, Eisert SL, Everhart RM, Durfee MJ, Moore
SL, Soria S, et al. Nurse-run, telephone-based outreach to
improve lipids in people with diabetes. American Journal of
Managed Care 2012;18(2):77–84. [4455486]
Heisler 2012 {published data only}
Heisler M, Hofer TP, Schmittdiel JA, Selby JV, Klamerus
ML, Bosworth HB, et al. Improving blood pressure control
through a clinical pharmacist outreach program in patients
with diabetes mellitus in 2 high-performing health systems.
Circulation 2012;125:2863–72. [4455488]
Hill 2003 {published data only}
Hill MN, Han HR, Dennison CR, Kim MT, Roary MC,
Blumenthal RS, et al. Hypertension care and control in
undeserved urban African American men: Behavioural and
physiological outcomes at 36 months. American Journal of
Hypertension 2003;16:906–13. [4455490]
Hirsch 2014 {published data only}
Hirsch JD, Steers N, Adler DS, Kuo GM, Morello
CM, Lang M, et al. Primary care-based pharmacist-
physician collaborative medication-therapy management
of hypertension: A randomized, pragmatic trial. Clinical
Therapeutics 2014;36(9):1244–54. [4455492]
Houweling 2009 {published data only}
Houweling ST, Kleefstra N, van Hateren KJJ, Kooy A,
Groenier KH, ten Vergert E, et al. Diabetes specialist nurse
as main care provider for patients with type 2 diabetes.
Journal of Medicine 2009;67(7):279–84. [4455494]
Houweling 2011 {published data only}
Houweling ST, Kleefstra N, van Hateren KJJ, Groenier KH,
Meyboom-de Jong B, Bilo HJG. Can diabetes management
be safely transferred to practice nurses in a primary care
setting? A randomised controlled trial. Journal of Clinical
Nursing 2011;20:1264–72. [4455496]
Hunt 2008 {published data only}
Hunt JS, Siemienczuk J, Pape G, Rozenfeld Y, MacKay J,
LeBlanc BH, et al. A randomised controlled trial of team-
based care: Impact of physician-pharmacist collaboration
on uncontrolled hypertension. Journal of General Internal
Medicine 2008;23(12):1966–72. [4455498]
Ishani 2011 {published data only}
Ishani A, Greer N, Taylor BC, Kubes L, Cole P, Atwood M,
et al. Effect of nurse case management compared with usual
care on controlling cardiovascular risk factors in patients
with diabetes. Diabetes Care 2011;34:1689–94. [4455500]
Jaber 1996 {published data only}
Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran
H. Evaluation of a pharmaceutical care model on diabetes
management. Annals of Pharmacotherapy 1996;30:238–43.
[4455502]
30Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Khunti 2007 {published data only}
Khunti K, Stone M, Paul S, Baines J, Gisborne L, Farooqi
A, et al. Disease management programme for secondary
prevention of coronary heart disease and heart failure in
primary care: a cluster randomised controlled trial. Heart
2007;93:1398–405. [4455504]
Klingberg-Allvin 2015 {published data only}
Klingberg-Allvin M, Cleeve A, Atuhairwe S, Tumwesigye
NM, Faxelid E, Byamugisha J, et al. Comparison of
treatment of incomplete abortion with misoprostol by
physicians and midwives at district level in Uganda: a
randomised controlled equivalence trial. Lancet 2015;385:
2392–8. [4455506]
Kuethe 2011 {published data only}
Kuethe M, Vaessen-Verberne A, Mulder P, Bindels P, van
Aalderen W. Paediatric asthma outpatient care by asthma
nurse, paediatrician or general practitioner: randomised
controlled trial with two-year follow-up. Primary Care
Respiratory Journal 2011;20(1):84–91. [4455508]
Litaker 2003 {published data only}
Litaker D, Mion LC, Planavsky L, Kippes C, Mehta N,
Frolkis J. Physician-nurse practitioner teams in chronic
disease management: the impact on costs, clinical
effectiveness, and patients’ perception of care. Journal of
Interprofessional Care 2003;17(3):223–7. [4455510]
Logan 1979 {published data only}
Logan AG, Milne BJ, Achber C, Campbell WP, Haynes
RB. Work-site treatment of hypertension by specially
trained nurses. A controlled trial. Lancet 1979;2:1175–8.
[4455512]
MacMahon Tone 2009 {published data only}
MacMahon Tone J, Agha A, Sherlock M, Finucane
F, Tormey W, Thompson CJ. An intensive nurse-led,
multi-interventional clinic is more successful in achieving
vascular risk reduction targets than standard diabetes care.
International Journal of Medical Science 2009;178:179–86.
[4455514]
Magid 2013 {published data only}
Magid DJ, Olson KL, Billups SJ, Wagner NM, Lyons EE,
Kroner A. A pharmacist-led American Heart Association
Heart360 web-enabled home blood pressure monitoring
program. Circulation Cardiovascular Quality and Outcomes
2013;6(2):157–63. [4455516]
Margolis 2013 {published data only}
Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen
SE, Kadrmas HM, et al. Effect of home blood pressure
telemonitoring and pharmacist management on blood
pressure control: a cluster randomized clinical trial. JAMA
2013;310(1):46–56. [4455518]
Marotti 2011 {published data only}
Marotti SB, Kerridge RK, Grimer MD. A randomised
controlled trial of pharmacist medication histories and
supplementary prescribing on medication errors in
postoperative medications. Anaesthesia and Intensive Care
2011;39(6):1064–70. [4455520]
McAlister 2014 {published data only}
McAlister FA, Majumdar SR, Padwal RS, Fradette M,
Thompson A, Buck B, et al. Case management for
blood pressure and lipid level control after minor stroke:
PREVENTION randomized controlled trial. Canadian
Medical Association Journal 2014;186:577–84. [4455522]
Moher 2001 {published data only}
Moher M, Yudkin P,Wright L, Turner R, Fuller A, Schofield
T, et al. Cluster randomised controlled trial to compare
three methods of promoting secondary prevention of
coronary heart disease in primary care. BMJ 2001;322:1–7.
[4455524]
New 2003 {published data only}
New JP, Mason JM, Freemantle N, Teasdale S, Wong LM,
Bruce NJ, et al. Specialist nurse-led intervention to treat
and control hypertension and hyperlipidaemia in diabetes
(SPLINT). Diabetes Care 2003;26:2250–5. [4455526]
Pagaiya 2005 {published data only}
Pagaiya N, Garner P. Primary care nurses using guidelines in
Thailand: a randomized controlled trial. Tropical Medicine
& International Health 2005;10(5):471–7. [4455528]
Rudd 2004 {published data only}
Rudd R, Houston Miller N, Kaufman J, Kraemer HC,
Bandura A, Greenwald G, et al. Nurse management for
hypertension. American Journal of Hypertension 2004;17:
921–7. [4455530]
Spitzer 1974 {published data only}
Spitzer WO, Sackett DL, Sibley JC, Roberts RS, Gent M,
Kerigin DJ, et al. The Burlington randomized trial of the
nurse practitioner. New England Journal of Medicine 1974;
290:251–6. [4455532]
Taveira 2010 {published data only}
Taveira T, Friedmann PD, Cohen LB, Dooley AG, Khatana
SAM, Pirraglia PA, et al. Pharmacist-led group medical
appointment model in type 2 diabetes. Diabetes Educator
2010;36(1):109–17. [4455534]
Taveira 2011 {published data only}
Taveira TH, Dooley AG, Cohen LB, Khatana SA, Wu
WC. Pharmacist-led group medical appointments for the
management of type 2 diabetes with comorbid depression in
older adults. Annals of Pharmacotherapy 2011;45:1346–55.
[4455536]
Thompson 1984 {published data only}
Thompson JF, McGhan WF, Ruffalo RL, Cohen DA,
Adamcik B, Segal JL. Clinical pharmacists prescribing drug
therapy in a geriatric setting: outcome of a trial. Journal of
the American Geriatrics Society 1984;32:154–9. [4455538]
Tobe 2006 {published data only}
Tobe S, Pylypchuk G, Wentworth J, Kiss A, Szalai JP,
Perkins N, et al. Effect of nurse-directed hypertension
treatment among First Nations people with existing
hypertension and diabetes mellitus: the Diabetes Risk
Evaluation and Microalbuminuria (DREAM 3) randomised
controlled trial. Canadian Medical Association Journal 2006;
174(9):1267–71. [4455540]
31Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tsuyuki 2015 {published data only}
Tsuyuki RT, Houle SKD, Charrois TL, Kolber MR,
Rosenthal MM, Lewanczuk R, et al. A randomized trial of
the effect of pharmacist prescribing on improving blood
pressure in the community. The Alberta clinical trial in
optimizing hypertension (RxACTION). Circulation 2015;
132(2):93–100. [4455542]
Tsuyuki 2016 {published data only}
Tsuyuki RT, Al Hamarneh YN, Jones CA, Hemmelgarn
BR. The effectiveness of pharmacist interventions on
cardiovascular risk. The multicenter randomized controlled
RxEACH trial. Journal of the American College of Cardiology
2016;67(24):2846–54. [4455544]
Vivian 2002 {published data only}
Vivian EM. Improving blood pressure control in a
pharmacist-managed hypertension clinic. Pharmacotherapy
2002;22(12):1533–40. [4455546]
Wallymahmed 2011 {published data only}
Wallymahmed ME, Morgan C, Gill GV, MacFarlane IA.
Nurse-led cardiovascular risk factor intervention leads to
improvements in cardiovascular risk targets and glycaemic
control in people with Type 1 diabetes when compared with
routine diabetes clinic attendance. Diabetic Medicine 2011;
28:373–9. [4455548]
References to studies excluded from this review
Adler 2004 {published data only}
Adler DA, Bungay KM, Wilson IB, Pei Y, Supran S,
Peckham E, et al. The impact of a pharmacist intervention
on 6-month outcomes in depressed primary care
patients. General Hospital Psychiatry 2004;26(3):199–209.
[4455550]
Akrimi 2013 {published data only}
Akrimi S, Lasrado M. Nurse-led heart failure clinic as an
effective strategy for patient review and up-titration of heart
failure medication within primary care. European Journal of
Heart Failure 2013;12 Suppl 1:S1–380. [4455552]
Ala 2011 {published data only}
Ala L, Bird D, Barry R, Rathbone N. Maintenance of
INR consistency during the initiation of warfarin. Nurse
Prescribing 2011;9:599–601. [4455554]
Al Hamareneh 2013 {published data only}
Al Hamarneh YN, Charrois T, Lewanczuk R, Tsuyuki
RT. Pharmacist intervention for glycaemic control in
the community (the RxINGstudy). BMJ Open 2013;
3:e003154. [4455556; DOI: 10.1136/bmjopen-2013-
003154]
Amariles 2012 {published data only}
Amariles P, Sabater-Hernandez D, Garcia-Jimenez E,
Rodriguez-Chamorro MA, Prats-Mas R, Marin-Magan F,
et al. Effectiveness of Dader Method for pharmaceutical
care on control of blood pressure and total cholesterol in
outpatients with cardiovascular disease or cardiovascular
risk: EMDADER-CV randomized controlled trial. Journal
of Managed Care Pharmacy 2012;18(4):311–23. [4455558]
Anaya 2008 {published data only}
Anaya JP, Rivera JO, Lawson K, Garcia J, Luna J Jr, Ortiz M.
Evaluation of pharmacist-managed diabetes mellitus under
a collaborative drug therapy agreement. American Journal of
Health-System Pharmacy 2008;65:1841–5. [4455560]
Andrus 2007 {published data only}
Andrus MR, Clark DB. Provision of pharmacotherapy
services in a rural nurse practitioner clinic. American Journal
of Health-System Pharmacy 2007;64:294–7. [4455562]
Bajorek 2005 {published data only}
Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield
GM. Optimizing the use of antithrombotic therapy
for atrial fibrillation in older people: a pharmacist-led
multidisciplinary intervention. Journal of the American
Geriatrics Society 2005;53:1912–20. [4455564]
Bajorek 2016 {published data only}
Bajorek B. Implementation and evaluation of a pharmacist-
led hypertension management service in primary care:
outcomes and methodological challenges. Pharmacy Practice
2016;14:723. [4455566]
Bebb 2007 {published data only}
Bebb C, Kendrick D, Coupland C, Madeley R, Stewart J,
Brown K, et al. A cluster randomised controlled trial of the
effect of a treatment algorithm for hypertension in patients
with type 2 diabetes. British Journal of General Practice
2007;57:136–43. [4455568]
Becker 1998 {published data only}
Becker DM, Raqueno JV, Yook RM, Kral BG, Blumenthal
RS, Moy TF, et al. Nurse-mediated cholesterol management
compared with enhanced primary care in siblings of
individuals with premature coronary disease. Archives of
Internal Medicine 1998;158:1533–9. [4455570]
Bellary 2008 {published data only}
Bellary S, O’Hare JP, Raymond NT, Gumber A, Mughal
S, Szczepura A, et al. Enhanced diabetes care to patients
of south Asian ethnic origin (the United Kingdom Asian
Diabetes Study): a cluster randomised controlled trial.
Lancet 2008;371:1769–76. [4455572]
Birchall 2011 {published data only}
Birchall A, Barnett D, Buckley N, Drewry K, O’Toole
L, Al-Mohammad A. Optimum or maximum, that is
the question: A retrospective analysis of pharmacological
therapy achieved in a hospital based, nurse led heart failure
clinic. European Heart Journal 2011;32(Suppl 1):4410.
[4455574]
Blackberry 2014 {published data only}
Blackberry ID, Furler JS, Ginnivan LE, Manski-Nankervis
J-A, Jenkins A, Cohen N, et al. An exploratory trial of
basal and prandial insulin initiation and titration for type
2 diabetes in primary care with adjunct retrospective
continuous glucose monitoring: INITIATION study.
Diabetes Research and Clinical Practice 2014;106:247–55.
[4455576]
Blozik 2010 {published data only}
Blozik E, Born AM, Stuck AE, Benninger U, Gillmann G,
Clough-Gorr KM. Reduction of inappropriate medications
32Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
among older nursing-home residents: a nurse-led, pre/post-
design, intervention study. Drugs & Aging 2010;27(12):
1009–17. [4455578]
Brook-Barclay 2014 {published data only}
Brook-Barclay L, Delaney CL, Scicchitano M, Quinn S,
Spark JI. Pharmacist influence on prescribing in peripheral
arterial disease (PIPER). Vascular Medicine 2014;19:
118–24. [4455580]
Bruggink-Andre de la Porte 2007 {published data only}
Bruggink-Andre de la Porte PWF, Lok DJA, van Veldhuisen
DJ, van Wijngaarden J, Cornel JH, Zuithoff NPA, et al.
Added value of a physician-and-nurse-directed heart failure
clinic: results from the Deventer-Alkmaar heart failure
study. Heart 2007;93:819–25. [4455582; DOI: 10.1136/
hrt.2006.095810]
Capoccia 2004 {published data only}
Capoccia KL, Boudreau DM, Blough DK, Ellsworth
AJ, Clark DR, Stevens NH, et al. Randomized trial of
pharmacist interventions to improve depression care and
outcomes in primary care. American Journal of Health-
System Pharmacy 2004;61:364–72. [4455584]
Carey 2008 {published data only}
Carey N, Courtenay M, James J, Hills M, Roland J. An
evaluation of a Diabetes Specialist Nurse prescriber on the
system of delivering medicines to patients with diabetes.
Journal of Clinical Nursing 2008;17:1635–44. [4455586]
Carter 2001 {published data only}
Carter BL, Malone DC, Billups SJ, Valuck RJ, Barnette
DJ, Sintek CD, et al. Interpreting the findings of the
IMPROVE study. American Journal of Health-System
Pharmacy 2001;58(14):1330–7. [4455588]
Carter 2008 {published data only}
Carter BL, Bergus GR, Dawson J, Farris KB, Doucette
WR, Chrischilles EA, et al. A cluster randomized trial to
evaluate physician/pharmacist collaboration to improve
blood pressure control. Journal of Clinical Hypertension
2008;10:260–71. [4455590]
Carter 2015 {published data only}
Carter BL, Vander Weg MW, Parker CP, Goedken
CC, Richardson KK, Rosenthal GE. Sustained blood
pressure control following discontinuation of a pharmacist
intervention for Veterans. Journal of Clinical Hypertension
2015;17:9. [4455592; DOI: 10.1111/jch.12577]
Cattell 2001 {published data only}
Cattell R, Conroy C, Sheikh A. Pharmacist integration into
the discharge process: A qualitative and quantitative impact
assessment. International Journal of Pharmacy Practice 2001;
9:59–64. [4455594]
Chantelois 2003 {published data only}
Chantelois EP, Suzuki NT. A pilot program comparing
physician- and pharmacist-ordered discharge medications
at a Veterans Affairs medical center. American Journal of
Health-System Pharmacy 2003;60:1652–6. [4455596]
Cheng 2014 {published data only}
Cheng JWM, Cooke-Ariel H. Pharmacists’ role in the care
of patients with heart failure: Review and future evolution.
Journal of Managed Care Pharmacy 2014;20:206–13.
[4455598]
Chiquette 1998 {published data only}
Chiquette, E, Amato MG, Bussey HI. Comparison of an
anticoagulation clinic with usual medical care. Archives of
Internal Medicine 1998;158:1641–7. [4455600]
Courtenay 2007 {published data only}
Courtenay M, Carey N, James J, Hills M, Roland J. An
evaluation of a specialist nurse prescriber on diabetes in-
patient service delivery. Practical Diabetes International
2007;24:69–74. [4455602]
Dawson 2012 {published data only}
Dawson T, Godley P, Tabor TA, Suh K, Megan C. Diabetes
medication management program: Impact of pharmacists
on management of oral hypoglycemic medications. Annual
Meeting of the American College of Clinical Pharmacy,
ACCP; 2012 Oct 21-24; Hollywood (FL), United States.
2012:32–e274. [4455604]
Dean 2014 {published data only}
Dean SC, Kerry SM, Khong TK, Kerry SR, Oakeshott
P. Evaluation of a specialist nurse-led hypertension clinic
with consultant backup in two inner city general practices:
randomized controlled trial. Family Practice 2014;31(2):
172–9. [4455606]
deClifford 2009 {published data only}
deClifford JM, Lam SS, Leung BK. Evaluation of a
pharmacist-initiated E-script transcription service for
discharged patients. Journal of Pharmacy Practice and
Research 2009;39:39–42. [4455608]
Dierick-van Daele 2010 {published data only}
Dierick-van Daele AT, Steuten LM, Metsemakers JF, Derckx
EW, Spreeuwenberg C, Vrijhoef HJ. Economic evaluation
of nurse practitioners versus GPs in treating common
conditions. British Journal of General Practice 2010;60:
e28–35. [4455610]
Driscoll 2014 {published data only}
Driscoll A, Srivastava P, Toia D, Gibcus J, Hare DL. A
nurse-led up titration clinic improves chronic heart failure
optimisation of beta-adrenergic receptor blocking therapy
in patients with CHF - a randomized controlled trial. BMC:
Research Notes 2014;7:668. [4455612; DOI: 10.1186/
1756-0500-7-668]
Ginson 2000 {published data only}
Ginson SH, Malmberg C, French DJ. Impact on
vaccination rates of a pharmacist-initiated influenza and
pneumococcal vaccination program. Canadian Journal of
Hospital Pharmacy 2000;53:270–5. [4455614]
Gray 1985 {published data only}
Gray DR, Garabedian-Ruffalo SM, Chretien SD.
Cost-justification of a clinical pharmacist-managed
anticoagulation clinic. Drug Intelligence and Clinical
Pharmacy 1985;19:575–80. [4455616]
Guder 2015 {published data only}
Guder G, Stork S, Gelbrich G, Brenner S, Deubner
N, Morbach C, et al. Nurse-coordinated collaborative
33Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
disease management improves the quality of guideline-
recommended heart failure therapy, patient-reported
outcomes, and left ventricular remodelling. European
Journal of Heart Failure 2015;17:442–52. [4455618; DOI:
10.1002/ejhf.252]
Hale 2013 {published data only}
Hale AR, Coombes ID, Stokes J, McDougall D, Whitfield
K, Maycock E, et al. Perioperative medication management:
expanding the role of the preadmission clinic pharmacist in
a single centre, randomised controlled trial of collaborative
prescribing. BMJ Open 2013;3(7):2013. [4455620]
Hancock 2012 {published data only}
Hancock HC, Close H, Mason JM, Murphy JJ, Fuat A,
de Belber M, et al. Feasibility of evidence-based diagnosis
and management of heart failure in older people in care: a
pilot randomised controlled trial. BMC Geriatrics 2012;12:
70–80. [4455622]
Harrison 2014 {published data only}
Harrison J, Shaw JP, Harrison JE. Anticoagulation
management by community pharmacists in New Zealand:
an evaluation of a collaborative model in primary care.
International Journal of Pharmacy Practice 2015;23(3):
173–81. [4455624]
Hawkins 1979 {published data only}
Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC.
Evaluation of a clinical pharmacist in caring for hypertensive
and diabetic patients. American Journal of Hospital Pharmacy
1979;36:1321–5. [4455626]
Hick 2001 {published data only}
Hick HL, Deady PE, Wright DJ, Silcock J. The impact
of the pharmacist on an elective general surgery pre-
admission clinic. Pharmacy World & Science 2001;23(2):
65–9. [4455628]
Ho 2014 {published data only}
Ho PM, Lambert-Kerzner A, Carey EP, Fahdi IE, Bryson
CL, Melnyk SD, et al. Multifaceted intervention to
improve medication adherence and secondary prevention
measures after acute coronary syndrome hospital discharge:
a randomized clinical trial. JAMA Internal Medicine
2014;174(2):186–93. [4455630; DOI: 10.10001/
jamainternmed.1013.12944]
Holland 2007 {published data only}
Holland R, Brooksby I, Lenaghan E, Ashton K, Hay L,
Smith R, et al. Effectiveness of visits from community
pharmacists for patients with heart failure: HeartMed
randomised controlled trial. BMJ 2007;334:1098.
[4455632]
Hotu 2010 {published data only}
Hotu C, Bagg W, Collins J, Harwood L, Whalley G,
Doughty R, et al. A community-based model of care
improves blood pressure control and delays progression
of proteinuria, left ventricular hypertrophy and diastolic
dysfunction in Maori and Pacific patients with type
2 diabetes and chronic kidney disease: a randomized
controlled trial. Nephrology, Dialysis, Transplantation 2010;
25(10):3260–6. [4455634]
Irewall 2015 {published data only}
Irewall AL, Ogren J, Bergstrom L, Laurell K, Soderstrom L,
Mooe T. Nurse-led, telephone-based, secondary preventive
follow-up after stroke or transient ischemic attack improves
blood pressure and LDL cholesterol: results from the first 12
months of the randomized controlled NAILED stroke risk
factor trial. PLoS One 2015;10(10):e0139997. [4455636;
DOI: 10.1371/journal.pone.0139997]
Irons 2002 {published data only}
Irons BK, Lenz RJ, Anderson SL, Wharton BL, Habeger
B, Anderson HG Jr. A retrospective cohort analysis of the
clinical effectiveness of a physician-pharmacist collaborative
drug therapy management diabetes clinic. Pharmacotherapy
2002;22:1294–300. [4455638]
Jacobs 2005 {published data only}
Jacobs JT. Treatment of depressive disorders in split versus
integrated therapy and comparisons of prescriptive practices
of psychiatrists and advanced practice registered nurses.
Archives of Psychiatric Nursing 2005;19:256–63. [4455640]
Jameson 2010 {published data only}
Jameson JP, Baty PJ. Pharmacist collaborative management
of poorly controlled diabetes mellitus: a randomized
controlled trial. American Journal of Managed Care 2010;
16:250–5. [4455642]
Jennings 2012 {published data only}
Jennings BT, McAdam Marx C. Implementation of a
pharmacist-managed diabetes program. American Journal of
Health-System Pharmacy 2012;69:1951–3. [4455644]
Jewell 1988 {published data only}
Jewell D, Hope J. Evaluation of a nurse-run hypertension
clinic in general practice. Practitioner 1988;232:484–7.
[4455646]
Jorstad 2013 {published data only}
Jorstad H, von Birgelen C, Alings AMW, Liem A, van
Dantzig JM, Jaarsma W, et al. Effect of a nurse-coordinated
prevention programme on cardiovascular risk after an
acute coronary syndrome: main results of the RESPONSE
randomised trial. Heart 2013;99:1421–30. [4455648]
Kinnersley 2000 {published data only}
Kinnersley P, Anderson E, Parry K, Clement J, Archard
L, Turton P, et al. Randomised controlled trial of nurse
practitioner versus general practitioner care for patients
requesting ’same day’ consultations in primary care. BMJ
2000;320:1043–8. [4455650]
Krein 2004 {published data only}
Krein SL, Klamerus ML, Vijan S, Lee JL, Fitzgerald JT,
Pawlow A, et al. Case management for patients with poorly
controlled diabetes: a randomized trial. American Journal of
Medicine 2004;116(11):732–9. [4455652]
Kwan 2007 {published data only}
Kwan Y, Fernandes OA, Nagge JJ, Wong GG, Huh J-H,
Hurn DA, et al. Pharmacist medication assessments in a
surgical preadmission clinic. Archives of Internal Medicine
2007;167:1034–40. [4455654]
34Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lin 2012 {published data only}
Lin HW, Lin CH, Chang CK, Yu IW, Lin CC, Li TC, et
al. PHP36 Economic, clinical and humanistic outcomes of
a collaborative pharmacist-physician medication therapy
management service for polypharmacy elderly. Value in
Health 2012;15(4):A24. [4455656]
Logan 1983 {published data only}
Logan AG, Milne BJ, Flanagan PT, Haynes RB. Clinical
effectiveness and cost-effectiveness of monitoring blood
pressure of hypertensive employees at work. Hypertension
1983;5(6):828–36. [4455658]
Lowey 2007 {published data only}
Lowey A,Moore S, Norris C,Wright D, Silock J, Hammond
P. The cost-effectiveness of a pharmacist-led treatment of
cardiac risk in patients with type 2 diabetes. Pharmacy and
World Science 2007;29:541–5. [4455660]
Lowrie 2012 {published data only}
Lowrie R, Mair FS, Greenlaw N, Forsyth P, Jhund PS,
McConnachie A, et al. Pharmacist intervention in primary
care to improve outcomes in patients with left ventricular
systolic dysfunction. European Heart Journal 2012;33:
314–24. [4455662]
Lowrie 2014 {published data only}
Lowrie R, Lloyd SM, McConnachie, Morrison J. A
cluster randomised controlled trial of a pharmacist-led
collaborative intervention to improve statin prescribing and
attainment of cholesterol targets in primary care. PLoS
One 2014;9(11):e113370. [4455664; DOI: 10.1371/
journal.pone.0113370]
Ma 2010 {published data only}
Ma A, Chen DM, Chau FM, Saberi P. Improving adherence
and clinical outcomes through an HIV pharmacist’s
interventions. AIDS Care 2010;22(10):1189–94.
[4455666]
Martinez 2013 {published data only}
Martinez AS, Saef J, Paszczuk A, Bhatt-Chugani H.
Implementation of a pharmacist-managed heart failure
medication titration clinic. American Journal of Health-
System Pharmacy 2013;70:1070–6. [4455668]
McAdam-Marx 2012 {published data only}
McAdam-Marx C, Jennings BT, Dahal A, Gunning
K. Pharmacist-led diabetes collaborative drug therapy
management program improves glycemic control in patients
with uncontrolled type 2 diabetes treated with insulin.
Annual Meeting of the American College of Clinical
Pharmacy, ACCP; 2012 Oct 21-24: Hollywood (FL),
United States. 2012. [4455670]
McCord 2006 {published data only}
McCord AD. Clinical impact of a pharmacist-managed
diabetes mellitus drug therapy management service.
Pharmacotherapy 2006;26:248–53. [4455672]
McFadzean 2003 {published data only}
McFadzean E, Isles C, Moffat J, Norrie J, Stewart D. Is there
a role for a prescribing pharmacist in preventing prescribing
errors in a medical admission unit?. Pharmaceutical Journal
2003;270:896–9. [4455674]
McGhan 1983 {published data only}
McGhan WF, Stimmel GL, Hall TG, Gilman TM. A
comparison of pharmacists and physicians on the quality of
prescribing for ambulatory hypertensive patients. Medical
Care 1983;21:435–44. [4455676]
McGowan 2008 {published data only}
McGowan N, Cockburn A, Strachan MWJ, Padfield PL,
McKnight JA. Initial and sustained cardiovascular risk
reduction in a pharmacist-led diabetes cardiovascular risk
clinic. British Journal of Diabetes and Vascular Disease 2008;
8:34–8. [4455678]
Meulepas 2008 {published data only}
Meulepas MA, Braspenning JCC, de Grauw WJ, Lucas
AEM,Wijkel D, Grol RPTM. Patient-oriented intervention
in addition to centrally organised checkups improves
diabetic patient outcome in primary care. Quality and Safety
in Health Care 2008;17:324–8. [4455680]
Michalets 2015 {published data only}
Michalets E, Creger J, Shillinglaw WR. Outcomes of
expanded use of clinical pharmacist practitioners in addition
to team-based care in a community health system intensive
care unit. American Journal of Health-System Pharmacy
2015;72:47–53. [4455682]
Monyatsi 2012 {published data only}
Monyatsi G, Mullan PC, Phelps BR, Tolle MA, Machine
EM, Gennari FF, et al. HIV management by nurse
prescribers compared with doctors at a paediatric centre in
Gaborone, Botswana. South African Medical Journal 2012;
102:34–7. [4455684]
Morello 2013 {published data only}
Morello CM, Bechtold A, Hirsch JD. Clinical outcomes
following discharge from a pharmacist-led diabetes intense
medical management clinic. Seventy-third Scientific Session
of the American Diabetes Association; 2013 June 21-25;
Chicago (IL), United States. 2013:62–A314. [4455686]
Murphy 2010 {published data only}
Murphy G, Daly M, Ryan J, Shanahan F, Harney S, Michael
M. Comparison of physician-and nurse prescriber-led dose
adjustment of DMARD therapy in RA. American College
of Rheumatology/Association of Rheumatology Health
Professionals Annual Scientific Meeting ACR/ARHP 10;
2009 Oct 16-21; Philadelphia (PA) United States. 2010:62.
[4455688]
Neto 2011 {published data only}
Neto PR, Marusic S, de Lyra Junior DP, Pilger D, Cruciol-
Souza JM, et al. Effect of a 36-month pharmaceutical
care program on the coronary heart disease risk in elderly
diabetic and hypertensive patients. Journal of Pharmacy &
Pharmaceutical Sciences 2011;14:249–63. [4455690]
Norman 2010 {published data only}
Norman IJ, Coster S, McCrone P, Sibley A, Whittlesea C. A
comparison of the clinical effectiveness and costs of mental
health nurse supplementary prescribing and independent
medical prescribing: a post-test control group study. BMC
Health Services Research 2010;10:4. [4455692]
35Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
O’Hare 2004 {published data only}
O’Hare JP, Raymond NT, Mughal S, Dodd L, Hanif
W, Ahmad Y, et al. Evaluation of delivery of enhanced
diabetes care to patients of South Asian ethnicity: the
United Kingdom Asian Diabetes Study (UKADS). Diabetic
Medicine 2004;21:1357–65. [4455694]
Obreli-Neto 2011 {published data only}
Obreli-Neto PR, Guidoni CM, Oliveira Baldoni A, Pilger
D, Cruciol-Souza JM, Gaeti-FrancoWP, et al. Effect of a 36-
month pharmaceutical care program on pharmacotherapy
adherence in elderly diabetic and hypertensive patients.
International Journal of Clinical Pharmacy 2011;33:642–9.
[4455696]
Omran 2013 {published data only}
Omran D, Majumdar SR, Johnson JA, Tsuyuki RT,
Lewanczuk RZ, Guirguis LM, et al. Effect of adding
pharmacists to primary care teams on medication
management and adherence to achieve blood pressure
control in patients with type 2 diabetes. Sixteenth Annual
Canadian Diabetes Association/Canadian Society of
Endocrinology and Metabolism Professional Conference
and Annual Meetings; 2013 Oct 17-19; Montreal (QC)
Canada. 2013:37. [4455698]
Omran 2015 {published data only}
Omran D, Majumdar SR, Johnson JA, Tsuyuki RT,
Lewanczuk RZ, Guirguis LM, et al. Pharmacists on
primary care team: effect on antihypertensive medication
management in patients with type 2 diabetes. Journal
of the American Pharmacists Association 2015;55:265–8.
[4455700]
Pape 2011 {published data only}
Pape GA, Hunt JS, Butler KL, Siemienczuk J, LeBlanc
BH, Gillanders W, et al. Team-based care approach to
cholesterol management in diabetes mellitus: 2-Year cluster
randomized controlled trial. Archives of Internal Medicine
2011;171:1480–6. [4455702]
Payton 2011 {published data only}
Payton H, Jaques N, Lacey F, Marriott J. Evaluating the
clinical impact of a pharmacist-led diabetes outpatient
clinic. Royal Pharmaceutical Society Conference; 2011 Sept
11-12; London, United Kingdom. 2011:19. [4455704]
Reid 2005 {published data only}
Reid F, Murray P, Storrie M. Implementation of a
pharmacist-led clinic for hypertensive patients in primary
care - a pilot study. Pharmacy World Science 2005;27:202–7.
[4455706]
Rochester 2010 {published data only}
Rochester CD, Leon N, Dombrowski R, Haines ST.
Collaborative drug therapy management for initiating and
adjusting insulin therapy in patients with type 2 diabetes
mellitus. American Journal of Health-System Pharmacy 2010;
67:42–8. [4455708]
Rothman 2005 {published data only}
Rothman RL, Malone R, Bryant B, Shintani AK, Crigler
B, Dewait DA, et al. A randomized trial of a primary
care-based disease management program to improve
cardiovascular risk factors and glycated hemoglobin levels in
patients with diabetes. American Journal of Medicine 2005;
118:276–84. [4455710]
Rudd 2010 {published data only}
Rudd KM, Dier JG. Comparison of two different models
of anticoagulation management services with usual medical
care. Pharmacotherapy 2010;30(4):330–8. [4455712]
Sadik 2005 {published data only}
Sadik A, Yousif M, McElnay JC. Pharmaceutical care
of patients with heart failure. British Journal of Clinical
Pharmacology 2005;60:183–93. [4455714]
Samtia 2013 {published data only}
Samtia AM, Rasool MF, Ranjha NM, Usman F, Javed
I. A multifactorial intervention to enhance adherence to
medications and disease-related knowledge in type 2 diabetic
patients in Southern Punjab, Pakistan. Tropical Journal of
Pharmaceutical Research 2013;12:851–6. [4455716]
Sanne 2010 {published data only}
Sanne I, Orrell C, Fox MP, Conradie F, Ive P, Zeinecker J,
et al. Nurse versus doctor management of HIV-infected
patients receiving antiretroviral therapy (CIPRA-SA): a
randomised non-inferiority trial. Lancet 2010;376:33–40.
[4455718]
Schneider 1982 {published data only}
Schneider PJ, Larrimer JN, Visconti JA, Miller WA.
Role effectiveness of a pharmacist in the maintenance of
patients with hypertension and congestive heart failure.
Contemporary Pharmacy Practice 1982;5:74–9. [4455720]
Scullin 2007 {published data only}
Scullin C, Scott MG, Hogg A, McElnay JC. An innovative
approach to integrated medicines management. Journal of
Evaluation in Clinical Practice 2007;13:781–8. [4455722]
Sease 2011 {published data only}
Sease JM, Blake EW, Gowan M, Shealy KM. Evaluation
of anticoagulation management and chronic disease
state control in a pharmacist-run pharmacotherapy/
anticoagulation clinic. Journal of Pharmacy Technology
2011;27:3–8. [4455724]
Seng 2011 {published data only}
Seng Tan P, Thomas PT, Chua SS. Clinical outcomes
of pharmacist-managed diabetes clinic in Malaysia.
Seventy-first Scientific Sessions of the American Diabetes
Association; 2011 June 24-28; San Diego (CA), United
States. 2011:60. [4455726]
Shum 2000 {published data only}
Shum C, Humphreys A, Wheeler D, Cochrane M-A,
Skoda S, Clement S. Nurse management of patients with
minor illnesses in general practice: multicentre, randomised
controlled trial. BMJ 2000;320:1038–43. [4455728]
Simpson 2011 {published data only}
Simpson SH, Lewanczuk RZ, Majumdar SR, Spooner R,
Tsuyuki RT, Johnson JA. Effect of adding pharmacists to
primary care teams on blood pressure control in patients
with type 2 diabetes. Diabetes Care 2011;34:20–6.
[4455730]
36Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sisk 2006 {published data only}
Sisk JE, Hebert PL, Horowitz CR, McLaughlin MA, Wang
JJ, Chassin MR. Effects of nurse management on the quality
of heart failure care in minority communities. Annals of
Internal Medicine 2006;145:273–83. [4455732]
Solomon 1998 {published data only}
Solomon DK, Portner TS, Bass GE, Gourley DR, Gourley
GA, Holt JM, et al. Clinical and economic outcomes in the
hypertension and COPD arms of a multicenter outcomes
study. Journal of the American Pharmaceutical Association
1998;38:574–85. [4455734]
Sonnex 2014 {published data only}
Sonnex K, Murphy A. Pharmacist inclusion in the multi-
disciplinary team reduces hospital admissions due to COPD
exacerbations. Health Services Research and Pharmacy
Practice Conference, HSRPP; April 3-4; Aberdeen, United
Kingdom. 2014:22. [4455736]
Stafford 2011 {published data only}
Stafford L, Peterson GM, Bereznicki LRE, Jackson SL.
Clinical outcomes of a pharmacist-led post-discharge
warfarin management service. Eleventh National
Conference on Anticoagulant Therapy; 2011 May 5-7;
Boston (MA), United States. 2011:31. [4455738]
Stone 2010 {published data only}
Stone RA, Rao RH, Sevick MA, Cheng C, Hough LJ,
Macpherson DS, et al. Active care management supported
by home telemonitoring in veterans with type 2 diabetes.
Diabetes Care 2010;33(3):478–84. [4455740]
Stromberg 2003 {published data only}
Stromberg A, Martensson J, Fridlund B, Levin L-A,
Karlsson JE, Dahlstrom U. Nurse-led heart failure clinics
improve survival and self-care behaviour in patients with
heart failure: results from a prospective, randomised trial.
European Heart Journal 2003;24:1014–23. [4455742;
DOI: 10.1016/SO195-668X(03)00112-X]
Tahaineh 2011 {published data only}
Tahaineh L, Albsoul-Younes A, Al-Ashqar E, Habeb A. The
role of a clinical pharmacist on lipid control in dyslipidemic
patients in North of Jordon. International Journal of Clinical
Pharmacy 2011;33:229–36. [4455744]
Taveira 2006 {published data only}
Taveira TH, Wu WC, Martin OJ, Schleinitz MD,
Friedmann P, Sharma SC. Pharmacist-led cardiac risk
reduction model. Preventive Cardiology 2006;9:202–8.
[4455746]
Till 2003 {published data only}
Till LT, Voris JC, Horst JB. Assessment of clinical
pharmacist management of lipid-lowering therapy in a
primary care setting. Journal of Managed Care Pharmacy
2003;9:269–73. [4455748]
To 2011 {published data only}
To L, Schillig JM, DeSmet BD, Kuriakose P, Szandzik
EG, Kalus JS. Impact of a pharmacist-directed
anticoagulation service on the quality and safety of heparin-
induced thromobocytopenia management. Annals of
Pharmacotherapy 2011;45:195–200. [4455750]
Vaisberg 2013 {published data only}
Vaisberg E, Moreno G, Tseng CH, Bell D, Clarke R, Wong
S, et al. Managing your medication for education and daily
support: The value of a clinical pharmacist in primary care
practices to improve diabetes care. Thirty-sixth Annual
Meeting of the Society of General Internal Medicine,
SGIM; 2013 April 24-27; Denver (CO), United States.
2013:28–S119. [4455752]
Vasileff 2009 {published data only}
Vasileff HM,Whitten LE, Pink JA, Goldsworthy SJ, Angley
MT. The effect on medication errors of pharmacists charting
medication in an emergency department. Pharmacy and
World Science 2009;31:373–9. [4455754]
Venning 2000 {published data only}
Venning P, Durie A, Roland M, Roberts C, Leese B.
Randomised controlled trial comparing cost effectiveness of
general practitioners and nurse practitioners in primary care.
BMJ (Clinical Research Ed) 2000;320:1048–53. [4455756]
Verret 2012 {published data only}
Verret L, Couturier J, Rozon A, Saudrais-Janecek S, St-Onge
A, Nguyen A, et al. Impact of a pharmacist-led warfarin self-
management program on quality of life and anticoagulation
control: a randomized trial. Pharmacotherapy 2012;32:
871–9. [4455758]
Voogdt-Pruis 2011 {published data only}
Voogdt-Pruis HR, Ree JW, Gorgels AP, Beusmans GH.
Adherence to a guideline on cardiovascular prevention:
A comparison between general practitioners and practice
nurses. International Journal of Nursing Studies 2011;48:
798–807. [4455760]
Warrington 2012 {published data only}
Warrington L, Ayers P, Baldwin AM, Wallace V, Riche
KD, Saulters R, et al. Implementation of a pharmacist-led,
multidisciplinary diabetes management team. American
Journal of Health-System Pharmacy 2012;69:1240–5.
[4455762]
Weigel 2012 {published data only}
Weigel R, Feldacker C, Tweya H, Chiwoko J, Gumulira J,
Phiri S. Nurse-led antiretroviral treatment for HIV infected
children: A comparative study from Lilongwe, Malawi.
Annual Conference of the Royal College of Paediatrics and
Child Health, RCPCH; 2012 May 22-24; Glasgow, United
Kingdom. 2012:97–A45. [4455764]
Wilson 2003 {published data only}
Wilson SJ-A, Wells PS, Kovacs MJ, Lewis GM, Martin J,
Burton E, et al. Comparing the quality of oral anticoagulant
management by anticoagulation clinics and by family
physicians: A randomised controlled trial. Canadian
Medical Association Journal 2003;169(4):293–8. [4455766]
Wittayanukorn 2013 {published data only}
Wittayanukorn S, Westrick SC, Hansen RA, Billor
N, Braxton-Lloyd K, Fox BI, et al. Evaluation of
medication therapy management services for patients with
cardiovascular disease in a self-insured employer health
plan. Journal of Managed Care Pharmacy 2013;19:385–95.
[4455768]
37Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wood 2008 {published data only}
Wood DA, Kotseva K, Connolly S, Jennings C, Mead A,
Jones J, et al. Nurse-coordinated multidisciplinary, family-
based cardiovascular disease prevention programme for
patients with coronary heart disease and asymptomatic
individuals at high risk of cardiovascular disease: a paired,
cluster-randomised controlled trial. Lancet 2008;371
(9629):1999–2012. [4455770]
Zimmerman 2014 {published data only}
Zimmerman AW, Morello CM, Hirsch JD. Cost avoidance
associated with a pharmacist-CDE led diabetes intense
medical management and education clinic. Seventy-fourth
Scientific Sessions of the American Diabetes Association;
2014 June 13-17; San Francisco (CA), United States. 2014:
63. [4455772]
References to studies awaiting assessment
Barton 2013 {published data only}
Barton GR, Fairall L, Bachmann MO, Uebel K,
Timmerman V, Lombard C, et al. Cost-effectiveness of
nurse-led versus doctor-led antiretroviral treatment in
South Africa: pragmatic cluster randomised trial. Tropical
Medicine and International Health 2013;18(6):769–77.
[4455774]
Neilson 2015 {published data only}
Neilson AR, Bruhn H, Bond CM, Elliott AM, Smith BH,
Hannaford PC, et al. Pharmacist-led management of
chronic pain in primary care: costs and benefits in a pilot
randomised controlled trial. BML Open 2015;5:e006874.
[4455776; DOI: 10.1136/bmjopen-2014-006874]
Tsuyuki 2014 {published data only}
Tsuyuki RT, Rosenthal MM, Pearson GJ. Improving
dyslipidemia management in the community: A
randomized trial of pharmacist prescribing, The RxACT
study. Canadian Journal of Cardiology 2014;30(10):S118–9.
[4455778]
References to ongoing studies
Mikuls 2015 {published data only}
Mikuls TR, Cheetham TC, Rashid N, Levy GD, Kerimian
A, Low KJ, et al. A pragmatic cluster-randomized controlled
trial of an automated, pharmacy-based intervention
to optimize allopurinol therapy in gout. Arthritis and
Rheumatology 2015;67:Suppl 10. [4455780]
Additional references
Atkins 2004
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y,
Flottorp Y, et al. GRADEWorking Group. Grading quality
of evidence and strength of recommendations. BMJ 2004;
328(7454):1490.
Bhanbhro 2011
Bhanbhro S, Drennan VM, Grant R, Harrios R. Assessing
the contribution of prescribing in primary care by nurses
and professionals allied to medicine: a systematic review of
literature. BMC Health Services Research 2011;11:330.
Bissell 2008
Bissell P, Cooper R, Guillaume L, Anderson C, Avery A,
Hutchinson A, et al. An evaluation of supplementary
prescribing in nursing and pharmacy. Final report for
the Department of Health. Research Report. University
of Sheffield. www.shef.ac.uk/polopoly˙fs/1.43225!/file/
Supplementary˙prescribing.pdf (accessed 3 November
2012).
Clark 2010
Clark CE, Smith LFP, Taylor RS, Campbell JL. Nurse led
interventions to improve control of blood pressure in people
with hypertension: systematic review and meta-analysis.
BMJ 2010;341:c3995. [DOI: 10.1136/bmj.c3995]
Cochrane EPOC Group 2013a
Cochrane Effective Practice and Organisation of Care
Group. Cochrane Effective Practice and Organisation
of Care (EPOC). Data collection form. EPOC
Resources for review authors. Oslo: Norwegian
Knowledge Centre for the Health Services; 2013.
epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/
13%20Data%20extraction%20and%20management%202013%2008%2012˙1.pdf
(accessed prior to 21 September 2016).
Cochrane EPOC Group 2013b
Cochrane Effective Practice and Organisation of Care
Group. Effective Practice and Organisation of Care
(EPOC). Data extraction and management. EPOC
Resources for review authors. Oslo: Norwegian
Knowledge Centre for the Health Services; 2013.
epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/
13%20Data%20extraction%20and%20management%202013%2008%2012˙1.pdf
(accessed prior to 21 September 2016).
Cochrane EPOC Group 2015
Cochrane Effective Practice and Organisation of Care
Group. Effective Practice andOrganisation ofCare (EPOC).
Suggested risk of bias criteria for EPOC reviews. EPOC
Resources for review authors. Oslo: Norwegian Knowledge
Centre for the Health Services; 2015. epoc.cochrane.org/
sites/epoc.cochrane.org/files/uploads/14%20Sug-
gested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews%202015%200
(accessed prior to 21 September 2016).
Cooper 2008
Cooper R, Guillaume L, Avery T, Anderson C, Bissell P,
Hutchinson A, et al. Nonmedical prescribing in the United
Kingdom Development and stakeholder Interests. Journal
of Ambulatory Care Management 2008;31(3):244–52.
Department of Health 1999
Department of Health. Review of prescribing, supply
and administration of medicines (the Crown Report).
webarchive.nationalarchives.gov.uk/20130107105354/http:
/www.dh.gov.uk/prod˙consum˙dh/groups/dh˙digitalassets/
@dh/@en/documents/digitalasset/dh˙4077153.pdf
(accessed 3 November 2012).
38Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Department of Health 2003
Department of Health. Supplementary prescribing by
nurses and pharmacists within the NHS in England. A guide
for implementation. webarchive.nationalarchives.gov.uk/+/
www.dh.gov.uk/en/Publicationsandstatistics/Publications/
PublicationsPolicyAndGuidance/DH˙4009717 (accessed 3
November 2012).
Department of Health 2006
Department of Health. Improving patients’ access to
medicines: A guide to implementing nurse and pharmacist
independent prescribing within the NHS in England.
April 2006. webarchive.nationalarchives.gov.uk/+/
www.dh.gov.uk/en/PublicationsandStatistics/Publications/
PublicationsPolicyandGuidance/DH˙4133743 (accessed 3
November 2012).
Driscoll 2015
Driscoll A, Currey J, Tonkin A, Krum H. Nurse-led
titration of angiotensin converting enzyme inhibitors,
beta-adrenergic blocking agents, and angiotensin receptor
blockers for people with heart failure with reduced ejection
fraction. Cochrane Database of Systematic Reviews 2015,
Issue 12. [DOI: 10.1002/14651858.CD009889.pub2]
Duckett 2005
Duckett S. Health workforce design for the 21st century.
Australian Health Review 2005;29(2):201–10.
Ellis 2006
Ellis N, Robinson L, Brooks P. Task substitution: where to
from here?. Medical Journal of Australia 2006;185(1):18–9.
Gielen 2014
Gielen SC, Dekker J, Franke AL, Mistiaen P, Kroezen
M. The effects of nurse prescribing: A systematic review.
International Journal of Nusring Studies 2014;51:1048–61.
Glenton 2013
Glenton C, Colvin CJ, Carlsen B, Swartz A, Lewin S, Noyes
J, et al. Barriers and facilitators to the implementation of lay
health worker programmes to improve access to maternal
and child health: qualitative evidence synthesis. Cochrane
Database of Systematic Reviews 2013, Issue 10. [DOI:
10.1002/14651858.CD010414.pub2]
Glynn 2010
Glynn LG, Murphy AW, Smith SM, Schroeder K,
Fahey T. Interventions used to improve control of blood
pressure in patients with hypertension. Cochrane Database
of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/
14651858.CD005182.pub4]
GRADEpro GDT 2014 [Computer program]
GRADE Working Group, McMaster University.
GRADEpro GDT. Version accessed 1 August 2015.
Hamilton (ON): GRADE Working Group, McMaster
University, 2014.
Greer 2016
Greer N, Bolduc J, Geurkink E, Rector T, Olson K, Koeller
E, et al. Pharmacist-led chronic disease management: A
systematic review of effectiveness and harms compared with
usual care. Annals of Internal Medicine 2016 Apr 26 [Epub
ahead of print]. [DOI: 10.7326/M15-3058]
Health Workforce Australia 2013
Health Workforce Australia. Health Professionals
prescribing Pathway (HPPP) Project -Final Report.
www.healthinfonet.ecu.edu.au/key-resources/bibliography/?
lid=26503 (accessed 30 November 2016).
Higgins 2011
Higgins JP, Green S, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org.
Home Office 2012
Home Office. Circular: nurse and pharmacist independent
prescribing, ’mixing of medicines’, possession authorities
under patient group directions and personal exemption
provisions for Schedule 4 Part II drugs. Home Office
circular 009/2012. www.gov.uk/government/publications/
nurse-and-pharmacist-independent-prescribing-mixing-
of-medicines-possession-authorities-under-patient-
group-directions-and-personal-exemption-provisions-for-
schedule-4-part-ii-drugs (accessed 12 January 2013).
Hooker 2006
Hooker R. Physician assistants and nurse practitioners: the
United States experience. Medical Journal of Australia 2006;
185(1):4–7.
HWA 2013
Health Workforce Australia 2013. Health Professionals
Prescribing Pathway (HPPP) Project - Final Report.
www.healthinfonet.ecu.edu.au/key-resources/bibliography/?
lid=26503 (accessed 12 February 2014).
Hypertension 1979
Hypertension Detection and Follow-up Program
Cooperative Group. Therapeutic control of blood
pressure in the Hypertension Detection and Follow-up
Program. Hypertension Detection and Follow-up Program
Cooperative Group. Preventive Medicine 1979;8(1):2–13.
Kay 2004
Kay OC, Brien JE. Pharmacist prescribing: review of the
literature. Journal of Pharmacy Practice and Research 2004;
34:300–4.
Latter 2010
Latter S, Blenkinsopp A, Smith A, Chapman S, Tinelli
M, Gerard K, et al. Evaluation of nurse and pharmacist
independent prescribing. Department of Health Policy
Research Programme Project 016 0108. University of
Southampton; Keele University, on behalf of Department
of Health. www.eprints.soton.ac.uk/184777/ (accessed 3
November 2012).
Laurant 2005
Laurant M, Reeves D, Hermens R, Braspenning J, Grol R,
Sibbald B. Substitution of doctors by nurses in primary
care. Cochrane Database of Systematic Reviews 2005, Issue 2.
[DOI: 10.1002/14651858.CD001271.pub2]
Law 2012
Law M, Ma T, Fisher J, Sketris I. Independent pharmacist
prescribing in Canada. Canadian Pharmacists Journal 2012;
145(1):17–23.
39Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Law 2013
Law AV, Gupta EK, Hess KM, Klotz RS, Le QA,
Schwartzman E, et al. Collaborative pharmacy practice: an
update. Integrated Pharmacy Research Practice 2013;2:1–16.
Machado 2007
Machado M, Bajcar J, Guzzo G, Einarson TR. Sensitivity
of patient outcomes to pharmacist interventions. Part
11: Systematic review and meta-analysis in hypertension
management. Annals of Pharmacotherapy 2007;41(11):
1770–81.
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA
Group. Preferred reporting items for systematic reviews and
meta-analyses: The PRISMA Statement. BMJ 2009;339:
2535.
Nkansah 2010
Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J,
Bond CM, et al. Effect of outpatient pharmacists’ non-
dispensing roles on patient outcomes and prescribing
patterns. Cochrane Database of Systematic Reviews 2010,
Issue 7. [DOI: 10.1002/14651858.CD000336.pub2]
NPC 2012
National Prescribing Centre, National Institute for Health
and Clinical Excellence. A single competency framework
for all prescribers. www.associationforprescribers.org.uk/
images/Single˙Competency˙Framework.pdf (accessed 30
October 2016).
NPS 2012
National Prescribing Service MedicineWise. NPS: Better
choices, Better health. Competencies required to prescribe
medicines: putting quality use of medicines into practice.
www.nps.org.au/˙˙data/assets/pdf˙file/0004/149719/
Prescribing˙Competencies˙Framework.pdf (accessed 12
December 2012).
Pande 2013
Pande S, Hiller JE, Nkansah N, Bero L. The effect of
pharmacist-provided non-dispensing services on patient
outcomes, health service utilisation and costs in low-
and middle-income countries. Cochrane Database of
Systematic Reviews 2013, Issue 2. [DOI: 10.1002/
14651858.CD010398]
Pharmacy Council NZ 2013
Pharmacy Council of New Zealand. Pharmacist Prescribers.
www.pharmacycouncil.org.nz/cms˙display.php?sn=225&
st=1&pg=1863 (accessed 26 December 2013).
Phillips 2008
Phillips PA, Hughes CF. Clinical process redesign - can the
leopard change its spots?. Medical Journal of Australia 2008;
188:S7–8.
RevMan 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Santschi 2014
Santschi V, Chiolero A, Colosimo AL, Platt RW, Taffe P,
Burnier M, et al. Improving blood pressure control through
pharmacist interventions: A meta-analysis of randomized
controlled trials. Journal of the American Heart Association
2014;3(2):e000718. [DOI: 10.1161/JAHA.113.000718]
Shaw 2014
Shaw RJ, McDuffie JR, Hendrix CC, Edie A, Lindsey-Davis
L, Nagi A, et al. Effects of nurse-managed protocols in the
outpatient management of adults with chronic conditions.
Annals of Internal Medicine 2014;161:113–21. [DOI:
10.7326/M13-2567]
Stewart 2010
Stewart D, Cunningham S, Diack L, McCaig D, MacLure
K, Bond C, et al. Prescribing Research Group, NHS
Education for Scotland. Report: Exploring and evaluating
pharmacist prescribing. www.openair.rgu.ac.uk/handle/
10059/1939 (accessed 12 Jan 2013).
Thomas 2006
Thomas J, Murtuza B, Lin Shu-Wen, Yogesh P. Survey
of pharmacist collaborative drug therapy management in
hospitals. American Journal of Health-System Pharmacy
2006;63:2489–99.
Tonna 2007
Tonna AP, Stewart D, West B, McCaig D. Pharmacist
prescribing in the UK - a literature review of current practice
and research. Journal of Clinical Pharmacy and Therapeutics
2007;32(6):545–56.
Weeks 2008
Weeks GR, Marriott JL. Collaborative prescribing: Views
of SHPA pharmacist members. Journal of Pharmacy Practice
and Research 2008;38:271–5.
Wheeler 2012
Wheeler A, Crump K, Lee M, Li L, Patel A, Yang R, et al.
Collaborative prescribing: a qualitative exploration of a role
for pharmacists in mental health. Research in Social and
Administrative Pharmacy 2012;8(3):179–92.
WHO 2012
World Health Organization. World Health Statistics 2012.
www.who.int/gho/publications/world˙health˙statistics/
EN˙WHS2012˙Full.pdf. France, (accessed 10 Feb 2013).
Yuksel 2008
Yuksel N, Eberhart G, Bungard TJ. Prescribing by
pharmacists in Alberta. American Journal of Health-System
Pharmacy 2008;65:2126–32.
References to other published versions of this review
Weeks 2014
Weeks G, George J, Maclure K, Stewart D. Non-medical
prescribing versus medical prescribing for acute and
chronic disease management in primary and secondary
care. Cochrane Database of Systematic Reviews 2014, Issue 7.
[DOI: 10.1002/14651858.CD011227]
∗ Indicates the major publication for the study
40Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ansari 2003
Methods Randomised controlled trial
Participants San Francisco Veterans Affairs Medical Center, San Francisco, USA
Patients receiving primary care for CHF who met the Framingham criteria for CHF
and had a left ventricular ejection fraction ≤ 45% or moderate or severe left ventricular
systolic dysfunction on their latest evaluation and no contraindications to β-blockers
74 health professionals randomised to one of three groups
Group 1 Health professionals provided education on initiation and up-titration of β-
blockers
Group 2 Nurse facilitator group
Group 3 Provider and patient notification on β-blocker therapy
Patients 169 randomised (51 control, 54 nurse facilitator, 64 provider/patient notifica-
tion)
Health professional delivering intervention - study nurse practitioner who with other
providers received substantial education on the use of β-blockers in heart failure
Interventions PATIENTS
The nurse practitioner assumed responsibility for initiating, titrating, and stabilising
appropriate CHF patients on β-blockers to target or maximum tolerated dose
Outcomes PATIENTS
Proportion of patients who were initiated or up-titrated and maintained on β-blockers
Proportion of patients reaching target doses of β-blockers
Adverse events - hospitalisations, emergency room visits, deaths
RESOURCE USE
Hospitalisations, emergency room visits
Drug use
Notes Median follow-up 12 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A stratified randomisation using computer-generated,
random numbers.”
Allocation concealment (selection bias) Unclear risk Allocation concealment was not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk All patients and health professionals were aware of the
group allocation
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Ansari 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “An independent research assistant assessed the use of
beta-blocker therapy.”
Incomplete outcome data (attrition bias) Unclear risk Incomplete outcome data were not reported.
Intention-to-treat.
Selective reporting (reporting bias) Unclear risk Specific adverse drug-related events were not reported.
Other bias Unclear risk Degree of supervision of two cardiologists, although
nurse practitioner assumed responsibility for β-blocker
therapy
Aubert 1998
Methods Randomised controlled trial
Participants Two primary care clinics within the Jacksonville Health Care Group, Jacksonville,
Florida, USA
Patients with diabetes mellitus (type 1 or 2)
Patients 138, (71 in nurse case management, 67 usual care)
Health professional delivering intervention - registered nurse with 14 years of clinical
experience and certified diabetes educator trained to follow a set of detailed management
algorithms under direction of a family care physician and an endocrinologist who were
responsible for diabetes management decisions
No unit of analysis errors
Interventions PATIENTS
To compare diabetes control in patients receiving nurse case management versus usual
care
Nurse-ledmanagement at baseline, 2weeks andquarterly, telephone callsweekly (insulin)
or 2-weekly (oral agents, diet/exercise)
Patients referred to 5 week,12-hour multidisciplinary diabetes education programme
PROVIDER
Twice-weekly meeting with physicians to review patient progress, medication adjust-
ments, and other issues
Medication adjustments or changes were communicated to the patients’ primary care
physician
Outcomes PATIENTS
Change in HbA1c at 12 months
Fasting glucose
Fasting lipids
Serum creatinine
Weight
Health-related quality of life (Behavioural Risk Factor Surveillance System, BRFSS)
Adverse events
RESOURCE USE
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Aubert 1998 (Continued)
Hospital admissions
Emergency department visits
Outpatient visits
Notes 12-month study. A complex intervention, not just prescribing and not just nurses in-
volved e.g. dieticians
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients randomly assigned in blocks based on a 1:1 al-
location ratio and a block size of three
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory measures.
Unclear if the quality of life questionnaire was influenced
by the group to which the patients were randomised
Incomplete outcome data (attrition bias) High risk Total attrition 38/138 (27.5%) at 12months, exact num-
bers in each group not stated but stated ’patients lost to
follow-up did not significantly differ by treatment group.
’ Two intention-to-treat analyses
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk Influence of collaborative meetings with physicians on
outcomes unclear
Increased loss to follow-up of younger patients in the
intervention group
Barr Taylor 2003
Methods Randomised controlled trial
Participants Kaiser Permanente Medical Center Santa Clara California, USA
Patients with long-standing diabetes, one or more major comorbid conditions, HbA1c
> 10%
Patients 169, (intervention 84, usual medical care 85)
Health professional delivering intervention - nurse care managers who had extensive
experience in managing lipids and hypertension and attended several days training on
local protocols for diabetes and cholesterol. They also attended diabetes group classes
and shadowed diabetes case managers and physicians treating diabetes
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Barr Taylor 2003 (Continued)
No unit of analysis errors
Interventions PATIENTS
The nurse reviewed the patients’ medical, lifestyle, and psychosocial status, performed
a foot examination, recorded BP, pulse and developed a self-management plan for the
patient. Patients attended group classes (1-2 hrs) once a week for 4 weeks. Telephone
follow-up calls reviewed patient goals, medication use, symptoms, glucose monitoring,
BP monitoring, and self-management. Calls were made before the fourth group session
and at 5, 8, 12, 16, 20, 28, 36, 44 weeks. The nurses used treatment algorithms to titrate
the patients medications for diabetes, cholesterol and hypertension. The primary care
physician was called if new medication was indicated or to report any unusual findings
Outcomes PATIENTS
HbA1c
Lipids (total cholesterol, LDL, HDL, triglycerides)
Fasting glucose
BP (systolic BP, diastolic BP)
Microalbuminuria
BMI
Psychosocial (Duke Activity Status Index and the SF-36 health survey)
Depression (Beck Depression Index)
Satisfaction
RESOURCE USE
Number of physician visits
PROCESS
Percentage with foot exam, dilated eye exam, flu shot, pneumovax
PROVIDER
Satisfaction
Notes 12-month study
Does not permit an analysis of the specific need for various intervention components
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomised, method of random sequence
generation not described
Allocation concealment (selection bias) Unclear risk Method of concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory values low risk.
Unclear if questionnaire completion can be biased by the
group allocation
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Barr Taylor 2003 (Continued)
Incomplete outcome data (attrition bias) Unclear risk Attrition - 14/85 (16.5%) usual care,17/84 (20%) nurse-
managed
Analysis on patients completing the study.
Selective reporting (reporting bias) Low risk Predefined outcomes reported (apart from urinalysis).
Other bias Unclear risk Patient and physician satisfaction surveys not validated
surveys
Becker 2005
Methods Cluster-randomised controlled trial
Participants Ten Baltimore Hospitals, USA
Black 30-59 year-old siblings with no known CHD, (systolic BP ≥ 140 or diastolic BP
≥ 90 mmHg, cholesterol≥ 3.37 mmol/L or current smoking) of a proband with CHD
aged < 60 years
Patients 364, (community-based care 196, “enhanced” primary care 168)
Health professional delivering intervention - nurse practitioner and community health
worker
Interventions PATIENTS
Community-based care versus “enhanced” primary care (control) to reduce CHD risk
Patients randomised to community-based care received care from a nurse practitioner
in a non-clinical site with an exercise room. BP, pharmacotherapy and compliance were
assessed. A community health worker provided dietary counselling, smoking cessation
and exercise counselling. Progress was reviewed by the study physician twice monthly.
Changes in pharmacotherapy were communicated to the primary care physician who
treated conditions outside the risk factors and were asked not to change risk factor
medication. Decisions on how to apply the guidelines were within the full purview
of the nurse practitioner. Prescriptions for risk factor therapy were provided free at
any pharmacy. Telephone monitoring was available. The enhanced primary care group
received the same risk specific materials and free risk factor pharmacotherapy
Outcomes PATIENTS
changes in
LDL
Systolic BP and diastolic BP
10-year Framingham risk scores for CHD
Lifestyle (dietary fats, sweets, smoking)
Notes 12-month study. Randomised at family level.
Risk of bias
Bias Authors’ judgement Support for judgement
45Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Becker 2005 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation schema.
Allocation concealment (selection bias) Unclear risk Not specified.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with the study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory values low. BP by nurse practitioner
(not blinded)
Incomplete outcome data (attrition bias) High risk Intention-to-treat, Attrition 27% community-
based care, 26% enhanced primary care 12
months
Selective reporting (reporting bias) Low risk None evident.
Other bias Unclear risk Application of guidelines rested with nurse prac-
titioner but multifactorial intervention with ef-
fect of prescribing on outcomes unclear
Bruhn 2013
Methods Randomised controlled trial (exploratory)
Participants Six general practices with prescribing pharmacists in Grampian (3) and East Anglia (3),
UK
Patients over 18 years with chronic pain, living in their own houses and who had received
two or more acute prescriptions and/or one repeat prescription in the last 120 days for
an analgesic and or an non-steroidal anti-inflammatory drug
Patients 196, (70 pharmacist medication review with face-to-face prescribing, 63 phar-
macist medication review and feedback to GP, 63 treatment as usual)
Health professional delivering intervention - prescribing and review arms were supple-
mentary or independent prescribing pharmacists who also undertook a 2-day course
updating them on pain management
No unit of analysis errors
Interventions PATIENTS
Tocompare the effectiveness of pharmacistmedication reviewwith orwithout pharmacist
prescribing with standard care for patients with chronic pain
Prescribing arm - medication and pain diary review, pharmaceutical care plan agreed,
prescribing of medications
Review arm - medication review focused on pain-related prescription medications and
pharmaceutical care plan detailing recommended medication changes for the GP
Treatment as usual - standard general practice care
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Bruhn 2013 (Continued)
Outcomes PATIENTS
SF-12 v2 general health and functioning scale
Health Utilities Index, (HUI3) health status and health-related quality of life
Clinical Practice Guidelines pain severity scale
Health Anxiety and Depression Scale (HADS)
Patient satisfaction
PROVIDERS
Semi-structured interviews with staff
Notes Exploratory 6-month trial and no power calculation done.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Telephone randomisation service with a
random number allocation which ensured
allocation concealment. The allocation was
1:1:1
Allocation concealment (selection bias) Low risk Telephone randomisation service with a
random number allocation which ensured
allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants due to the na-
ture of the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if questionnaire completion by pa-
tients can be biased according to the group
to which they were randomised. Outcome
measures self-reported
Incomplete outcome data (attrition bias) High risk 3 months attrition. Prescribing group 24.
3% (17/70), review 15.9% (10/63), treat-
ment as usual 12.7% (8/63)
6 months attrition 28.6% (20/70), 23.8%
(15/63), 14.3% (9/63), respectively
Selective reporting (reporting bias) Low risk Predefined outcome measures reported.
Other bias Unclear risk Recruitment rate 14% (196/1397) and
only 25% of eligible patients entered the
trial
Unclear if patient satisfaction question-
naire validated.
HADS is a screening tool, but used to clas-
sify people by severity of depression and
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Bruhn 2013 (Continued)
anxiety
Chenella 1983
Methods Randomised controlled trial
Participants A general hospital inpatient unit, Los Angeles County-University of Southern California
Medical Center, USA
Hospital patients referred to the anticoagulant service by their primary physicians
Patients 81, (42 in the pharmacist prescriber group, 39 in the physician prescriber group)
Health professional delivering intervention - 7 certified pharmacist prescribers. Each
prescribing pharmacist had aminimumof sixmonths clinical experience treating patients
with anticoagulants and had undergone a certification process. one physician undertook
the physician prescribing
Practice -1
No unit of analysis errors
Interventions PATIENTS
Pharmacist versus physician independent management of anticoagulant therapy of in-
patients
Patients in the pharmacist prescriber group had a pharmacist write daily heparin and
warfarin dosage adjustments which were administered to the patients. The physician
independently monitored laboratory results for the pharmacist patient group and simu-
lated heparin and warfarin doses. In the physician group roles were reversed. Pharmacists
and physician recorded dosage adjustments in a blinded fashion. Interaction between
pharmacist and physician and vice-versa if clinical safety a concern
Outcomes PATIENTS
Heparin dosage (units/24 hours)
Warfarin dosage (mg)
Partial thromboplastin time (sec)
Number of days to achieve therapeutic proconversion and prothrombin
Adverse events
Notes Study period 5 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation process not reported. Patients were ran-
domised to one of two treatment groups
Allocation concealment (selection bias) Unclear risk Method of concealment not reported. Protocol not lo-
cated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Patients probably blinded.
Pharmacists and physician not blinded.
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Chenella 1983 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory measures of anticoagulation.
Unclear method of reporting adverse events.
Incomplete outcome data (attrition bias) Low risk All 81 consecutive hospitalised patients had results re-
ported
Selective reporting (reporting bias) Low risk All predefined outcomes reported.
Other bias Unclear risk Familiarity and interaction of physician and pharmacist
may have influenced results
Choe 2005
Methods Randomised controlled trial
Participants A university affiliated ambulatory care clinic, USA
Patients with poorly controlled type 2 diabetes (HbA1c 8% or above)
Patients 80, (41 intervention, 39 control patients)
Single practice
Health professional delivering intervention - one pharmacist who was already established
as a pharmacotherapy consultant at the clinic. All therapeutic recommendations were
discussed with the primary care physician before significant therapy alterations. Medi-
cation management protocols provided guidance. Some autonomy of prescribing
No unit of analysis issues
Interventions PATIENTS
Pharmacist case management versus usual medical care
A clinical pharmacist provided evaluation and modification of pharmacotherapy, self-
management diabetes education and reinforcement of diabetes complications, screening
processes through clinic visits and telephone follow-up
Outcomes PATIENTS
HbA1c
PROCESS
Rates of diabetes process measures - HbA1c and LDL measurement, dilated retinal
examination, urine microalbuminuria screening or use of ACE inhibitors, monofilament
testing
Notes Follow-up HbA1c measurement was 13.6 months for intervention group and 14.9
months for control group
Risk of bias
Bias Authors’ judgement Support for judgement
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Choe 2005 (Continued)
Random sequence generation (selection
bias)
Low risk Hand drawing of lots, zero control, 1 for intervention,
stratified into 4 groups based on baseline HbA1c
Allocation concealment (selection bias) Unclear risk Method of concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients, providers and case managers were not blinded
to the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective laboratory outcome measures.
Incomplete outcome data (attrition bias) Unclear risk Outcome measures obtained for 81% of patients, attri-
tion 5/41 (12%) intervention,10/39 (26%) control
Data imputed.
Selective reporting (reporting bias) Low risk Expected outcomes reported.
Other bias High risk Unclear level of autonomous prescribing practice. i.e.
some autonomy in decision making versus a great deal of
autonomy to make medication adjustments
Physicians could discuss non-intervention cases with the
pharmacist
Cohen 2011
Methods Randomised controlled trial
Participants Ambulatory care clinic, Providence Veterans Affairs Medical Center, Providence Rhode
Island, USA
Patients were veterans with type 2 diabetes and cardiovascular risk factors. HbA1c > 7%,
LDL > 2.59 mmol/L (or > 1.81 mmol/L for those with coronary artery disease), and BP
> 130/80 mmHg documented in last 6 months
Patients 99, (50 intervention, 49 control)
Health professional delivering intervention - pharmacists (number not reported) with
prescribing privileges
No unit of analysis errors
Interventions PATIENTS
A complex multiprofessional intervention (pharmacist, nurse, dietician etc) with phar-
macist prescribing activity a small part of the intervention versus standard care
Regular visits to primary care provider plus 4 once-weekly 2-hour sessions followed by
5 monthly booster sessions with 4-6 participants. Educational component for first hour
by multidisciplinary team covering chronic conditions and complications and recom-
mendations on care. Session delivered by pharmacist, dietician, nurse, physical therapist
Second hour intervention delivered by a clinical pharmacist (nationally certified diabetes
educator or a Rhode Island certified diabetes outpatient educator) that aimed to achieve
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behavioural change. Medication regimens were modified as required by the pharmacist.
Individual assistance with exercise /diet was available after 4 weekly sessions
Outcomes PATIENTS
Change in proportion of participants achieving target glycaemic and cardiac risk factor
goals as recommended by the ADA (systolic BP < 130 mmHg, LDL < 100 mg/dL (2.
59 mmol/L), HbA1c < 7%),
absolute change from baseline for health-related quality of life, SF-36 for Veterans (VR-
36)
Assessment of perceived competence
Summary of Diabetes Self-Care Activities
Medication adherence
PROCESS
Prescribed medicines
RESOURCE USE
Primary care provider visits
Notes 6-month study.
Complex multifactorial intervention and cannot relate findings solely to pharmacist
prescribing activity
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’randomised controlled trial’, participants assigned to in-
tervention or standard primary care on a 1:1 ratio
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective outcome laboratory results. Unclear if provider
undertaking BP readings was blinded. Unclear if ques-
tionnaire completion by patients can be biased according
to the group to which they were randomised
Incomplete outcome data (attrition bias) Low risk 103 patients randomised, 4 participants withdrew con-
sent, one standard care, 3 intervention. These were not
included in the analysis
3 patients died during the study, 2 in intervention, 1
standard care and included in analysis
Selective reporting (reporting bias) Low risk Expected outcomes reported.
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Other bias Unclear risk LDL significantly lower in intervention arm at baseline.
Multifactorial intervention with effect of prescribing on
outcomes unclear
DeBusk 1994
Methods Randomised controlled trial
Participants 5 Kaiser Permanente Medical centres in San Francisco Bay area, USA
Men and women aged 70 years or younger hospitalised for acute myocardial infarction.
Patient enlisted on hospital day 3 or when stabilised
Patients 585, (intervention 293, usual medical care 292)
Health professional delivering the intervention - programme nurses who participated in
80 hours of training by specialists in cardiology, psychiatry, lipid therapy, nutrition and
nursing practice. Training focused on exercise testing, and training, diet, drug manage-
ment of hyperlipidaemia, smoking cessation and psychosocial interventions. Lipid drug
therapy by algorithm
Interventions PATIENTS
Effectiveness of physician-directed nurse-managed home-based case management for
coronary risk factor modification versus usual medical care
In addition to usual care, patients were encouraged tomonitor health habits (self-reports)
and set subgoals
Patients - After discharge, follow-up by nurse initiated telephone contacts, computer-
generated progress reports and visits to the nurse
Nursing effort involved 9 hours per patient in the first year covering lifestyle, lipid-
lowering drug therapy (2.5 hours) and liaison
Changes in drug therapy at 120, 150, and 180 days based on response. Nurses could
change a drug dosage or discontinue a drug but required permission from the primary
care physician to add a new drug. Nurses provided detailed counselling on drug therapy
Outcomes PATIENTS
Smoking cessation
Nutritional management
Lipid-lowering therapy
Exercise training
Adverse events
Notes 12-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned using a computer programme, done
centrally
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DeBusk 1994 (Continued)
Allocation concealment (selection bias) Low risk Nurses notified of assignments by telephone from co-
ordinating centre staff
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory measures low risk. Unclear risk of nurse man-
ager influence on other outcome assessments (smoking
cessation, nutrition, exercise)
Incomplete outcome data (attrition bias) Unclear risk Dropouts at 12 months, intervention 11.6%, usual care
15.4%, reasons given
Selective reporting (reporting bias) Low risk None apparent.
Other bias High risk Influence on prescribing by primary care physician for
new drugs and telephone consultations from lipid spe-
cialist and senior nurse co-ordinator
Denver 2003
Methods Controlled trial
Participants Outpatient nurse-led clinic, Whittington Hospital North Islington, London, UK
Adult patients with type 2 diabetes and BP≥ 140/80 mmHg, in receipt of BP treatment
and without any serious or life-threatening conditions
Patients 120, (nurse-led clinic 60, conventional primary care 60)
Health professional delivering intervention - hypertension nurse
No unit of analysis errors
Interventions PATIENTS
Effectiveness of a nurse-led hypertension clinic versus conventional primary care in gen-
eral practice on lowering BP in type 2 diabetic patients with uncontrolled hypertension
at risk of cardiovascular disease
Nurse-led clinic patients were seen monthly for 3 months and then 6-weekly for 3
months. At each visit BP was measured and compliance with the drug regimen reviewed
(based on agreed guidelines). Advice on healthy living was provided and side-effects of
existing antihypertensive treatment discussed
Intervention focused on intensifying antihypertensive treatment. Hypertension nurses
and primary care physicians used the same guidelines. The nurse could initiate treat-
ment changes (drug titration or new drug added).New prescriptions were provided by
attending physicians. Patients in both groups reviewed by the nurse at six months and
baseline measures repeated
Outcomes PATIENTS
Change in systolic BP
Lipids (total cholesterol, HDL, total triglycerides)
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Denver 2003 (Continued)
HbA1c
Urinary albumin excretion
Serum creatinine
Changes in absolute stroke and CHD risk scores
Notes 6-month study
Influence of attending physician on prescribing unclear
Multifactorial intervention. Importance of changing treatment to achieve target BP
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Three investigators independently assessed and randomly re-
ferred patients from their clinic. Patients were then allocated to
conventional primary care or nurse-led clinic on an alternate
basis
Allocation concealment (selection bias) Unclear risk Allocation concealment not specified.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Laboratory measures low.
BP - high as nurse measured intervention group BP at each visit
and both groups at 6 months. Unclear if CHD and stroke risk
scoring influenced by provider
Incomplete outcome data (attrition bias) Low risk Intention-to-treat analysis, low attrition 4/60 conventional pri-
mary care, 1/60 nurse-led clinic
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Influence of attending physician on prescribing.
Einhorn 1978
Methods Randomised controlled trial
Participants Profamilia (Colombian Association for FamilyWelfare) central clinic, Bogota, Colombia
New clients seeking contraceptive services
Clients 1532, (physician 769, nurse 763)
Health professional delivering intervention - family planning nurses
Practice - 1
No unit of analysis issues
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Einhorn 1978 (Continued)
Interventions CLIENTS
Family planning services provided by nurses versus physicians
Prescription of oral contraceptives
Insertion of intrauterine devices (IUD)
Breast, pelvic, vaginal, and abdominal examinations
Treatment of cervico-vaginitis
Outcomes CLIENTS
Unwanted pregnancy
Side-effects
PROCESS
Method prescribed to client at first and next visit
Incidence of interim method prescriptions
Deferment of IUD insertions
Changing of methods by provider
Number and reason for clinic revisits
Notes 6-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk During a six-week period clients attending the clinic were
randomly assigned to either a physician group or a family
planning nurse group. Method of sequence generation
unclear
Allocation concealment (selection bias) Unclear risk Concealment not explained.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not explained.
Incomplete outcome data (attrition bias) High risk 36.3% of clients had no revisits.
No details of number recruited.
Selective reporting (reporting bias) Unclear risk Outcomes stated are rather vague.
Other bias Unclear risk Bias related to sex, all nurses female and most physicians
male
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Ellis 2000
Methods Randomised controlled trial
Participants Nine Veterans Affairs medical centres (VMAC), USA (subanalysis using data from the
IMPROVE study)
VAMC patients at high risk for drug-related adverse events who had a diagnosis of
dyslipidaemia at baseline in the IMPROVE study
High risk if three or more of the following: 5 or more drugs, 12 or more doses/day, 4
or more drug changes in the previous year, 3 or more concurrent diseases, history of
noncompliance, treatment with drugs requiring therapeutic monitoring
Patients 437, (208 intervention group, 229 control group)
Health professional delivering intervention - 78 ambulatory care clinical pharmacists
No unit of analysis errors
Interventions PATIENTS
Clinical pharmacists providing pharmaceutical care in addition to usual medical care
versus usual medical care in the management of dyslipidaemia
Pharmacists adjusted drug regimens to improve care and disease control and identify
and prevent drug-related problems. Pharmacists followed patients until outcome goals
achieved. Each clinical pharmacist was to practice according to the defined scope of
practice in the institution. Depending on the site and scope of practice drug therapy
could be adjusted and laboratory tests ordered. Collaboration with physicians varied
Pharmacists determined frequency of follow-up appointments but patients were to be
seen at least 3 times, baseline, 6 months, 12 months
Outcomes PATIENTS
The percentage of patients achieving guideline LDL goals
RESOURCE USE
Cost estimation of pharmacist versus usual care for hospitalisations, clinic visits, all drugs,
lipid agents, laboratory
Healthcare visits
Notes Pharmacists managed entire pharmaceutical care needs rather than just managing dys-
lipidaemia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Potential participants for the IMPROVE study were ran-
domised by the central co-ordinating centre at the Uni-
versity of Colorado Health Science Center. This study
analysed only patients with a diagnosis of dyslipidaemia
at baseline therefore randomisation was not conducted
strictly for patients with lipid disorders
Allocation concealment (selection bias) Unclear risk Concealment process not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective outcome laboratory and cost measure.
Incomplete outcome data (attrition bias) Low risk Intention-to-treat analysis used.
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Effect on patient management of close collaboration be-
tween pharmacists and physicians at some sites unclear
Fairall 2008
Methods Cluster-randomised controlled trial
Participants 31 primary care antiretroviral clinics, (16 intervention, 15 control) Free State Province
South Africa
Cohort 1. Adults ≥ 16 years with CD4 counts of 350 cells per µL or less who were not
receiving antiretroviral therapy - 5390 patients enrolled for intervention, 3862 control
Cohort 2 . Adults who had received antiretroviral therapy for at least six months and
were being treated at enrolment. 3029 intervention patients, 3202 control
Healthcare professional delivering intervention - prescribing nurses who received at least
four educational outreach training sessions about antiretroviral therapy prescribing and
side-effects with guidelines and algorithms (PALSA PLUS) to start and monitor patients
on antiretroviral therapy and identify those needing referral to a doctor
Interventions PATIENTS
Prescribing of antiretroviral treatment by nurses versus doctors
Training delivered and trial co-ordinator visited every intervention clinic to establish a
team responsible for support of decentralised care (phase 1). Nurses assumed responsibil-
ity for prescribing antiretroviral therapy for patients already receiving treatment (phase
2). Nurses began to initiate antiretroviral therapy for eligible patients (phase 3)
Equivalence trial - nurse-led antiretroviral therapy would be as effective in maintenance
of viral suppression as doctor-led treatment
Outcomes PATIENTS
Cohort 1: Primary outcome
Time to death from enrolment
Secondary outcomes
Measures of health status (changes in weight, CD4 cell counts, viral loads, hospital
admissions, inpatient days)
Indicators of quality of care (antiretroviral therapy initiation, time from enrolment to
start of antiretroviral therapy, detection of tuberculosis, co-trimoxazole provision, pro-
gramme retention 1 year after enrolment, baseline CD4 cell count in patients who started
antiretroviral therapy, clinic consultations with nurses and doctors)
Cohort 2: Primary outcome
Proportion with undetectable viral loads (< 400 copies/mL) 12 months after enrolment
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Secondary outcomes
Measures of health status (time to death censored 12-18months after enrolment, changes
in weight and CD4 cell counts, hospital admissions, inpatient days)
Indicators of quality of care (programme retention, diagnosis of tuberculosis, co-trimox-
azole provision, switching of antiretroviral therapy regimens, clinic consultations with
doctors and nurses)
Notes 12-18 month follow-up. Equivalence trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Clinics and their patients were randomly as-
signed. Within each stratum clinics were ran-
domly assigned to intervention and control ac-
cording to sequences of random numbers in a
random number table (even for control, odd for
intervention)
Allocation concealment (selection bias) Low risk Trial statistician undertook randomisation before
trial started
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients and clinicians could not be masked to
group assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Register of deaths and laboratory values.
All interim analysis was blind but data analysts
were not masked after the database was locked for
final analysis
Incomplete outcome data (attrition bias) Low risk Data for primary outcomes available for 94% of
participants. Intention-to-treat analysis
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Control group unintentionally favoured by Gov-
ernement programme to improve access to doc-
tors during the trial. Hesitency of nurses to initi-
ate antiretroviral therapy when they had the op-
tion to refer to doctors (only a quarter of patients
who started antiretroviral therapy had treatment
initiated by nurses)
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Finley 2003
Methods Randomised controlled trial
Participants Kaiser Permanente Medical Center, San Rafael, California, USA
Patients who were members of the health maintenance organisation had just started
antidepressant therapy for depressive symptoms and referred to the protocol by their
primary care provider
Patients 125, (75 intervention, 50 control)
Health professional delivering intervention - two clinical pharmacists. Both had doctor
of pharmacy degrees with several years of direct patient care. One was board certified as
a psychiatric pharmacy who mentored the other investigator during a 2-month training
period
Interventions PATIENTS
Collaborative care model of clinical pharmacists providing drug therapy management
and treatment follow-up versus usual care
Pharmacist care manager undertook a 30-minute intake interview to assess severity of
psychopathology, identify potential stressors and other predisposing factors. Medical,
psychiatric, and drug therapy histories recorded and whether any exclusion criteria were
present. Patient education undertaken. Pharmacists could prescribe ancillary drugs e.
g. for sleep and titrate antidepressant drugs but if a change in antidepressant drug was
indicated approval from the primary care provider was required. If changes to the antide-
pressant regimen were warranted the pharmacists communicated this recommendation
to the provider. The designated psychiatric mentor met with the clinical pharmacists
each week and was available for consultation. Pharmacy care managers made follow-up
telephone calls to patients at weeks 1, 2, 4, 10, 16. Patients had clinic visits at weeks 6
and 24
Outcomes PATIENTS
Adherence to antidepressant drug therapy
Clinical and functional severity (Brief Inventory for Depressive Symptoms (BIDS) and
Work and Social Disability Scale)
Patient satisfaction
RESOURCE USE
Change in all clinic or emergency department visits
Drug costs
PROVIDERS
Experience and satisfaction of primary care providers
Notes 6-month study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly assigned to the collaborative
care model or back to usual care in a 3:2 ratio (sequence
generation not described)
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Allocation concealment (selection bias) Low risk The investigators opened a sealed envelope that deter-
mined study group assignment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and providers aware of study group assign-
ments.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if questionnaires completed by patients can be
biased according to the group to which they were ran-
domised
Incomplete outcome data (attrition bias) High risk Clinical outcome surveys incomplete or not available.
control 26/50 (52%), intervention 21/75 (28%)
Patient satisfaction survey attrition high, control 17/50
(34%), intervention 16/75 (21%)
Provider satisfaction attrition 12/30 (40%)
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias High risk High female population (85% intervention, 84% con-
trol).
Physican practices may have improved after establishing
the clinical pharmacy services
Unclear if patient and provider satisfaction surveys were
validated surveys
Effect of USD 20 reimbursement for returning surveys.
Influence of the psychiatric mentor on prescribing un-
clear.
Fischer 2012
Methods Randomised controlled trial
Participants Community health centre - Denver Health’s Westside Family Health Center (Westside
Clinic) Denver, Colorado, USA
Patients aged > 17 years with diabetes with at least two visits in the past year (Latino
ethnicity 59%, African America 21%)
Patients 762, (381 intervention, 381 control)
Health professional delivering intervention - 3 nurses sharing role
No unit of analysis errors
Interventions PATIENTS
An algorithm-driven telephone care by nurses as an adjunct to usual care versus usual
care to improve lipid control in patients with diabetes. Nurses independently checked
laboratory results and initiated and titrated lipid therapy over the telephone with a
2-week follow-up call to assess side-effects and a 6-week call to recheck lipids after
medication changes. Nurses also promoted behavioural change through motivational
interviewing and self-management techniques. The nurses used algorithms for glycaemic
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and BP control and vaccinations. The nurse used pre-printed prescriptions signed by the
physician who offered educational and management support
Outcomes PATIENTS
Proportion of patients with an LDL less than 100 mg/dL (2.59 mmol/L)
Proportion of patients with cardiovascular disease and an LDL < 70 mg/dL (1.8 mmol/
L)
Percentage of patients with HbA1c < 7 mg/dL
Percentage of patients with BP < 130/80 mmHg
RESOURCE USE
Hospital inpatient admissions
Emergency department visits
Outpatient visits
Average hospital charges per patient
Notes 20-month study but unclear time points for measurements.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This randomised controlled trial but no detail on se-
quence generation
Allocation concealment (selection bias) Unclear risk Allocation concealment not specified.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory measures low risk.
Investigators doing analysis were not blinded to control
versus intervention groups
Incomplete outcome data (attrition bias) Low risk Intention-to-treat analysis.
Missing data on medication analysis, side-effects, adher-
ence due to incomplete data base
Nurse unable to contact 65/381 (17%) intervention pa-
tients.
Selective reporting (reporting bias) Unclear risk Some secondary outcome detail not reported e.g. post-
intervention BP, HbA1c
Other bias High risk Baseline differences - higher rate of cardiovascular disease
and insulin use in control group, higher percentage of
females in intervention group
Nurses interacted with control patients.
No data provided on the input of physician champion to
decision making, changing prescriptions etc
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Heisler 2012
Methods Cluster-randomised controlled trial
Participants Sixteen primary care teams at 5 medical centres (3 Veterans Affairs (VA) and 2 Kaiser
Permanente (KP)), USA
Eight intervention primary care teams (1797 patients), 8 usual care primary care teams
(2303 patients)
Interventions PATIENTS
Apharmacist-led intervention (Adherence and IntensificationofMedications) in patients
with diabetes and poor BP control versus usual care
Pharmacists used electronic prescribing and clinical data systems to reach out to patients
with uncontrolled hypertension and either poor refill adherence or insufficient medica-
tion intensification in response to high BP. Supported by up-to-date medication refill
information pharmacists delivered tailored adherence counselling by use of motivational
interviewing and medication management with follow-up once a behaviour or pharma-
cological change was made
Health professional delivering the intervention - five clinical pharmacists, two part-time
(2 full-time equivalent at KP and 2 full-time equivalent at VA). Pharmacists undertook a
3-day interactive training focusing on motivational interviewing and the study protocol,
procedures and the medication management tool (MMT). Fidelity was assessed during
the intervention. A booster session occurred six months into the intervention with feed-
back on one or more telephone encounters by an expert in motivational interviewing
Pharmacist encounters were offered at 3-month intervals (0, 3, 6, 9, 12 months)
Encounters took place at the clinic or by phone. At intake the pharmacist assessed
adherence, explored barriers to adherence, discussed BP, HbA1c, LDL levels, explored
goals, set a short-term action step if there were barriers to adherence. If no adherence
problems the pharmacist could make BP medication changes by using site approved
algorithms
Clinical pharmacists copied the patient’s primary care physician on medication changes.
Pharmacists consulted or referred back to the primary care physician those patients
requiring more than 3 antihypertensive medications
Patients were eligible for discharge whenmedication adherence issues had been addressed
and target BP reached or the patient was on maximum tolerated medications
Outcomes PATIENTS
Relative change in systolic BP from 6months preceding to 6 months after the 14-month
intervention
Shorter-term changes in BP
RESOURCE USE
Hospitalisations, primary care visits, emergency room visit
PROCESS
Proportion of patients with BP medication changes
Notes High performing setting with at least 80% BP control
Randomisation
2-stage cluster sampling - first team clusters at each site were selected and then primary
care teams within the 5 sites were randomly assigned to treatment versus control. 16
primary care teams were randomly assigned for 8 intervention, and 8 control teams, 2+2
62Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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at three sites, 1+1 at two sites
In the second stage, participants within each team were randomly sampled for activation
by a priority order for outreach
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory values low risk. Systolic BP came from
the sites usual clinical care electronic database (ex-
cluded BP by Adherence and Intensification of
Medications pharmacists)
Incomplete outcome data (attrition bias) High risk Intention-to-treat analysis - all contacted patients
included in the analysis. In the intervention arm
only 53% of participants had a pharmacist en-
counter
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Multifactorial intervention with effect of pre-
scribing on outcomes unclear
Hill 2003
Methods Randomised controlled trial
Participants Outpatient General Clinical Research Center, Johns Hopkins, Baltimore, USA
Hypertensive urban African Americanmen aged 21 to 54 with systolic BP≥ 140 mmHg
or diastolic BP ≥ 90 mmHg on or off hypertensive medication
Patients 309 (157 intensive intervention, 152 less intensive)
Health professional delivering intervention - nurse practitioner/community health
worker/physician
Interventions PATIENTS
Amore intensive comprehensive and individualised educational-behavioural-pharmaco-
logical intervention by a nurse practitioner/community health worker/physician team
versus a less intensive education and referral intervention in the community. Nurse prac-
titioner visits every 1-3 months. Men in the more intensive group received free medica-
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tion from the nurse practitioner who made therapeutic decisions including medication
titration in accordance with a protocol based on JNC-V1 guidelines. The community
health worker made at least one home visit and assisted with support referrals. The
physician was available for consultation. Therapy further individualised with primary
providers (where present)
Outcomes PATIENTS
Changes at 36 months in:
BP
Left ventricular mass
Serum creatinine
Socio-demographic and behavioural risk factors (items from National Health Interview
Survey and Hill-Bone Compliance Scale)
RESOURCE USE
Healthcare utilisation by asking if there was a provider for hypertension and whether
they were on antihypertensive medication
Notes 36-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Personnel blinded to group assignment for BP and left
ventricular mass. Laboratory measures
Incomplete outcome data (attrition bias) Low risk 70% follow-up at 12, 24, 36 months.
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias High risk Multifaceted intervention by team. Unclear influence on
prescribing of nurse practitioner by physicians. Medica-
tions free to the more intensive intervention group
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Hirsch 2014
Methods A randomised controlled trial
Participants University of California-San Diego general internal medical clinic, USA
Patients drawn form the electronic medical record of 10 primary care physicians who
were ≥ 18 years with uncontrolled hypertension ( ≥ 140/90 mmHg or ≥ 130/≥ 80
mmHg if diabetic) on current treatment with at least one antihypertensive medication
and had continuous active status with the clinic
Patients 166 (75 intervention group, 91 usual care)
Health provider delivering intervention - two clinical pharmacists with a Doctor of
Pharmacy degree, at least one year of pharmacy practice residency training and at least
7 years experience in ambulatory care
Practice - 1
No unit of analysis errors
Interventions PATIENTS
Pharmacist-managed BP control of hypertensive patients by the PharmD-primary care
physician medication management team versus usual care
The clinical practice protocol allowed the pharmacist to independently initiate, adjust
or discontinue treatment with antihypertensive medications. A physician was available
for consultation
Number of interventions - four 30-minute pharmacist visits (baseline 3, 6, 9 months)
and as needed, independent of primary care physician visits
Outcomes PATIENTS
Systolic BP (change at 6 months)
Percentage of patients at BP goal
Change in diastolic BP
LDL and HDL cholesterol
Patient satisfaction using the 22-item Pharmacist Service Questionnaire
PROCESS
Number and types of medication changes
Number and types of antihypertensive drug therapy problems
Notes Patients received USD 22 for each pharmacist visit, USD 25 for the 9-month visit
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly assigned via a computer-gener-
ated random sequence
A random subset of usual care patients was selected for
retrospective chart review (process unclear)
Allocation concealment (selection bias) Unclear risk Concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design. Primary care physicians
had patients in both groups
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Hirsch 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Pharmacist measured BP at each study visit.
Incomplete outcome data (attrition bias) Unclear risk After enrolment 11/75 (15%) of intervention group lost
at 6 months, 23/75 (31%) of intervention group lost at
9 months versus 91/91 in usual care
19 intervention patients returned to primary care physi-
cians with measured data included
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Baseline Intervention group younger, lower Charlson
comorbidity index, more likely to be male, and lower
total number of medications. Payment of patients for
pharmacist visit
Houweling 2009
Methods Randomised controlled trial
Participants Diabetes outpatient clinics of two hospitals, Isala Clinics, Zwolle and Bethesda General
Hospital, Hoogeveen, the Netherlands
Patients with type 2 diabetes referred by GPs
Patients 93 (intervention 50, standard care 43)
Health professional delivering intervention - nurse specialising in diabetes trained to
follow a detailed treatment and management protocol aimed at optimising glycaemia,
BP, and lipids. Protocols allowed nurse specialising in diabetes to prescribe medication
and order laboratory tests, initiate therapy with 14 medications and change doses for 30
medications
Interventions PATIENTS
Secondary care management of diabetes by supervised nurses versus medical care
Outcomes PATIENTS
Mean decrease in HbA1c from baseline to one year
BP
Total cholesterol
LDL
LDL/HDL
Proportion of patients meeting targets
Health-related quality of life SF-36
Diabetes-related symptoms (Diabetes Symptom Checklist-type 2, DSC-type 2)
Patient satisfaction (Patient Evaluation of the Quality of Diabetes Care, PEQD)
RESOURCE USE
Healthcare consumption
Costs
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Houweling 2009 (Continued)
Notes In some cases the protocol specified consultation with medical internist
12-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Population randomised with sequential numbers in
closed envelopes with even numbers assigned to the in-
tervention group and odd numbers to control
Allocation concealment (selection bias) Low risk Non-transparent closed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory measures (low risk).
Independent medical investigator saw patients at base-
line, 6 months, 12 months
Unclear if completion of questionnaires can be biased
according to randomisation group
Incomplete outcome data (attrition bias) Low risk Attrition-low: intervention group 4/50 (8%), standard
care 5/43 (12%)
SF-36 4/84, 4/84 satisfaction survey.
Data analysis excludes lost to follow-up.
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Unclear impact of consultation of nurse specialising in
diabetes with internist as per protocol
Houweling 2011
Methods Randomised controlled trial
Participants A primary care group general practice with five GPs, north-east region of theNetherlands
Patients with type 2 diabetes mellitus, on medication and whose HbA1c levels had been
measured in the last three years
Patients 230 (intervention 116, GP 114)
Health professional delivering intervention - practice nurses (primarily 2) who received
one week of training on a detailed treatment and management protocol aimed at opti-
mising glucose, BP, lipids, eye and foot care. Practice nurses could prescribe 14 different
medications, adjust doses for 30 medications, order laboratory tests, adjust doses but not
order insulin
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Houweling 2011 (Continued)
Interventions PATIENTS
Primary care nurse management of type two diabetes versus management by GPs
Outcomes PATIENTS
HbA1c (mean decrease after 14 months)
BP
Cholesterol and cholesterol/HDL ratio
Health-related quality of life (SF-36)
Diabetes-related symptoms (DSC-type 2)
Patient satisfaction (PEQD)
PROCESS
Proportion of patients achieving target ranges of glycaemic control (HbA1c below 7.5%
and 8.5%)
BP below 14/90 mmHg
Opthalmologist referrals
Measures for feet at risk
Referral to internist for starting insulin
Proportion with drug intensification
RESOURCE
Healthcare consumption
Notes 14-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Population randomised by two independent medical in-
vestigators using sequential numbers in closed envelopes
with even numbers assigned to the intervention group
and odd numbers to control group
Allocation concealment (selection bias) Low risk Non-transparent closed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible by study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Laboratory measures (low risk).
BP not blinded (high risk).
Unclear if completion of questionnaires can be biased
according to randomisation group
Incomplete outcome data (attrition bias) Low risk Low lost to follow-up - practice nurse intervention group
14/116 (12%), GP usual care 10/114 (9%)
Data analysis excludes lost to follow-up.
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Houweling 2011 (Continued)
Selective reporting (reporting bias) Low risk Outcomes outlined in methods reported.
Patient satisfaction results summarised.
Other bias Unclear risk Mean number of visits in practice nurse group 6.1 versus
2.8 in the GP group (P < 0.001). Visits also longer
Hunt 2008
Methods Randomised controlled trial
Participants Nine community-based primary care clinics (Providence Primary Care Research Net-
work), Oregon, USA
Patients with hypertension and uncontrolled BP
Patients 463 (pharmacist arm 230, usual care 233)
Health professional delivering intervention - 5 pharmacy practitioners with a post-bac-
calaureate doctor of pharmacy degree, 1-2 years ambulatory medicine residency training
and was board certified in pharmacotherapy
Interventions PATIENTS
Pharmacists participating in the active management of hypertension in the primary care
office according to collaborative treatment protocols versus usual care
Pharmacists reviewed the participants’ medications and lifestyle habits, assessed vital
signs, screened for adverse drug reactions, identified barriers to adherence, provided edu-
cation, optimised the antihypertensive regimen and scheduled follow-up appointments.
Antihypertensive regimen optimisation included alterations to titrate the dose of an ex-
isting medication, add a new agent, switch a medication or consolidate antihypertensive
therapy. The pharmacist had access to the patients’ medical record as well as to the pri-
mary care physician to discuss the hypertension treatment plan or other medical issues
Outcomes PATIENTS
Difference in mean systolic and diastolic BP between team-based care and usual care
Proportion achieving BP goal attainment (< 140/90 mmHg)
Self-management knowledge and behaviour (internally designed)
Medication adherence (Morisky scale)
Home BP monitoring
Quality of life (Medical Outcomes Study SF-36)
Satisfaction (six healthcare and five specific hypertension domain questions)
RESOURCE UTILISATION
Clinic visits to primary care physician and pharmacist in intervention and control arms
PROCESS
Antihypertensive use
Notes 12-month study.
Did not need to consult physician to change medications.
Risk of bias
Bias Authors’ judgement Support for judgement
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Hunt 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Participants randomly assigned with equal allocation and
without restriction to intervention or control using a
computer-generated random sequence
Allocation concealment (selection bias) Unclear risk Not specified.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk At study-endBPwas assessed by registered nurses blinded
to the participants randomisation allocation
Incomplete outcome data (attrition bias) Unclear risk Intention-to-treat analysis.
191 participants (41%) withdrew after randomisation
88/230 (38.3%) intervention, 103/233 (44.2%) usual
care but groups comparable - 142 pharmacist, 130 usual
care. Reasons discussed. Only factor associated with
higher withdrawal rate was enrolment in commercial in-
surance
Selective reporting (reporting bias) Unclear risk Predefined outcomes reported.
Other bias Unclear risk Physcians in this study cared for patients in both groups
and co-signed the chart note following every pharmacist-
patient interaction. Six control patients also received a
pharmacist consultation (at primary care physician re-
quest). Thismay bias toward null hypothesis. Control pa-
tients were also offered a number of active interventions
e.g. mailed educational material, appointment prompts,
physician prompts where BP elevated
Ishani 2011
Methods Randomised controlled trial
Participants Minneapolis VA Health Care System, Minneapolis, Minnesota, USA
Diabetic veterans who had BP > 140/90 mmHg, HbA1c > 9%, or LDL > 100 mg/dL
Patients 556 (278 intervention, 278 usual care)
Health professional delivering intervention - nurse case managers whomade adjustments
to medications according to protocols established for the study
Interventions PATIENTS
To determine whether nurse case management with a therapeutic algorithm could ef-
fectively improve rates of control for hypertension, hyperglycaemia and hyperlipidaemia
compared with usual care among veterans with diabetes. Intervention group patients in
collaboration with the study nurse established lifestyle goals, were provided with home
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Ishani 2011 (Continued)
BP monitors and had medications adjusted. The nurse case managers contacted patients
initially two-weekly, decreasing as targets were reached to review and adjust therapy
Outcomes PATIENTS
Percentage of patients with control of all three cardiovascular risk factors (BP < 130/80
mmHg, LDL < 100 mg/dL, HbA1c < 8%)
Percentage of individuals achieving individual treatment goals
Change in absolute values for BP, LDL, HbA1c between groups at one year
Notes 12-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation according to a computer-generated ran-
domisation schedule with a block size of six
Allocation concealment (selection bias) Unclear risk Allocation concealment not specified.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory measures low risk.
Unclear risk around independence and blinding to study
group of those performing final BP measurement
Incomplete outcome data (attrition bias) Unclear risk Intention-to-treat analysis.
Attrition at final visit: intervention 55/278 (20%), usual
care 70/278 (25%)
Selective reporting (reporting bias) Low risk Not evident.
Other bias Unclear risk Nineteen patients included who were randomised in er-
ror as a value for entry did not exceed the threshold
Jaber 1996
Methods Randomised controlled trial
Participants General internal medicine clinic, Detroit Receiving Hospital, University Health Center,
Detroit, USA
Urban African-American patients with non-insulin dependant diabetes mellitus
(NIDDM)
Patients 39 (17 intervention, 22 controls)
Health professional delivering intervention - a pharmacist delegated full prescribing
authority under an approved hyperglycaemic agents protocol
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Jaber 1996 (Continued)
No unit of analysis errors
Interventions PATIENTS
Pharmacists providing pharmaceutical care versus physicians
Diabetes-related management aspects were solely provided by a pharmacist including
pharmacotherapeutic evaluation and dosage adjustments, individualised education on
diabetes and its complications, training on the recognition and treatment of hypogly-
caemia and hyperglycaemia, medication counselling, instructions on dietary regulation
and an exercise plan, training for self-monitoring of blood glucose. Weekly follow-up
until target glycaemia control then 2-4 weekly visits
Outcomes PATIENTS
Fasting plasma glucose
HbA1c
BP
Serum creatinine
Creatinine clearance
Microalbumin to creatinine ratio
Lipids (total cholesterol, triglycerides, HDL, LDL)
Quality of life (Health Status Questionnaire V2 derived from the SF-36)
Patient compliance
Adverse events
PROCESS
Medication use
Notes 4-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible patients were assigned to an intervention or con-
trol group in a randomised, parallel design fashion
Allocation concealment (selection bias) Unclear risk Allocation concealment not explained.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory values low risk.
Unclear if questionnaire results canbe biased by the group
allocation
Incomplete outcome data (attrition bias) High risk Attrition: 6/23 (26%) intervention group dropped out
or were discharged. Reasons provided
Selective reporting (reporting bias) Unclear risk Predefined outcomes reported.
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Jaber 1996 (Continued)
Other bias Unclear risk Multifactorial intervention with effect of prescribing on
outcomes unclear
Khunti 2007
Methods Cluster-randomised controlled trial
Participants Twenty primary care practices with 53 GPs, Leicester, UK
Patients with CHD, CHF or both
Patients 1316. Intervention 608 (final cases included 505 - CHD 461, heart failure 147,
confirmed left ventricular systolic dysfunction 51, excluded 103). Controls 708 (final
cases included - 658, CHD 691, heart failure 215, confirmed left ventricular systolic
dysfunction 75, excluded 50)
Health professional delivering intervention - two specialist nurses trained in the man-
agement of CHD and CHF
No unit of analysis errors
Interventions PATIENTS
Specialist nurse care versus usual care by the healthcare team in the control practices for
secondary prevention of CHD and CHF
Nurse intervention included patient assessment, confirmation of diagnosis by investiga-
tions, medication management and titration, home visits for house bound patients and
liaison between primary and secondary care
Outcomes PATIENTS
The proportion of patients with a history of myocardial infarction receiving a beta-
blocker
in patients with CHD a recorded serum cholesterol < 5 mmol/L in the previous year
The proportion of patients with left ventricular systolic dysfunction being treated with
an ACE inhibitor
Quality of life (SF-36)
Seattle Angina Questionnaire
Left Ventricular Dysfunction Questionnaire (LVD-36)
PROCESS
CHD - BMI, BP control
CHF - proportion of patients with a presumed diagnosis of CHF having an echocar-
diogram, proportion of patients having confirmation or rejection of the diagnosis of left
ventricular systolic dysfunction by an echocardiogram
Medication use - secondary prevention, appropriate left ventricular systolic dysfunction
medications
Notes Practices matched as closely as possible for size, number of GP partners, measure of
deprivation, teaching and training status
Control group practices provided the same open access echocardiography and access to
the secondary care cardiology clinic as the intervention group
12-month study.
It is difficult to determine which facet or facets of a complex multifactorial intervention
led to improvements in care
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Khunti 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation procedure used computer-gener-
ated case control pairs. Pairing of GP practices
based on list size, number of GPs, Jarman depri-
vation indicator, teaching and training status
Allocation concealment (selection bias) Unclear risk Not practical.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if questionnaire responses and some sec-
ondary prevention measures were biased by the
group allocation
Low risk with laboratory and process measures.
Data extracted by trained nurse data collectors.
Incomplete outcome data (attrition bias) High risk Attrition - intervention 103/608, control 50/708.
Intention-to-treat analysis of 1163 patients, 505
intervention, 658 control and of these:
39/505 intervention and 15/658 control patients
did not complete trial per protocol (reasons pro-
vided); higher attrition rate in the intervention
group
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Multifactorial intervention with effect of pre-
scribing on outcomes unclear
Klingberg-Allvin 2015
Methods Randomised controlled trial
Participants Women with signs of first trimester incomplete abortion at six healthcare facilities in six
districts in rural, peri-urban and urban settings in central Uganda
Patients 1010, midwife group 506, physician group 504
Health professional delivering the intervention -midwives involved in post-abortion care
at the facilities and who underwent a five day training module focusing on diagnosing
incomplete abortion, treatment with misoprostol, manual vacuum aspiration, contra-
ceptive methods and counselling
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Klingberg-Allvin 2015 (Continued)
Interventions PATIENTS
Clinical assessment and treatment with misoprostol by a physician or midwife
Provision of analgesics (ibuprofen or paracetamol) and oral antibiotics according to
national guidelines for post-abortion care
Outcomes PATIENTS
Abortion not needing surgical intervention within 14-28 days after initial treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer random number generator to generate a list
of codes with each code linked to one of the two study
groups
Allocation concealment (selection bias) Low risk Sequentially numbered opaque sealed envelopes used.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if research assistants who were midwives mea-
sured primary and secondary outcomes and treated pa-
tients
Incomplete outcome data (attrition bias) Low risk Low exclusion, 11 of 1010 women excluded after ran-
domisation. Low loss to follow-up
Per protocol and intention-to-treat population almost
identical
Selective reporting (reporting bias) Low risk Not evident.
Other bias Low risk Larger loss to follow-up in the midwife group, but the
difference with the physician group was small
Kuethe 2011
Methods Randomised controlled trial (three arms, non-inferiority design)
Participants Large general hospital and 18 GPs’ practices in Noord Brabant, the Netherlands
Children 6-16 years old with moderate stable asthma using inhaled corticosteroid for at
least 9 months prior to study
Patients 107 (45 from general practice, 62 from hospital practice randomised in 3 arms
to GP 37, paediatrician 34, asthma nurse 36)
Health professional delivering intervention - hospital-based specialised asthma nurse
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Kuethe 2011 (Continued)
No unit of analysis errors
Interventions PATIENTS
To test non-inferiority of care by a specialised asthma nurse versus standard care (GP or
paediatrician)
Nurse used guidelines of the Dutch Paediatric Association with support from a paedia-
trician at any time
Outcomes PATIENTS
Lung function tests including - airway hyper-responsiveness ( PD20), FENO FEV1
Asthma control - Asthma Control Questionnaire
Exacerbations
PROCESS
Medication use - dose, % use of long-acting beta agonists/inhaled corticosteroid
RESOURCE USE
Planned visits
Unplanned visits
School absence
Parental absence from work
Notes Two-year follow-up.
The asthma nurse could consult the paediatrician at all times (15 (42%) of asthma nurse
participants required a consultation with a paediatrician)
Extra emergency visits as required.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised computer-generated
list (stratified by type of treating physician
before recruitment)
Allocation concealment (selection bias) Low risk Sealed numbered envelopes with desig-
nated follow-up arms.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Lung function parameters low risk but no
mention of blinding assessors
Unclear if completion of questionnaire can
be biased by group randomisation
Incomplete outcome data (attrition bias) Low risk Attrition at 2 years - GP 2/37, paediatri-
cian 1/34, asthma nurse 3/36 (explanation
provided)
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Kuethe 2011 (Continued)
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk GPs with a special interest in paediatric
asthma selected. Results may differ from an
unselected sample of GPs
Consultations with paediatricians influ-
ence on outcomes.
Unclear medical influence on nurse pre-
scribing.
Litaker 2003
Methods Randomised controlled trial
Participants Department of General Internal Medicine, Cleveland Clinic Foundation (a tertiary care
teaching hospital) Ohio, USA
Patients with mild or moderate hypertension and type 2 diabetes without end-organ
complications
Patients 157 (nurse practitioner - physician team 79 versus usual care (primary care
physician) 78)
Health professional delivering intervention - nurse practitioner with training on use of
treatment algorithms. Issues outside algorithms discussed with primary care physician
Interventions PATIENTS
Chronic disease management involving nurse practitioner-physician versus primary care
physician
Use of treatment algorithms, patient education on self-management, monitoring and
feedback primarily by nurse practitioner
Outcomes PATIENTS
HbA1c
HDL
Satisfaction with care
Health-related quality of life - Health Survey Short Form (SF-12)
Diabetes quality of life,
PROCESS
Preventive care (vaccinations, foot, eye exams)
Patient education (e.g. smoking cessation, weight control, adherence)
RESOURCE USE
Costs for personnel involved in management
Time spent
Notes 12-month study. Team management beneficial effect on HDL. Effect on diabetic con-
trol disappeared 12 months after study completion. Study terminated at 16 months.
Multifactorial intervention
Risk of bias
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Litaker 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory values. BP assessment not blinded. Unclear
if group allocation affected survey results
Incomplete outcome data (attrition bias) Low risk Not evident.
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias High risk Physicians involved in 216 (40%) of nurse practitioner
visits. Influence of physician on prescribing unclear
Logan 1979
Methods Randomised controlled trial
Participants Government or industry workplaces, Metropolitan Toronto, Canada
Volunteers with untreated hypertension
Patients 457 (232 worksite care by nurse, 225 regular care by family physician)
Health professional delivering intervention - two experienced nurses who were taught
to treat hypertension according to a standard protocol. Nurses were allowed to prescribe
and change drug therapy at the worksite without prior physician approval. Every week
patient charts were reviewed at the hospital with the supervising physician
No unit of analysis errors
Interventions PATIENTS
Treatment of hypertension in the workplace by nurses versus treatment in the community
by the family doctor
Nurses saw their patients every two weeks if diastolic BP was 105 mmHg or higher or
every month if less until target goal reached. Visits were then lengthened to two to three
months
Outcomes PATIENTS
Reduction in diastolic BP to less than 90 mmHg if entry BP > 95 mmHg or reduction
in BP of at least 6 mmHg if entry diastolic BP of 95 mmHg or less
Medication compliance
78Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Logan 1979 (Continued)
Notes 6-month study.
Comparing an intervention, not just prescribing versus standard care
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Eligible participants stratified for age, sex, diastolic BP
and site of work and randomised within strata but no
details of sequence generation given
Allocation concealment (selection bias) Unclear risk Details not provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk BP - work evaluations at 6 months were done by a spe-
cially trained BP technician who was unaware of group
allocation
Insufficient information given on compliance question-
naire. Pill count at home cannot be ’unobtrusive’
Incomplete outcome data (attrition bias) Low risk Explanation provided, dropouts or not having a 6-month
assessment - worksite care by nurse 26/232, regular care
21/225
Intention-to-treat.
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Unclear whether weekly chart review by supervising
physician had any influence on outcomes
Standard group measured less frequently.
MacMahon Tone 2009
Methods Randomised controlled trial
Participants Hospital-based diabetes service, Beaumont Hospital, Dublin, Ireland
Patients with type 2 diabetes and one additional cardiovascular risk factor (smoking, per-
sistent microalbuminuria or previously diagnosed macrovascular disease). Total choles-
terol > 4.8 mmol/L or LDL > 2.6 mmol/L or BP > 130/80 mmHg or both. Patients
were recruited if over 30 years, treated with diet, oral hypoglycaemic agents or treated
with oral hypoglycaemic agents for at least 1 year prior to commencing insulin
Patients 200 (intensive nurse-led 101, standard care 99)
Health professional delivering intervention - nurse with 5 years experience as a diabetes
nurse specialist and a higher diploma in diabetes
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MacMahon Tone 2009 (Continued)
Interventions PATIENTS
Intensive nurse-led clinic versus standard diabetesmanagement (annual review) in achiev-
ing recommended vascular risk reduction targets in patients with type 2 diabetes. Patients
seen every 2-3 months and annual review in the diabetes clinic
At each visit lifestyle advice was reinforced (diet, weight reduction, exercise, alcohol
consumption, smoking cessation). Patient feedback on achieving targets. Mediactions
were titrated in response to BP, blood glucose readings, and biochemical results
Outcomes PATIENTS
BP
Total cholesterol
LDL
HDL
Triglycerides
HbA1c
Weight
Smoking
Adverse events
PROCESS
Antihypertensive use
Aspirin prescribing
Notes One-year study.
Difficult to evaluate which single intervention or combination of interventions respon-
sible for risk reduction
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Standard randomisation table used. Patients randomised
on the basis of the date of presentation for their first visit
and last digit of their hospital number
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory values low risk.
BP not reported as blinded.
Incomplete outcome data (attrition bias) Low risk Low attrition 7/101, 5/99.
Selective reporting (reporting bias) Unclear risk Predefined outcomes reported.
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MacMahon Tone 2009 (Continued)
Other bias Unclear risk Confounding factors - intensive education and more reg-
ular reviews. Multifactorial intervention with effect of
prescribing on outcomes unclear
Magid 2013
Methods Randomised controlled trial
Participants Ten Kaiser Permanente Colorado primary care clinics, USA
Adults 18 to 79 years with a diagnosis of hypertension and their two most recent clinic
BP readings were above goal, systolic BP ≥ 140 mmHg or diastolic BP ≥ 90mmHg
(systolic BP ≥ 130 mmHg or diastolic BP ≥ 80 mmHg for DM or chronic kidney
disease), were prescribed ≤ 3 antihypertensive medications, had a primary care provider
at one of the 10 participating clinics and had access to a computer and Internet
Patients 348 (175 intervention, 173 usual care)
Health professional delivering intervention - clinical pharmacy specialist (at least one at
each clinic)
No unit of analysis errors
Interventions PATIENTS
A pharmacist-led Heart360 Web enabled home BP monitoring (HBPM) verus usual
care in patients with uncontrolled hypertension
Both groups received the same educational material
Clinical pharmacist reviewed current BP medications, provided counselling on lifestyle
changes and adjusted or changed antihypertensive medications as needed. Patients mea-
sured and uploaded BP into web-based monitoring programme 3 times per week. The
clinical pharmacy specialist reviewed home BPmeasurements and adherence,mademed-
ication adjustments (initiate, change, adjust doses, order laboratory tests), communi-
cated with patients via telephone or secure email. Medication changes were notified to
the primary care physician
Outcomes PATIENTS
Proportion of patients who attained their goal BP at 6 months
Change in systolic and diastolic BP between baseline and 6 months
Patient satisfaction
Adherence
PROCESS
Change in antihypertensive medication intensity
Ease of system use
RESOURCE USE
Clinic visits, emergency department visits, hospitalisations, telephone encounters, email
encounters
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Magid 2013 (Continued)
Random sequence generation (selection
bias)
Low risk A random allocation sequence was computer-generated
using stratified randomisation with an allocation ratio of
1:1
Allocation concealment (selection bias) Unclear risk The sequence was concealed from the patient until the
baseline visit. Concealment from investigators not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not feasible with study design. Patients self-re-
ported BP. Intervention and usual care patients could be
treated by the same physician and may have treated usual
care patients more aggressively. Primary care physicians
consulted pharmacists for 22 usual care patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk BP at 6 months taken by a research assistant blinded
to study group assignment using baseline measurement
protocol. Baseline measurement by clinic nurse
Incomplete outcome data (attrition bias) Low risk Intention-to-treat analysis of randomised patients and
estimates made for data of 22 missing patients 9/173
usual care (5%), 13/175 (7%) intervention
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Trend to higher mean baseline BP in intervention group.
Margolis 2013
Methods Cluster-randomised controlled trial
Participants Sixteen primary care clinics (Health Partners Medical Group), Minneapolis-St Paul,
Minnesota, USA
Patients with uncontrolled BP (≥ 140/90 mmHg or ≥ 130/80 mmHg if diabetic or
chronic kidney disease was present)
Patients 450 adults (8 clinics telephone intervention 228, 8 clinics usual care 222)
Health professional delivering intervention - 4 doctoral pharmacists with 8 hours for-
mal training on the study protocol and observed conducting a telephone visit on two
occasions. Clinical practice agreements allowed pharmacists to prescribe and change an-
tihypertensive therapy within specified parameters
Interventions PATIENTS
Home BP telemonitoring with pharmacist case management of BP versus usual care
Patients were instructed to transmit at least 6 BPmeasurements weekly.During the first 6
months patients and pharmacists met every 2 weeks via telephone until BP was sustained
for 6 weeks then reduced to monthly. During intervention months 7 to 12, telephone
visits occurred every 2 months. After 12 months telemonitoring was discontinued and
patients’ care was returned to their primary care physician with no support from a study
pharmacist
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Margolis 2013 (Continued)
During telephone visits pharmacists emphasised lifestyle change, and medication adher-
ence. They assessed and adjusted antihypertensive drug therapy based on an algorithm
using the percentage of home BP readings meeting goal ( ≥ 75% no change, ≤ 75%
treatment intensification). If the patient experienced adverse effects the dose would be
lowered or drugs switched. Usual care could include referral by the primary care physi-
cian to a pharmacist for medication management
Outcomes PATIENTS
Control of systolic BP to less than 140 mmHg and diastolic BP to less than 90 mmHg at
6 and 12 months (< 130/80 mmHG in patients with diabetes or chronic kidney disease)
Change in BP
Quality of life (Medical Outcomes Study Short Form-12 V2)
Self-efficacy for measuring BP
Patient satisfaction (six items from the Consumer Assessment of Healthcare Providers
and Systems adult survey v4)
BP control at 18 months
Adherence (Morisky scale)
Safety and adverse effects (hospitalisations, emergency department visits, urgent care,
same day medical visits for BP problems, hypotension, fainting, loss of consciousness
and allergic reactions)
PROCESS
Medication use (number and type)
RESOURCE USE
Programme costs per patient
Notes 12-month intervention and 6 months follow-up.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Cluster-randomisation (clinics matched by size
and clinic BP control at baseline)
Allocation concealment (selection bias) High risk Not possible to conceal.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design after randomisa-
tion.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk At 6, 12, 18 months research staff were not
blinded to study group but trained to treat both
groups identically. Record of medication events
reviewed independently
Incomplete outcome data (attrition bias) Low risk Low attrition at follow-up visits 6 months, 90%
telemonitoring, 89% usual care
12 months 86% both groups.
18 months 82% both groups.
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Margolis 2013 (Continued)
Selective reporting (reporting bias) Unclear risk Predefined outcomes reported.
Other bias Unclear risk Difficult to distinguish effect of telemonitoring
from pharmacist case management
Participants generally well-educated with higher-
income levels (not representative of broader com-
munity)
Marotti 2011
Methods Randomised controlled three arm parallel-group trial
Participants John Hunter Hopsital. New South Wales. Australia
Elective surgical patients taking regular medications with a postoperative stay of one
night or more
Patients 357 (control 118, pharmacist medication history 119, pharmacist medication
history and prescribing 120)
Healthcare delivering intervention - pharmacist
Interventions PATIENTS
Pharmacist medication history and supplementary prescribing versus pharmacist med-
ication history versus usual care to determine whether the number of missed doses of
regular medication was significantly different between the three arms
The pharmacist medication history in both groups was taken at the time of admission on
the day of surgery. In the supplementary prescribing group the pharmacist prescribed the
patients’ regular medicines on the inpatient medication chart (without medical review)
. Local protocols guided which medications were to be withheld and for how long for
each type of surgery
Outcomes PATIENTS
Reduction in the number of medication doses missed inappropriately during the inpa-
tient stay
The number of medications charted at an incorrect dose
The number of medications charted at an incorrect frequency
The number of missed doses postoperatively of significant medications (beta blockers,
HMG-CoA reductase inhibitors, antiplatelets, anticoagulants)
Notes Training/experience not stated, numbers of pharmacists not specified. 5-month study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised via a computer-
generated list.
Allocation concealment (selection bias) Unclear risk List held by an independent investigator.
84Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Marotti 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomemeasures were collected after dis-
charge by an independent technician (ret-
rospective chart review and patient records)
Incomplete outcome data (attrition bias) Low risk Cancelled surgery or lost to follow-up:
control 9/118, pharmacist medication his-
tory 10/119, pharmacist medication his-
tory and supplementary prescribing 8/120.
Intention-to-treat analysis. Patients who
had surgery cancelled had no postoperative
data and were excluded from part of the
analysis
Selective reporting (reporting bias) Unclear risk Predefined outcomes reported.
Other bias Unclear risk Post-discharge taking of the medication
history over the phone in the control group
may have resulted in medications being
omitted from the medication history
Reasonswere not collected formissed doses
(potentially missing appropriate reasons)
McAlister 2014
Methods Randomised controlled trial
Participants Stroke prevention clinics Edmonton, Alberta, Canada
Patients older than 18 years who had an ischaemic stroke or transient ischaemic attack
confirmed by a stroke specialist at one of 3 stroke prevention clinics
Patients 279 (pharmacist intervention 143, nurse control 136)
Health professional delivering intervention - 4 pharmacists - no standardised training
but similar career stage
Interventions PATIENTS
Nurse-led case management from a stroke prevention clinic i.e. screening, monthly
visits, and feedback to primary care physician (the control) versus pharmacist-led case
management with active prescribing (intervention)
Pharmacists saw patients monthly for 6 months. Pharmacists performed same tasks
as nurses in the control arm as well as initiating or titrating antihypertensive and or
lipid-lowering therapy using treatment algorithms and targets. The nurse in the control
arm saw patients monthly and provided lifestyle advice (exercise, low-salt diet, smoking
cessation, medication adherence) and checked BP and LDL
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McAlister 2014 (Continued)
Outcomes PATIENTS
The proportion of participants at 6 months who attained optimal BP & lipid control
(systolic BP < 140 mmHG & fasting LDL ≤ 2 mmol/L)
Mortality
Self-reported adherence
BMI
Smoking status
Quality of life (EQ-5D)
Disability (Modified Rankin score)
Overall self-rated health
Overall rating of health satisfaction
Physical activity
Adverse events
PROCESS
Medication (changes, numbers, type)
Notes 6-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done centrally by use of computer-
generated random numbers with variable-sized block
randomisation stratified by stroke prevention clinic to
preserve allocation concealment
Allocation concealment (selection bias) Low risk Secure Internet-based allocation method that ensures al-
location concealment from research personnel
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design. All participants and
nurses/pharmacists/doctors aware of treatment groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The primary and secondary outcomes collected and anal-
ysed in an independent and blinded manner by research
personnel who were not involved in the patient’s care and
blinded to patient’s randomisation group and baseline
measurements. Laboratory measurements independently
analysed
Incomplete outcome data (attrition bias) Unclear risk 31/143 (22%) excluded form intervention versus 9/136
(7%) from control (reasons provided) but unlikely to
bias result as similar numbers remained in the trial, 130
intervention and 136 nurse control. Intention-to-treat
analysis. Bias toward the null hypothesis as data for 225/
279 patients
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McAlister 2014 (Continued)
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Multifactorial intervention with effect of prescribing on
outcomes unclear
Moher 2001
Methods Cluster-randomised controlled trial
Participants 21 general practices, Warwickshire, England
Practice level randomisation 7 audit, 7 GP recall, 7 nurse recall
Patients aged 55 to 75 with established CHD
Patients at final audit 1906 (559 audit, 682 GP recall, 665 nurse recall)
Health professional delivering intervention - nurse in the nurse recall arm who received
education to implement guidelines for secondary prevention
Interventions PATIENTS
Assessing three differentmethods of promoting secondary preventionofCHDinprimary
care
Audit group (audit of notes and summary feedback to primary healthcare team) versus
GP recall group (disease register and systematic recall to GP) versus nurse recall group
(disease register and patient recall to nurse-led clinic). Agreed clinic protocol for sec-
ondary prevention
Outcomes PATIENTS
3 risk factors (BP target, cholesterol, smoking status)
BP > 140 mmHg systolic BP or > 90 mmHg diastolic BP
Cholesterol ≥ 5.5 mmol/L
Continine levels
Quality of life (Dartmouth COOP charts, EuroQol scores)
PROCESS
Prescribing (antihypertensives, lipid-lowering drugs, antiplatelet drugs)
Notes 18-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation based on computer-generated
random numbers.
Allocation concealment (selection bias) Low risk Randomisationwas carried out under observation
of a statistician blind to the identity of the practice
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
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Moher 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory values andBP carried out by a research
nurse blind to allocation group and no previous
involvement
Incomplete outcome data (attrition bias) Unclear risk Attrition at follow-up. Proprtions adequately as-
sessed:
nurse recall 85% (556/665), GP recall 76% (521/
682) audit group, audit group 52% (293/559)
Selective reporting (reporting bias) Low risk Not apparent.
Other bias Unclear risk Unclear autonomy of nurse prescribing in nurse
recall group.
New 2003
Methods Randomised controlled trial
Participants Hope Hospital, Salford, UK
Patients with diabetes and raised BP (≥ 140/80 mmHg) or raised total cholesterol (≥ 5.
0mmol/L) or both. Patients were receiving shared care with their GP and HopeHospital
for their annual diabetes review
Patients 1407 (nurse hypertension clinic 506, usual care 508, nurse hyperlipidaemia
clinic 345, usual care 338)
Health professional delivering intervention - two nurse specialists, trained to degree
level and previous experience of managing diabetes, hypertension and dyslipidaemia and
patient education. Local training by clinicians
Interventions PATIENTS
Independent specialist nurse-led clinics (one for hypertension, one for hyperlipidaemia)
versus usual care
Patients were randomised to receive the hypertension or hypercholesterolaemia interven-
tions separately and patients with both were randomised to one intervention and were a
control for the other
Nurses provided lifestyle advice, and titration of drug therapies according to local guide-
lines. Patients attended nurse-led clinics every 4-6 weeks until targets were achieved.
Lifestyle modifications were reinforced and medications titrated according to response.
The specialist nurse discussed patients who required additional medications with the
doctor who initiated additional therapy when appropriate. The protocol forbade the
nurse from managing the other intervention e.g. cholesterol in the BP arm
Outcomes PATIENTS
The odds ratio of achieving targets in hypertension and hyperlipidaemia attributable to
the specialist nurse-led intervention
Cholesterol control
BP control
Adverse events - mortality
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New 2003 (Continued)
Notes 12-month study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Remote randomisation service. Separate randomisation’s
for each condition
Allocation concealment (selection bias) Low risk Fully concealed process. Emailed randomisation to re-
spective nurses
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data abstracted at 1-year by staff blinded to allocation.
Laboratory measurement low risk.
Incomplete outcome data (attrition bias) Unclear risk BP clinic attrition 99/506 (19.6%) usual care 132/508
(26%).
Lipid clinic 34/345 (9.8%), usual care 41/338 (12%).
Intention-to-treat.
Selective reporting (reporting bias) Low risk None apparent.
Other bias Unclear risk Nurse discussed additional therapies with doctor who
initiated them when appropriate
Pagaiya 2005
Methods Cluster-randomised controlled trial
Participants Eighteen nurse-led health centres in Khon Kaen, Thailand
Practice - 18, matched pairs, 9 intervention, 9 control, 220 patients per centre
Health centre unit of allocation and analysis
Interventions PROVIDERS
Education and implementation of prescribing and clinical guidelines by nurses in rural
health centres versus usual nurse care
Intervention centres received an initial 3-day training course around four clinical guide-
lines. For children - acute respiratory infections and diarrhoea, for adults - diazepam pre-
scribing and management of diabetes mellitus. Training strategies were lectures, group
discussions, role-play and presentations. Educational outreach visits by nurse supervisors
occurred 3-4 months after training. Each visit lasted 1.5-2 hours with discussion on use
of the guidelines, problems, adequacy of drugs and equipment. Random auditing and
feedback followed
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Pagaiya 2005 (Continued)
Outcomes PROCESS
Antibiotic prescribing
Diazepam prescribing
Prescribing costs per patient
PATIENT
Management of diabetes
Notes 6-month study.
Analysis adjusted for clustering effect.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eighteen nurse-led health centres were matched
and sent to the second author blind to the identity
of the health centres, to allocate at random into
nine intervention and nine control centres using
random number tables
Allocation concealment (selection bias) Unclear risk Randomisation per centre. Author could not fore-
see allocation using random number tables. The
choice of intervention sites was concealed from
health centre staff
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk While the intervention site was concealed from
staff they would have been aware through train-
ing that they were an intervention site and this
may have affected performance. Similarly control
centres would be aware of their status
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Random selection of patient records but unclear
who undertook the assessment
Incomplete outcome data (attrition bias) Low risk Data reported for all centres.
Selective reporting (reporting bias) Low risk Not evident.
Other bias Unclear risk Diabetes management outcome - limited data.
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Rudd 2004
Methods Randomised controlled trial
Participants Twoprimary caremedical clinics, Kaiser PermanenteMountainViewClinic and Primary
Care Clinics of the Standford University Medical Center, California, USA
Patients with hypertension eligible for drug therapy (threshold 150 mmHg systolic BP,
95 mmHg diastolic BP or both)
Patients 150 (usual care plus nurse management intervention 74, usual care 76)
Health professional delivering intervention - nurse
Interventions PATIENTS
Nurse-managed home-based management of hypertension versus usual care
Nurse care manager counselled intervention patients on use of automated BP device
and reporting, drug adherence and recognition of side-effects. Printedmaterial provided.
Follow-up phone contacts 1 week and 1, 2, 4 months. Patients could phone the nurse
with questions or concerns. Patients monitored their BP twice a day
The nurse used standardised algorithms to modulate drug therapy based on patients’
reports of home BP. The nurse contacted the physician to obtain permission to initiate
any new BP drug but could change medication dosage. When 80% of home BP reading
achieved 130/85 mmHg over 2 weeks no further changes to drug therapy were made.
The cardiologist could be consulted by phone about problematic cases
Outcomes PATIENTS
Change in BP from baseline to 6-month visit
Adherence
PROCESS
BP medication use (number, variety, changes)
Frequency of drug changes
Notes 6-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation using computer-generated assignment.
Allocation concealment (selection bias) Unclear risk Not specified.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk At 3 and 6 months a research assistant blinded to group
assignment measured clinic BP and interviewed patients
about medications taken
Incomplete outcome data (attrition bias) Low risk 8 patients (6%) in usual care group and 5 patients (4%)
in the intervention group were classed as dropouts at 6
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Rudd 2004 (Continued)
months. Reasons provided
Selective reporting (reporting bias) Low risk None apparent.
Other bias Unclear risk Effect of medical advice and approval of new drugs on
BP and nurse prescribing. Reported < 5% of treatment
decisions required telephone discussions with the physi-
cian
Spitzer 1974
Methods Randomised controlled trial
Participants Two family practices, Ontario, Canada
Families 1598 (4325 members), nurse practitioner group 540 families (1529 members)
, conventional group 1058 families (2769 members)
Health professional delivering intervention - twonurse practitionerswho attended special
training conducted by the schools of nursing and medicine at McMaster University to
become co-practitioners
Interventions PATIENTS
Nurse practitioners versus physicians plus conventional nurse in primary care
Outcomes PATIENTS
Quality of care (assessing 10 indicator conditions and the manner in which 13 common
drugs were prescribed)
Health status
Satisfaction with health service
Deaths
PROVIDERS
Clinical judgement (management of ten indicator conditions and prescribing of 13
common drugs)
Clinician activities
PROCESS
Practice activities
RESOURCE USE
Financial performance
Notes 12-month experimental period (12-month follow-up).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible families were stratified by practice of origin and
randomly allocated in a ratio of 2:1
Allocation concealment (selection bias) Unclear risk Concealment not specified.
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Spitzer 1974 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Interviewers and data gatherers divorced from experi-
mental participant
Incomplete outcome data (attrition bias) Low risk Attrition - only seven families out of 1598 eligible families
refused their assignment (two conventional, five nurse
practitioner group)
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias High risk Doctors involved in high percentage of nurse practitioner
visits. Unclear effects on prescribing
Taveira 2010
Methods Randomisd controlled trial
Participants Ambulatory care clinic - Providence Veterans AffairsMedical Center, Rhode Island, USA
Veterans 18 years or older with type 2 diabetes with HbA1c between 7% and 9% within
the last 6 months and willing to participate and discuss their diabetes and cardiac risk
factors in a group setting
Patients 109 (58 intervention, 51 usual care)
Health professional delivering intervention - clinical pharmacist who completed one year
of postdoctoral pharmacy practice residency as well as certification in diabetes education
and physical assessment and underwent 6 months of clinic-based internist-supervised
pharmacologic management of diabetes, dyslipidaemia, and hypertension)
No unit of analysis errors
Interventions PATIENTS
Apharmacist-ledVeterans affairsMultidisciplinary Education andDiabetes Intervention
for Cardiac risk reduction (VA-MEDIC) plus usual care versus usual care
VA-MEDIC consisted of 4 weekly 2-hour sessions in a classroom setting with 4 to 8
participants. Family and friends could attend. Each session consisted of two parts. Part
1: Education session of 40-60 minutes provided by nurse, nutritionist, physical therapist
or pharmacist focused on 1 or 2 diabetes self-care behaviours. Part 2: A behavioural
and pharmacologic intervention of 60-80 minutes conducted by a clinical pharmacist
who treated hypertension, dyslipidaemia & tobacco use. Medication titration based on
algorithms
Outcomes PATIENTS
Percentage of patients attaining target goals for HbA1c (< 7%), BP (systolic BP < 130
mmHg, diastolic BP < 80mmHg), non-HDL cholesterol < 3.4mmol/L, LDL cholesterol
< 2.6 mmol/L, smoking cessation
Self-care behaviours
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Taveira 2010 (Continued)
PROCESS
Medication changes
Notes Data obtained from the electronic medical record at 4 months
Small number of smokers.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned to intervention arm or standard
care using a simple coin toss randomisation
Allocation concealment (selection bias) Unclear risk Method of concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome group: no blinding but physiological outcomes
unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) Low risk Intention-to-treat analysis. Low attrition 6/64 interven-
tion (9%) and 3/44 (7%) standard care withdrew
Data on self-care behaviours not formally collected.
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias High risk Self-care behaviours survey not validated.
Population white male Veterans.
Limited duration of 4-week intervention and 4-month
follow-up
Multifactorial intervention with effect of prescribing on
outcomes unclear
Taveira 2011
Methods Randomised controlled trial
Participants Ambulatory care clinic - Providence Veterans AffairsMedical Center, Rhode island, USA
Veterans with type 1 and type 2 diabetes with HbA1c > 6.5% within the last 6 months
and concomitant depression as defined by the International Classification of Diseases
(ICD) codes 311, 296.2 and 296.3 who were willing to participate and discuss their
diabetes and cardiovascular risk factors in a group setting and able to provide written
informed consent
Patients 86 (44 intervention, 42 standard care)
Zero type 1 diabetic patients recruited
Health professional delivering intervention - a clinical pharmacist who had at least 1 year
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Taveira 2011 (Continued)
of ambulatory care/clinical training experience and was certified in diabetes education
at state or national level
Interventions PATIENTS
Veterans AffiarsMultidisciplinary Education inDiabetes and Intervention in for Cardiac
Risk Reduction in Depression (VA-MEDIC-D) plus standard care versus standard care
VA-MEDIC-D consisted of participants attending 4 once-weekly sessions of 2 hours
followed by 5 monthly booster 90-minute group sessions held in a classroom with 4-6
participants. Family friends could attend
Each session consisted of two parts. Part 1: Standardised education session of 40-60 min-
utes by a nurse, nutritionist, clinical pharmacist focusing on 1 or 2 self-care behaviours
e.g. goals for healthy eating
Part 2: Pharmacist conducted behavioural and pharmacologic intervention for hyper-
tension, hyperlipidaemia, hyperglycaemia and tobacco use. 60-80 minute sessions. A
group assessment of daily self-care activities was made and self-care enhanced through
group counselling. Individual risk report of laboratory tests andmedication was reviewed
and drugs initiated or titrated by the pharmacist according to established algorithms for
BP, cholesterol, diabetes and tobacco cessation. The pharmacist undertook behavioural
change goal setting. No changes were made for psychiatric medications
Outcomes PATIENTS
Change in the proportion of participants who attained a HbA1c < 7% at 6 months
Proportion of participants who attained ADA guidelines for BP and fasting lipids and
the absolute change in values
Self-care (Perceived Competence for Diabetes Scale PCDS)
Adherence to self-care behaviours (Summary of Diabetes Self-Care Activities SDSCA)
Change from baseline in depression symptoms (assessed by the Patient Health Ques-
tionnaire -PHQ9) even though depression treatment was not part of the intervention
Deaths
RESOURCE USE
Emergency department visits and hospitalisations
Notes Complex multifactorial intervention.
6-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned to intervention arm or stan-
dard care using a simple coin toss randomisation
Allocation concealment (selection bias) Unclear risk Method of concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
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Taveira 2011 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding of assessment but outcome (HbA1c),
cholesterol unlikely to be influenced by lack of blinding
Unclear who measured BP.
It is unclear if response to questionnaires were influenced
by the group allocation
Incomplete outcome data (attrition bias) Low risk Intention-to-treat analysis. 0/44 intervention and 2/44
standard care lost to follow-up
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Multifactorial intervention with effect of prescribing on
outcomes unclear
Thompson 1984
Methods Controlled before-and-after study
Participants A purposively selected skilled nursing facility, Los Angeles, USA
Patients in a skilled nursing care facility with a length of stay > 2 months
Patients, pre-study year (treatment group 60, control group 75). Study year (pharmacist
treatment group 67, control group 72)
Health professional delivering intervention - two clinical pharmacists who were Univer-
sity of Southern California School of Pharmacy faculty members with six or more years
experience in clinical patient care. Each was trained in physical assessment and basic
diagnostic skills
Interventions PATIENTS
Drug therapy prescribing and patient care management by clinical pharmacists versus
usual care
Each patient’s medical, social, functional and drug history was reviewed. Physical assess-
ment was performed. Appropriate laboratory tests ordered and physical assessment pa-
rameters determined. Medications were reviewed with the options of continuing present
medications, making dose adjustments or entirely discontinuing or changing the type
or class of medication. Patients were examined monthly. Supervising physician refrained
from prescribing any medications, changing any of the clinical pharmacists orders or
ordering any drug-related laboratory tests
Outcomes PATIENTS
Deaths
RESOURCE USE
Average number of drugs per patients
Discharge to lower level care
Hospitalisations
Notes 12-month study.
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Thompson 1984 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants could not be randomly assigned to
treatment or control groups because of logistic lim-
itations imposed by the organisation of medical
care. Control and treatment patients were matched
with no significant differences between the pre-
study year and study years for sex, age, length of
stay, number of medications, diagnoses, discharge
rate, hospitalisations, and mortality rate
Allocation concealment (selection bias) High risk As above.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Numerical counts with low risk of bias.
Incomplete outcome data (attrition bias) Low risk Data complete.
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Different physicians were involved in both groups
and some improved treatment effects potentially
due to the influence on and collaboration with pre-
scribing pharmacist
Tobe 2006
Methods Randomised controlled trial (open-label study with 2 parallel groups)
Participants Battlefords Tribal Council Indian Health Services, Saskatchewan, Canada
First Nations people 18 and older with existing hypertension (systolic BP≥ 130 mmHg,
diastolic BP ≥ 80 mmHg) and diabetes
Patients 99 (intervention 50, control 49) - included in analysis: 48 intervention, 47
control
Healthcare professional delivering intervention - home care nurse following a predefined
treatment algorithm of pharmacologic antihypertensive therapy. Hypertension specialist
consulted if BP not controlled or for accelerated titration
No unit of analysis errors
97Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tobe 2006 (Continued)
Interventions PATIENTS
Community-based treatment strategy implemented by home care nurses to control hy-
pertension versus home care visits and follow-up by primary care physicians
Patients seen at baseline, 6 weeks, 3, 6, 9, 12 months
Outcomes PATIENTS
Difference between the groups in the change in systolic BP after 12 months
All participants received healthy lifestyle classes
Change in diastolic BP
Change in urine albumin
Adverse events
Notes 12-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation used a permuted block de-
sign stratified by the seven reserves
Allocation concealment (selection bias) Low risk Randomisationwas performed bymeans of
opaque sealed envelopes opened at the end
of the baseline visit by the home care nurse
in the presence of the physician and patient
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design. Randomi-
sation opened in front of home care nurse,
physician, patient
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk BP taken by home care nurses.
Low risk - laboratory tests.
Incomplete outcome data (attrition bias) Low risk Intention-to-treat. 2 participants withdrew
from both intervention and control groups
(reasons provided and participants not in-
cluded in analysis). Intervention analysis
includes 1 lost to follow-up and 3 stopped,
control 2 lost to follow-up and 3 stopped
intervention
Selective reporting (reporting bias) Low risk Predefined outcomes reported.
Other bias Unclear risk Unclear level of influence of the supervising
hypertension specialist on nurse titration of
medication
Both groups shared family physicians.
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Tsuyuki 2015
Methods Randomised controlled trial
Participants Twenty-three sites (community pharmacies, hospital outpatient clinics, primary care
settings) in Alberta, Canada
Community pharmacists (20), hospital pharmacists (2) primary care clinic pharmacists
(6)
Adults with uncontrolled BP as defined by Canadian Hypertension Education Program
guidelines (140/90 mmHg for most and130/80 mmHg for those with diabetes)
Patients 248 (181 intervention, 67 usual care)
Healthcare professional delivering intervention - pharmacists with authorisation to pre-
scribe (Health Professions Act of Alberta) entailing a minimum of one year of practice
experience and completion of an application process to demonstrate skills in patient
assessment, judgement, care planning and follow-up. Prescribing decisions required to
be communicated to the patient’s primary care physician. Pharmacists received training
in BP assessment and treatment and had access to hypertension experts for consultation
as required
Interventions PATIENTS
Pharmacist prescribing for community-dwelling patientswith uncontrolled hypertension
versus usual care
BP control by pharmacist care (assessment of and counselling about cardiovascular risk
and BP control, review of antihypertensive medications and prescribing/titrating drug
therapy, BP wallet record card, lifestyle advice, written information)
Outcomes PATIENTS
Change in systolic BP from base line to 6 months between intervention and usual care
Change in diastolic BP
Number of patients at Canadian Hypertension Education Program target
RESOURCE USE
Number of new antihypertensive medication starts
Number of antihypertensive dose changes
Number of antihypertensive drug changes
Number of new prescriptions for aspirin and cholesterol-lowering medications
Notes 6-month study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised secure website (EPICORE).
Allocation concealment (selection bias) Unclear risk Method of concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
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Tsuyuki 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Performed by patients via automated device, study phar-
macists requested to leave room
Incomplete outcome data (attrition bias) Low risk While sample size of 340 in protocol was not reached due
to funding limits this affected the remuneration substudy,
not the main study with a priori sample size of 240
Attrition 26 (14%) intervention, 6 (9%) usual care.
Selective reporting (reporting bias) Low risk Not evident.
Other bias Unclear risk The usual care group received pharmacist education at
the discretion of the pharmacist and BP measurement at
threemonths in addition tousualmedical carewhichmay
represent greater than usual care. Intervention patients
were seen more frequently
Cluster-randomisation not employed.
Effect of fee for service.
Tsuyuki 2016
Methods Randomised controlled trial
Participants 723 patients who were at high risk of cardiovascular events in 56 community pharmacies
in Alberta, Canada
Adults with diabetes, chronic kidney disease, atherosclerotic vascular disease, primary
prevention patients with multiple risk factors. Subjects had at least one uncontrolled
risk factor, BP > 140/90 mmHg or > 130/80 mmHg if diabetic, LDL-c > 2.0 mmol/L,
HbA1c > 7% or current smoker
Patients 723 (370 pharmacist intervention, 353 usual pharmacist/physician care)
Healthcare professional delivering intervention - community pharmacists prescribing
within their scope of practice and undergoing an online training programme in cardio-
vascular risk reduction
Interventions PATIENTS
The pharmacist intervention group received a medication therapy management consul-
tation comprising a patient assessment, laboratory assessment and individualised assess-
ment with education. Pharmacists prescribed medications and ordered laboratory tests
as per their scope of practice to achieve treatment targets. Patients received monthly
follow-up visits for three months
Outcomes PATIENTS
Change in risk for cardiovascular disease events at 3 months
Improvement in LDL
Improvement in systolic BP
Improvement in HbA1c
Improvement in smoking cessation
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Tsuyuki 2016 (Continued)
Notes The study duration was 3 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised in a 1:1 ratio to intervention
or usual care groups using a centralised secure website
(EPICORE)
Allocation concealment (selection bias) Unclear risk Method of concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Low risk laboratory tests.
Unclear risk with BP assessment.
Incomplete outcome data (attrition bias) Low risk Loss to follow-up or withdrawals 2.8% usual care, 5.1%
intervention group
Selective reporting (reporting bias) Low risk Not evident.
Other bias Unclear risk Limited duration study of 3 months.
Vivian 2002
Methods Randomised controlled trial
Participants Generalmedicine clinic for themanagement of hypertension at aVeteransAffairsMedical
Center, Philadelphia, USA
Patients over 18 years with a confirmed diagnosis of essential hypertension (systolic BP
> 140 mmHg or diastolic BP > 90 mmHg), receiving antihypertensive drug therapy and
BP > 140/90 mmHg), receiving all drugs from the VA Medical Center pharmacy and
not receiving care at the pharmacist-managed clinic
Patients 56 (27 intervention, 29 control)
Health professional delivering intervention - one pharmacist
Practice - 1
No unit of analysis errors
Interventions PATIENTS
BP control in a pharmacist-managed hypertension clinic versus traditional care from a
primary care physician
Patients were scheduled to meet monthly with the pharmacist who had prescribing
authority to make appropriate changes in prescribed drugs, adjust dosages, and provide
drug counselling in accordance with guidelines. The pharmacist did not make changes
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Vivian 2002 (Continued)
in other drugs that may affect BP. Primary care providers cared for comorbid conditions
but could not change antihypertensive medication
Control group - care from traditional pharmacy services and primary care providers as
needed (at least once a year)
Outcomes PATIENTS
BP
Changes in compliance - compliance evaluation survey
Patient satisfaction
Quality of life (Medical Outcomes Study Short Form-36 survey)
Notes Study period 6 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described ’patients were ran-
domly assigned’
Allocation concealment (selection bias) Unclear risk Concealment process not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Measurement of BP at start and end undertaken ’by a
clinical pharmacist’ (one of three)
Patient completed surveys. Unclear effect of filling sat-
isfaction forms in the pharmacy clinic and influence of
group to which patient randomised. Compliance evalu-
ation questionnaire not validated
Incomplete outcome data (attrition bias) Low risk Low attrition. Two patients in the control group with-
drew, 2/29, one in the intervention arm, 1/27. Reasons
provided. No intention-to-treat analysis
Selective reporting (reporting bias) Low risk All predefined outcomes reported.
Other bias Unclear risk Monthly follow-up in intervention arm versus ’at least
yearly’ in the control arm
Most patients African Americans and all men.
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Wallymahmed 2011
Methods Randomised controlled trial
Participants Diabetes Centre, Aintree University Hospitals, Liverpool, England
Patients > 18 years with type 1 diabetes for at least 5 years, HbA1c ≥ 8%, and at least
one other risk factor for the development of cardiovascular disease
Patients 81 (nurse-led group 40, routine group 41)
Health professional delivering intervention - single diabetes nurse consultant in an out-
patient clinic
No unit of analysis errors
Interventions PATIENTS
Nurse-led cardiovascular risk reduction versus routine care with review by doctors in a
diabetes clinic with follow-up and referral to themultidisciplinary team for diabetes con-
trol problems. In nurse-led management included lifestyle advice, information and ad-
vice on injection technique, and pharmacological interventions (glycaemic control, hy-
pertension, lipids). Management was protocol driven on a ’treat to target’ basis. Changes
in medications were made by a letter to the GP with a copy to the patient. In usual care
recommendations for initiation or changes to medication were communicated to the
patients’ GP. Patients were reviewed monthly for the first 6 months then 6-monthly for
2 years. Review in the routine diabetic clinic occurred annually
Outcomes PATIENTS (at baseline, 6, 12, and 24 months)
HbA1c
Lipids (total cholesterol, LDL, HDL)
Serum creatinine
Urinary albumin/creatinine ratio
Weight
BMI
BP (systolic and diastolic BP)
Daily insulin dose
Medication - nurse-led group, serum creatinine and potassium (ACE inhibitors or an-
giotensin 2 receptor blockers), liver function tests for statins
PROCESS
Medication use
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised.
Allocation concealment (selection bias) Low risk Computer-generated blind envelope system.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible with study design.
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Wallymahmed 2011 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory measures low risk.
Provider measuring BP not reported.
Incomplete outcome data (attrition bias) Low risk 96.2% (78/81) completed the 2-year study, low attrition
1/40 nurse-led, 2/41 routine care
During the study non-attendance was high, nurse-led
22%, consultant routine care 26%, routine care by dia-
betes nursing service for glycaemic control 40%
Selective reporting (reporting bias) Unclear risk Pedefined outcomes reported apart from 6-month rou-
tine care data
Other bias Unclear risk In routine care, initiation or changes to lipid-lowering
and antihypertensive medication were communicated by
letter to theGP andmay not have been actioned. Unclear
detail of nurse prescribing method. Unclear influence on
prescribing outcomes of multidisciplinary team and an-
nual clinic review
ACE: angiotensin-converting enzyme
ADA: American Diabetes Association
BMI: body mass index
BP: blood pressure
CD4: cluster of differentiation 4
CHD: coronary heart disease
CHF: congestive heart failure
DM: diabetes mellitus
DSC: diabetes symptom checklist
GP: general practitioner
HbA1c: glycated haemoglobin
HDL: high-density lipoprotein
LDL: low-density lipoprotein
PEQD: patients’ evaluation of the quality of diabetes care
SF-12: 12 item Short Form health survey
SF-36: 36 item Short Form health survey
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adler 2004 No pharmacist prescribing element.
Akrimi 2013 Not RCT, CBA, or ITS.
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(Continued)
Al Hamareneh 2013 Does not meet CBA criteria.
Ala 2011 Single centre non-RCT.
Amariles 2012 No non-medical (pharmacist) prescribing element.
Anaya 2008 Unclearmedical input into pharmacist prescribing.Does not have three time pointmeasurements
before and after intervention
Andrus 2007 Retrospective chart review of pharmacist clinical interventions, single centre not randomised, no
control group, not ITS
Bajorek 2005 Not randomised, no control group, reference to a historical control
Bajorek 2016 Pharmacists did not undertake a prescribing role.
Bebb 2007 Unclear and varied use of prescribing algorithm by doctors and nurses
Becker 1998 Doctor wrote script.
Bellary 2008 Medical consultation with non-medical prescriber on prescribing changes
Birchall 2011 Not RCT, CBA, or ITS.
Blackberry 2014 Medical role in prescribing decisions.
Blozik 2010 No nurse prescribing.
Brook-Barclay 2014 No pharmacist prescribing role.
Bruggink-Andre de la Porte 2007 Physician and nurse proposed treatment.
Capoccia 2004 Independence of non-medical prescribing role by pharmacist unclear
Carey 2008 Not RCT, CBA, or ITS.
Carter 2001 Unclear non-medical prescribing role of pharmacist.
Carter 2008 Pharmacist could not independently prescribe.
Carter 2015 Even though a RCT the aim of this study was to test the effect of experiencing the intervention
and then discontinuing it versus continuing the intervention. There was no control group that
never received a pharmacist intervention, which is the basis for exclusion
Cattell 2001 Transcribing where medical staff primary decision maker.
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Chantelois 2003 Pharmacist discharge prescriptions reviewed, electronically co-signed, edited, or cancelled by a
physician
Cheng 2014 Review only.
Chiquette 1998 Single site, not contemporaneous data collection.
Courtenay 2007 Not RCT, CBA, or ITS.
Dawson 2012 Not RCT, CBA, or ITS.
Dean 2014 Medication prescription by doctors.
deClifford 2009 Not RCT, CBA, or ITS and doctor signed prescription.
Dierick-van Daele 2010 Nurse had no authority to prescribe.
Driscoll 2014 Cardiologist reviwed treatment and completed prescriptions.
Ginson 2000 Physician signature required on pharmacist prescription.
Gray 1985 Not RCT, CBA, or ITS.
Guder 2015 Joint nurse and physician up-titration of medication.
Hale 2013 Medical signature required.
Hancock 2012 Unclear nurse prescribing autonomy. Prescriptions managed within care home and associated
general practice
Harrison 2014 Does not meet ITS criteria of three data points before and after intervention
Hawkins 1979 Pharmacist prescribing intervention unclear. Focus on compliance support rather than drug
selection or change
Hick 2001 Non-randomised pharmacist transcription.
Ho 2014 No pharmacist prescribing.
Holland 2007 No non-medical (pharmacist) prescribing.
Hotu 2010 No prescribing by health workers.
Irewall 2015 Medical consultation on pharmacological management.
Irons 2002 Non-randomised study with mixed prescribers in control group
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Jacobs 2005 Not RCT, CBA, or ITS.
Jameson 2010 Primary care physician approved any changes in medication or therapy. Pharmacist could adjust
insulin doses as needed
Jennings 2012 Descriptive study.
Jewell 1988 Autonomy and method of nurse prescribing by algorithm not clear
Jorstad 2013 Unclear nurse prescribing autonomy.
Kinnersley 2000 Nurse prescriptions signed by doctor.
Krein 2004 Nurse practitioner’s medication changes required approval by the primary care (medical) provider
Kwan 2007 Physician determined and signed medication orders.
Lin 2012 No pharmacist prescribing element.
Logan 1983 No nurse prescribing.
Lowey 2007 No comparison group or period for pharmacist intervention.
Lowrie 2012 Consulation by pharmacist with family doctor before medication changes
Lowrie 2014 No pharmacist prescribing role.
Ma 2010 Retrospective single site study.
Martinez 2013 Not RCT or CBA.
McAdam-Marx 2012 Not RCT, CBA, or ITS.
McCord 2006 Non-randomised study. Retrospective chart review.
McFadzean 2003 Not RCT, CBA, or ITS.
McGhan 1983 Non-randomised study, no pre-intervention for CBA.
McGowan 2008 Pharmacist made treatment recommendations - no prescribing.
Meulepas 2008 CBA study with a delayed intervention in the control group. Extent of nurse prescribing and
autonomy unclear
Michalets 2015 Does not meet CBA criteria.
Monyatsi 2012 Cross-sectional study of chart documentation.
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Morello 2013 Not RCT, CBA, or ITS.
Murphy 2010 Not RCT, CBA, or ITS.
Neto 2011 Unclear if any prescribing role by pharmacist.
Norman 2010 Non-randomised study, no pre-intervention for CBA study.
O’Hare 2004 Unclear medical and nursing use of prescribing algorithm.
Obreli-Neto 2011 No prescribing by pharmacist.
Omran 2013 Unclear pharmacist prescribing role.
Omran 2015 Pharmacist prescribing authorisation not evident.
Pape 2011 No prescribing by pharmacist.
Payton 2011 Not RCT, CBA, or ITS.
Reid 2005 Not RCT, CBA, or ITS.
Rochester 2010 Does not meet CBA or ITS criteria.
Rothman 2005 All medication changes required the approval of the primary care proivider
Rudd 2010 Single centre retrospective medical record review.
Sadik 2005 No pharmacist prescribing.
Samtia 2013 No pharmacist prescribing role.
Sanne 2010 Medical prescribing only.
Schneider 1982 Shadow prescribing by pharmacist.
Scullin 2007 Extent and outcomes of discharge transcribing role by pharmacists unclear
Sease 2011 Retrospective review.
Seng 2011 No pharmacist prescribing.
Shum 2000 Nurse prescriptions required medical signature.
Simpson 2011 Physician authorised medication changes.
Sisk 2006 Physician role in prescribing.
108Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Solomon 1998 Prescribing role in pharmaceutical care unclear.
Sonnex 2014 Non-randomised, not CBA or ITS.
Stafford 2011 Not RCT, CBA, or ITS.
Stone 2010 Adjustment of medications by nurse practitioner medically supervised
Stromberg 2003 Cardiologist consulted on changes to medications.
Tahaineh 2011 Clinical pharmacist made prescribing recommendations to physicians
Taveira 2006 Does not meet ITS criteria.
Till 2003 Retrospective analysis.
To 2011 Not RCT, CBA, or ITS.
Vaisberg 2013 Unclear pharmacist prescribing role.
Vasileff 2009 Not RCT, CBA, or ITS.
Venning 2000 Non-medical prescribing nurses required doctor to sign prescriptions
Verret 2012 Patient self-management versus usual care.
Voogdt-Pruis 2011 Nurses did not have direct prescribing rights.
Warrington 2012 Does not meet CBA criteria.
Weigel 2012 Not RCT, CBA, or ITS.
Wilson 2003 Unclear degree of physician and pharmacist prescribing roles in intervention group
Wittayanukorn 2013 Non-randomised study with no non-medical prescribing.
Wood 2008 No non-medical prescribing.
Zimmerman 2014 Non-randomised, not CBA or ITS.
CBA: controlled before-and-after
ITS: interrupted time series
RCT: randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
Barton 2013
Methods Cost-effectiveness analysis alongside a pragmatic cluster-randomised controlled trial in 31 primary care clinics (16
intervention, 15 controls)
Participants HIV-infected patients in SouthAfrica.Cohort one: patients not yet receiving anti-retroviral therapy. 5390 intervention
patients, 3862 controls. Cohort 2: patients receiving at least six months antiretroviral therapy; 3029 intervention
patients, 3202 controls
Interventions Nurses who received at least four educational outreach training sessions about antiretroviral therapy prescribing and
undertook initiation and represcribing of antiretroviral therapy versus usual medical care
Outcomes A cost-effectiveness study of nurse-led versus doctor-led antiretroviral treatment in South Africa was undertaken on
data derived from Fairall 2008. Nurse-led antiretroviral therapy was found to be associated with higher mean health
service costs than doctor-led care but the levels of uncertainty were high given the wide confidence intervals around
the incremental costs and effects. There may have also been an underestimation of the benefit of the intervention.
The increased costs were largely explained by more frequent clinic visits with longer consultations for intervention
patients. Total nurse and doctor costs were higher for intervention patients in the two cohorts (those not receiving
and those already receiving antiretroviral therapy). In the cohort not receiving antiretroviral therapy at enrolment the
mean antiretroviral prescription costs were higher in the intervention group
Notes
Neilson 2015
Methods Regression analysis of costs and effects using intention-to-treat and expected value of sample information
Participants 125 patients with chronic pain and with complete resource use and SF-6 dimension questionnaire data at baseline,
three and six months
Interventions Patients were randomised to either pharmacist medication review with face-to-face pharmacist prescribing or phar-
macists medication review with feedback to general practitioner or treatment as usual
Outcomes The differences in costs and effects in terms of QALYs associated with pharmacist prescribing and or review compared
with treatment as usual in managing chronic pain in primary care was undertaken on data derived from Bruhn 2013.
Adjusted mean cost differences per patient relative to treatment as usual were GBP 77 for prescribing (95% CI -82
to 237) and GBP 54 for review (95% CI -103 to 212). Pharmacist-led interventions for chronic pain appeared more
costly and provide similar QALYs. The estimates were imprecise due to the small size of the pilot trial
Notes
Tsuyuki 2014
Methods Randomised controlled trial
Participants 99 adult patients from 14 community pharmacies in Alberta, Canada with uncontrolled dyslipidaemia (as defined
by the 2009 Canadian Dyslipidaemia Guidelines)
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Tsuyuki 2014 (Continued)
Interventions Pharmacist prescribing versus usual pharmacist, physician care. Follow-up at 6, 12, 18, and 24 weeks
Outcomes Unadjusted proportion of patients achieving LDL-c target was higher in the intervention group (43% versus 18%,
P < 0.007) and the intervention group had a greater reduction in LDL-c (1.59 mmol/L, SE 0.15 mmol/L versus 0.
42 mmol/L, SE 0.1, P < 0.0001)
Notes
CI: confidence interval
LDL-c: low-density lipoprotein
QALYs: quality-adjusted-life-years
SE: standard error
SF-6: Short Form-6
Characteristics of ongoing studies [ordered by study ID]
Mikuls 2015
Trial name or title A pragmatic cluster-randomised controlled trial of an automated, pharmacy-based intervention to optimise
allopurinol therapy in gout
Methods Cluster-randomised controlled trial of 103 clusters comparing pharmacist-led interventions versus usual care
An expert panel endorsed allopurinol treatment algorithms for pharmacist-led interventions to adjust allop-
urinol dosing
Participants Patients 441 intervention, 810 usual care
Patients with gout receiving new allopurinol prescriptions
Interventions Dose titration to treat to target to achieve and maintain a serum urate ≤ 6.0 mg/dL
Outcomes
Starting date July 2014
Contact information Ted R Mikuls, University of Nebraska Medical Center, Omaha, NE
Notes Ongoing study
111Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Non-medical prescribing group versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Systolic blood pressure mmHg 21 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 6 months 11 2076 Mean Difference (IV, Fixed, 95% CI) -6.76 [-8.24, -5.27]
1.2 12 months 12 4229 Mean Difference (IV, Fixed, 95% CI) -5.31 [-6.46, -4.16]
1.3 6 months systolic blood
pressure removing cluster effect
(Margolis)
10 1628 Mean Difference (IV, Fixed, 95% CI) -6.13 [-7.83, -4.44]
1.4 12 months systolic blood
pressure excluding cluster trials
(Khunti and Margolis)
10 2627 Mean Difference (IV, Fixed, 95% CI) -4.84 [-6.29, -3.39]
1.5 Systolic blood pressure
at 6 months (more NMP
prescribing autonomy)
4 695 Mean Difference (IV, Fixed, 95% CI) -2.98 [-5.36, -0.59]
2 HbA1c (%) 8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 HbA1c 6 mths 3 271 Mean Difference (IV, Fixed, 95% CI) -0.42 [-0.75, -0.09]
2.2 HbA1c 12 mths 6 775 Mean Difference (IV, Fixed, 95% CI) -0.62 [-0.85, -0.38]
3 Low-density lipoprotein (LDL)
mmol/L
11 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 LDL 6 mths 6 1213 Mean Difference (IV, Fixed, 95% CI) -0.25 [-0.34, -0.17]
3.2 LDL 12 mths 7 1469 Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.29, -0.14]
4 Low-density lipoprotein
pharmacist vs nurse 6 mths
6 1213 Mean Difference (IV, Fixed, 95% CI) -0.25 [-0.34, -0.17]
4.1 Pharmacist 4 629 Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.20, 0.02]
4.2 Nurse 2 584 Mean Difference (IV, Fixed, 95% CI) -0.52 [-0.67, -0.38]
5 Adherence (continuous) 4 700 Std. Mean Difference (IV, Fixed, 95% CI) 0.15 [0.00, 0.30]
6 Adherence (dichotomous) 4 935 Risk Difference (M-H, Fixed, 95% CI) 0.06 [-0.00, 0.12]
7 Health-related quality of life 8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Physical component
(SF12 or 36)
8 2385 Mean Difference (IV, Fixed, 95% CI) 1.17 [0.16, 2.17]
7.2 Mental component (SF-
12 or 36)
6 2246 Mean Difference (IV, Fixed, 95% CI) 0.58 [-0.40, 1.55]
8 Health facility resource use 5 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
8.1 Emergency Department
visits
3 4626 Risk Difference (M-H, Fixed, 95% CI) 0.01 [-0.02, 0.03]
8.2 Hospitalisations 5 4870 Risk Difference (M-H, Fixed, 95% CI) -0.01 [-0.03, 0.01]
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A D D I T I O N A L T A B L E S
Table 1. Fixed-effect outcomes versus random-effects for clinical surrogate markers
Outcome or subgroup Fixed-effect estimate Random-effects estimate
1.1 Systolic blood pressure (mmHg) -5.85 (-6.76 to -4.94) -6.59 (-8.48 to -4.71)
1.1.1 6 months -6.76 (-8.24 to -5.27) -7.34 (-11.09 to -3.60)
1.1.2 12 months -5.31 (-6.46 to -4.16) -5.91 (-7.71 to -4.10)
1.2 HbA1c (%) -0.55 (-0.74 to -0.36) -0.55 (-0.76 to -0.35)
1.2.1 HbA1c (6 months) -0.42 (-0.75 to -0.09) -0.45 (-0.09 to -0.01)
1.2.2 HbA1c (12 months) -0.62 (-0.85 to -0.38) -0.62 (-0.85 to -0.38)
1.3 LDL (mmol/L) -0.23 (-0.28 to -0.17) -0.22 (-0.42 to -0.02)
1.3.1 LDL (6 months) -0.25 (-0.34 to -0.17) -0.13 (-0.39 to 0.12)
1.3.2 LDL (12 months) -0.21 (-0.29 to -0.14) -0.3 (-0.62 to 0.02)
LDL: low-density lipoprotein
Table 2. Outcomes of studies not included in meta-analyses
Study Patient group Comparison Outcome
Bruhn 2013 Chronic pain To compare the effectiveness
of pharmacist medication review
with or without pharmacist pre-
scribing with standard care
Compared with baseline
the Chronic Pain Grade improved
in prescribing arm 47.7% (21/44;
P = 0.003) and review arm 38.6%
(17/44; P = 0.001) but not TAU
31.3% (15/48; ns) SF-12 mental
component score showed no effect
for prescribing or review arms and
deterioration in TAU arm. Hospi-
tal Anxiety and Depression scores
improved in prescribing arm for
depression (P = 0.022) and anxiety
(P = 0.007) and between groups
(P = 0.022 and P = 0.045 respec-
tively)
Chenella 1983 Anticoagulation Pharmacist versus physician inde-
pendent management of anticoag-
ulant therapy for inpatients
There were no differences between
groups for mean heparin and war-
farin doses, partial thromboplas-
tin time, days to reach therapeutic
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Table 2. Outcomes of studies not included in meta-analyses (Continued)
levels, mean prescribed and simu-
lated heparin doses
Choe 2005 Type 2 diabetes Pharmacist case management ver-
sus usual medical care
Patients in the pharmacist case
managed group received greater
reductions in HbA1c (2.1% vs
0.9%, P = 0.03). Three of five
process measures were conducted
more frequently in the interven-
tion group than control group.
LDL measurement (100% vs 85.
7%, P = 0.02), retinal examina-
tion (97.3% vs 74.3%, P = 0.004),
monofilament foot screening, (92.
3% vs 62.9%, P = 0.002)
Einhorn 1978 Family planning Family planning services provided
by nurses versus physicians
Nurses’ clients were as equally as
successful as physicians in contin-
uing contraceptive use and pre-
venting pregnancy. Nurses were
less likely than physicians to pro-
vide patients on their first visit
with IUDs, prescribe oral contra-
ceptives, or sterilisation. Nurses
were more likely to give temporary
prescriptions than physicians until
the next visit (25% vs 16%, P <
0.001) for reasons including pos-
sible pregnancy and patients not
menstruating
Ellis 2000 Dyslipidaemia Clinical pharmacists providing
pharmaceutical care in addition
to usual medical care versus usual
medical care
The absolute change in total
cholesterol (17.7 vs 7.4mg/dL, P=
0.028) and LDL (23.4 vs 12.8mg/
dL, P = 0.042) was greater in the
intervention than control group
Fairall 2008 HIV Prescribing of antiretroviral treat-
ment by nurses versus doctors
Cohort 1 - not receiving antiretro-
virals. Time to death did not differ
(HR 0.94, 95% CI 0.76 to1.15)
Cohort 2 - received antiretrovirals
for at least six months. Viral load
suppression 12 months after en-
rolment was equivalent in inter-
vention and control. Risk differ-
ence 1.1% (95% CI -2.4 to 4.6)
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Table 2. Outcomes of studies not included in meta-analyses (Continued)
Finley 2003 Depression Collaborative care model of clin-
ical pharmacists providing drug
therapy management and treat-
ment follow-up versus usual care
Clinical improvements noted in
both groups but not significant.
Intervention group had higher
drug adherence at six months
(67% vs 48%; OR 2.17, 95% CI
1.04 to 4.51; P = 0.038)
Fischer 2012 Lipid control in diabetes Algorithm-driven telephone care
by nurses as an adjunct to usual
care versus usual care
The percentage of patients with an
LDL < 100 mg/dL increased from
52% to 58.5% in the intervention
group and decreased from 55.6%
to 46.7% in the control group (P
< 0.01). The intervention did not
affect glycaemic and BP outcomes
Heisler 2012 Blood pressure control in diabetes A pharmacist-led intervention
(Adherence and Intensification of
Medications) in patients with dia-
betes and poor BP control versus
usual care
The mean systolic BP decrease
from 6months before to 6months
after the 14-month intervention
was not different (8.9 mmHg de-
cline in the intervention arm and
9.0 mmHg decline in the control
arm). There was no difference in
the mean HbA1c and LDL lev-
els between groups after the end
of the intervention period (exam-
ining 12 months). At the end of
the first quarter after activation,
there was a significantly greater
drop in systolic BP in the inter-
vention group versus control, 9.
7 mmHg vs 7.2 mmHg; MD 2.4
mmHg (95% CI 1.5 to 3.4 P < 0.
001)
Houweling 2011 Type 2 diabetes Primary care nursemanagement of
type two diabetes versus manage-
ment by GPs
After
14 months between-group differ-
ences for reduction in HbA1c, BP,
and lipid profile were not signif-
icant. Mean systolic and diastolic
BPs were lower in both groups.
Most process indicators were sig-
nificantly better in the nurse care
group.More patientswere satisfied
with their care in the nurse group
however the physical component
of the SF-26 was better in the GP
group
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Table 2. Outcomes of studies not included in meta-analyses (Continued)
Ishani 2011 Cardiovascular risk factors in dia-
betes
Nurse case management versus
usual care to improve hyperten-
sion, hyperglycaemia, and hyper-
lipidaemia in veterans with dia-
betes
A greater number of patients in
the nurse case management had all
three measures under control (21.
9% vs 10.1%, P < 0.01). A greater
number of intervention grouppar-
ticipants achieved individual treat-
ment goals. HbA1c < 8% (73.7%
vs 65.8% P = 0.04), BP < 130/80
mmHg (45% versus 25.4%, P < 0.
01) but not for LDL < 100 mg/dL
(57.6% vs 55.4%, P = 0.61)
Jaber 1996 Non-insulin dependent diabetes Pharmacists providing pharma-
ceutical care versus physicians
Improvement was seen in glycated
haemoglobin in the intervention
group at 4 months (9.2% ± 2.
1 vs 12.1% ± 3.7, P = 0.003)
, and fasting plasma glucose (8.5
± 2.3 vs 11.0 ± 3.9 mmol/L, P
= 0.015). There was little or no
change within or between groups
for BP, lipid profile, renal function,
weight, or quality of life measures
Klingberg-Allvin 2015 Women with signs of incomplete
abortion
Midwives diagnosing and treating
incomplete abortion with miso-
prostol compared to physicians
452 (95.8%) women in the mid-
wife group and 467 (96.7%) in
the physician group had complete
abortion. The model risk differ-
ence for midwife versus physician
group was -0.8% (95% CI -2.9 to
1.4) falling within the predefined
equivalence range (-4% to 4%)
Kuethe 2011 Children with asthma Non-inferiority of care provided
by a hospital-based specialised
asthma nurse versus a GP or pae-
diatrician
The corrected daily dose of in-
haled corticosteroids as well as the
percentage of children prescribed
long-acting beta agonists/inhaled
corticosteroids was not signifi-
cantly different between groups at
one and two years
Logan 1979 Hypertension Treatment of hypertension in the
workplace by nurses versus treat-
ment in the community by the
family doctor
Patients in the nurse group were
more likely to be put on antihyper-
tensive medications (94.7% vs 62.
7%, P < 0.001), to reach goal BP
in the first six months (48.5 vs 27.
5%, P < 0.001) and to take drugs
prescribed (67.6 vs 49.1%, P < 0.
005)
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Table 2. Outcomes of studies not included in meta-analyses (Continued)
Marotti 2011 Postoperative patients Pharmacist medication history
and supplementary prescribing
versus pharmacist medication his-
tory versus usual care
The marginal mean number of
missed doses per patient was 3.21
(95% CI 2.89 to 3.52) in the con-
trol group, which was reduced in
the pharmacist prescribing group
1.07 (95% CI 0.90 to 1.25, P = 0.
002) but not in the pharmacist his-
tory group 3.30 (95% CI 2.98 to
3.63). The number ofmedications
charted at an incorrect dose or fre-
quency was reduced in the phar-
macist history group. The phar-
macist prescribing group had less
dose errors than the pharmacist
history group (P = 0.004)
Moher 2001 Secondary prevention of coronary
heart disease in primary care
Audit group verus GP recall group
versus nurse recall group (disease
register and patient recall to nurse-
led clinic)
Little or no difference occurred in
assessment between the nurse and
GP recall group. Mean BP, total
cholesterol, cotinine levels varied
little between groups as did pre-
scribing of hypotensive and lipid-
lowering agents. Prescribing of an-
tiplatelet drugs was higher in the
nurse recall group vs GP recall
group, MD 8% (95% CI 1% to
15%, P = 0 .031)
Pagaiya 2005 Primary care nurses Education and implementation of
prescribing and clinical guidelines
by nurses in rural health centres
versus usual nurse care
Antibiotic prescribing in children
0 to 5 years for respiratory tract
infections fell, (42% at baseline to
27% at follow-up, control 27% to
30%, P = 0.022). Guidelines had
no effect on prescribing antibi-
otics for diarrhoea but oral rehy-
dration prescribing increased. Di-
azepam prescribing for adults fell,
(intervention 17% to 10%, con-
trol 21% to 18%, P = 0.029)
Spitzer 1974 Patients attending primary care Nurse practitioners versus physi-
cians plus conventional nurse in
primary care
Similar mortality experience, no
differences in physical function-
ing capacity, social or emotional
function. Quality of care similar.
In 510 prescriptions, an adequate
rating was given to 75% of con-
ventional group and 71% in the
nurse practitioner group, probably
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Table 2. Outcomes of studies not included in meta-analyses (Continued)
leading to little difference between
groups
Taveira 2010 Type 2 diabetes A pharmacist-led Veterans affairs
Multidisciplinary Education and
Diabetes Intervention for Cardiac
risk reduction (VA-MEDIC) plus
usual care versus usual care
After four months there was a dif-
ference (P < 0.05) in the percent-
age of VA-MEDIC patients versus
controls in attaining target goals
for systolic BP < 130 mmHg and
HbA1c < 7% but not lipid control
or tobacco use
Thompson 1984 Drug therapy in a geriatric setting Drug therapy prescribing and pa-
tient care management by clinical
pharmacists versus usual care
The clinical pharmacist group
probably had a lower number of
deaths (P = 0.05), a higher num-
ber of patients being discharged to
lower levels of care (P = 0.03) and
a lower average number of drugs
per patient (P = 0.04)
Tsuyuki 2016 Patients with cardiovascular risk
factors associated with hyperten-
sion, diabetes, dyslipidaemia and
smoking
Community pharmacist care ver-
sus usual care
At 3 months the intervention
group patients had greater im-
provements in LDL cholesterol (-
0.2mmol/L, P <0.001, systolic BP
(-9.37 mmHg, P < 0.001), glyco-
sylated haemoglobin (-0.92%, P <
0.001) and smoking cessation (20.
2%, P < 0.002)
BP: blood pressure
CI: confidence interval
GP: general practitioner
HbA1c: glycated haemoglobin
HR: hazard ratio
IUD: inter uterine device
LDL: low-density lipoprotein
MD: mean difference
OR: odds ratio
TAU: treatment as usual
Table 3. Primary outcome - medication adherence
Study Medication adherence measure Outcome
Bruhn 2013 Morisky Medication Adherence
Scale
Assessed adherence at baseline with patients in both
groups reporting full adherence
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Table 3. Primary outcome - medication adherence (Continued)
Cohen 2011 Medication possession ratios The medication possession ratio (total days’ supply of
medication divided by total number of expected med-
ication intake days) used in this study found little or
no difference between the pharmacist prescribing arm
and usual care, even though more medications were pre-
scribed in the pharmacist arm. Adherence was high and
ranked above 80%
Finley 2003 Medication possession ratios Determined the medication possession ratio from com-
puterised prescription refill records. Full drug adherence
was defined as a medication possession ratio value of
0.83 or more during the six-month follow-up. Medi-
cation possession ratios at three and six months were
probably not different between intervention and con-
trol arms even though patients in the intervention group
were more likely to change antidepressants. An addi-
tional measure, the Health Plan Employer Data Infor-
mation Set guidelines for successful antidepressant treat-
ment, showed there was little or no difference between
groups in compliance with the early phase of treatment,
but there was a significant difference in compliance in
the intervention group continuation phase
Hunt 2008 Morisky Medication Adherence
Scale
Reported no differences at study end in the proportions
of subjects reporting high medication adherence. There
was an improvement in adherence with the groups from
baseline to study end. Adherence did not predict goal
attainment
Hirsch 2014 Not described Non-adherence was identified in five of 33 patients with
drug therapy problems at baseline, one of 12 patients at
six months and one of four patients at nine months
Logan 1979 Patient claim and pill counts High adherence was judged if patients claimed to be tak-
ing their medication as instructed and 80% or more of
drugs prescribed were consumed as determined by pill
counts. In the nurse intervention group patients were
more adherent than the control group
Magid 2013 Medication possession ratios Little or no difference between groups in the mean med-
ication possession ratio adherence score over the six-
month study
Margolis 2013 Morisky Medication Adherence
Scale
Reported adherencemeasured by theMorisky scalemod-
ified for blood pressure medications
Adherence to antihypertensive medications at sixmonths
increased in the pharmacist intervention telemonitoring
group but decreased in the usual care group. There was
probably no difference between groups at 12 and 18
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Table 3. Primary outcome - medication adherence (Continued)
months
Rudd 2004 Electronic drug event monitor The drug event monitor provided the average number of
days on which patients took the correct number of doses
prescribed. While adherence was high in both groups,
the nurse-managed patient group had higher adherence
than usual care
Vivian 2002 Patient self-reporting and drug refill information from
the pharmacy
Non-adherence was judged as missing more than three
doses aweek or pharmacy records indicated a failure to re-
fill drugs within two weeks after the scheduled refill date.
Little or no difference in adherence between or within
the two groups at baseline or the end of the study was
found. Over 90% of patients in both groups indicated
they took their drugs as directed. The study was under-
powered to detect a significant difference in adherence
Table 4. Secondary outcomes - patient and provider satisfaction
Study Satisfaction tool measure Outcome
Barr Taylor 2003 Not specified 19/57 respondents stated that the nurse care manage-
ment programme was moderately helpful
32/57 found it extremely helpful.
9/13 physicians with two or more patients recom-
mended adoptionof the nursemanagement programme
In other health care settings: 9 physicians felt the pro-
gramme decreased their time with patients, while 4
thought it increased the time spent
Bruhn 2013 11 patient satisfaction statements derived from a local
prescribing feasibility study
For the prescribing intervention, patients were generally
positive about the pharmacist prescribing service - 85%
(39/46) were totally satisfied, while 9% (4/44) would
have preferred to see their GP. In semi-structured in-
terviews with GPs and pharmacists, all pharmacists and
most GPs were positive about the intervention. Phar-
macists found their role satisfying, interesting, and chal-
lenging. 17 of 23 GPs were positive about the phar-
macists’ role. The cost-effectiveness of the pharmacists’
role, given limited resources, was one issue raised in the
GP focus group
Finley 2003 Not specified Patients reported greater treatment satisfaction with the
collaborative care model than the control group in 6 of
11 measures including the overall treatment for depres-
sion, personal nature of the care, listening to concerns,
explanations about why antidepressants were prescribed
and how to take them, availability for advice, and over-
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Table 4. Secondary outcomes - patient and provider satisfaction (Continued)
all satisfaction with the organisation
18/37 primary care provider questionnaire respondents
were satisfied with workflow, patient welfare. and the
pharmacists’ abilities
Houweling 2009 Patient Evaluation of the Quality of Diabetes Care
(PEQD)
Patients’ evaluations of their satisfaction with diabetes
care from the specialist diabetes nurse were significantly
more positive than the control group
Houweling 2011 Patient Evaluation of the Quality of Diabetes Care
(PEQD)
The total satisfaction sum score for 14 PEQDmeasures
for practice nurses was 66.4%, compared to 51.7% in
theGP group whichmay be confounded by the amount
of time given to each patient. On average GPs spent a
total of 28 minutes per patient, whereas practice nurses
spent 128 minutes per patient
Hunt 2008 Satisfation in the SF-36 healthcare domain Satisfaction with hypertension care was high in both
groups, but with little or no difference in any of the
11 satisfaction measures. Satisfaction was not associated
with blood pressure goal attainment
Hirsch 2014 22-item Pharmacist Service Questionnaire.
0-100 scale
Patient satisfaction with the clinical pharmacist were
high, with mean scores 92.4 (±10.9) at 6 months (n =
49) and 92.7 (±11) at 9 months (n = 44)
Litaker 2003 Patient Satisfaction Questionaire Improvements in four areas of satisfaction in the inter-
vention group linked to an increased time spent with
patients and an emphasis on patient-centred education
and self-management (i.e. quality and quantity of con-
tact) from base line to study end. Between-group com-
parisons at study end demonstrated little or no signifi-
cant difference in patient satisfaction measures, includ-
ing overall care and general satisfaction
Logan 1979 Not specified 6% of patients were dissatisfied with care provided by
nurses but details of the survey instrument were not
provided: (assumed 12/206 intervention patients at 6
months but not specified)
McAlister 2014 Not specified Little or no difference in overall health care satisfaction
between pharmacist- and nurse-led care
Magid 2013 Not specified Patients at 6 months reporting they were very or com-
pletely satisfied with their hypertension care was proba-
bly higher in the intervention group than the usual care
group
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Table 4. Secondary outcomes - patient and provider satisfaction (Continued)
Margolis 2013 Six items from the Consumer Assessment of Healthcare
Providers and Systems adult survey (version 4)
Satisfaction items concerning clinicians listening care-
fully, explaining things clearly, and respecting what pa-
tients said showed larger improvements amongst pa-
tients in the telemonitoring intervention group than
usual care at 6 months but not at 12 or 18 months
Spitzer 1974 Not specified 96% of patients in the nurse practitioner group and
97% of patients in the conventional care group were
satisfied with the health services received in the experi-
mental period
Vivian 2002 Not specified Little or no significant differences in patient satisfac-
tion between groups. More patients in the intervention
group felt that the pharmacist spent more time with
them than did control patients, although there was little
difference. There was no difference in satisfaction with
pharmacy services or changes in patient satisfaction in
either group from baseline to study end. This study was
underpowered to detect a significant difference in pa-
tient satisfaction
GP: general practitioner
Table 5. Primary outcome - adverse events
Study Adverse event
Ansari 2003 There was little or no difference in the proportions of patients between control (provider education), nurse
facilitator and provider/patient notification for hospitalisations and emergency room visits. There were few
deaths with the higher number (7) in the control group which had more patients on haemodialysis, two of
whom died
Aubert 1998 There appeared little or no difference between intervention and usual care groups for severe low blood
glucose events at baseline and during the study period. Mean weight gain differences from insulin treatment
in each group or mean weight loss differences with oral agents showed little or no difference
Chenella 1983 Reported no patients had major bleeding, but four patients in the pharmacist prescriber group had minor
bleeding (one laceration before hospital). One patient in physician prescriber group died, after receiving
heparin and warfarin for a stroke in evolution but there was no evidence of bleeding
DeBusk 1994 The first year mortality was 3.4% in usual care and 4.1% in the intervention group. However, a longer
study is required to show a difference, namely, 2 years plus a 5- to 10-year follow-up
Fairall 2008 The time to death did not differ between primary care nurses and doctors initiating therapy
Hirsch 2014 Pharmacists identified two adverse drug reactions from 33 drug therapy problems at baseline, two from 12
at six months and none at nine months
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Table 5. Primary outcome - adverse events (Continued)
Ishani 2011 Adverse events were similar between groups, with no participants withdrawing from the study due to an
adverse event, and there was no difference in the rate of hospitalisation or death between the groups
Jaber 1996 Reported 17 hypoglycaemic reactions in the intervention group and two in the control group. All were
considered mild to moderate. The difference was possibly related to increased training in recognition,
documentation, and questioning in the intervention group. Three patients were hospitalised, two in the
control and one in the intervention group, and these appear unrelated to treatment
Klingberg-Allvin 2015 In treating incomplete abortion bleeding, the same or less than normal menstrual cycle was probably not
different between the intervention midwife and usual care physician groups. There was little difference in
pain after treatment as assessed by a visual analogue scale. 30 (6%) of women reported unscheduled visits in
the midwife group and 18 (4%) in the physician group. Reasons included vaginal bleeding and abdominal
pain. Reported side-effects after treatment were similar in both groups (nausea, vomiting, abdominal pain,
chills, and fever)
Kuethe 2011 There were no differences between groups (general practitioner, paediatrician, asthma nurse) with respect
to the number of severe asthma exacerbations as expressed by the number of prednisolone courses
MacMahon Tone 2009 Forty drug-related adverse events occurred in the intensive intervention group as compared to 10 in the
standard group. While the adverse events are known for the drugs in question no further comment was
offered
McAlister 2014 Reported few clinical events at six months in a pharmacist-led intervention for secondary prevention after
ischaemic stroke. There were nine cardiovascular events and no deaths in the pharmacist group versus eight
cardiovascular events and one death in the nurse-led group
Margolis 2013 There were 60 adverse events in usual care and 49 in the telemonitoring group; most events were non-
cardiac hospitalisations. There were two allergic reactions to blood pressure medication in the usual care
group, six events in the telemonitoring group related to hypotension, dizziness, loss of consciousness which
compared to one in the usual care group, four events in usual care related to hypertension versus one in
the intervention group
New 2003 In patients randomised to specialist nurse-led clinics for blood pressure control, lipid control or both, there
were less deaths in the intervention group (25, (3.2%) versus 36 (5.7%) in the usual care group) odds ratio
0.55 (95% confidence interval 0.32 to 0.92) P = 0.02
Spitzer 1974 During the 12-month experimental period, there were four deaths in the nurse practitioner group and 18
in the conventional care group. There was probably little or no difference in the crude death rate between
groups
Taveira 2011 There were no diabetes-related admissions or deaths for either group during the six-month study
Thompson 1984 The pharmacist prescribing group in a geriatric setting may have had a slightly lower 12-month mortality
than usual care (3/67 versus 10/72, P = 0.05)
Tobe 2006 The incidence of adverse events probably did not differ between the intervention (home care nurse group)
and control (primary care physician group) in First Nations people with diabetes and hypertension. Ten
patients in the intervention group and seven in the control group required admission to hospital for adverse
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Table 5. Primary outcome - adverse events (Continued)
events
Table 6. Secondary outcome - quality of life
Study Measures Outcome
Aubert 1998 Four generic quality of life measures from the
Behavioural Risk Factor Surveillance System
Intervention and control groups reported improvedper-
ception of health status after 12 months, but interven-
tion patients were twice as likely to report this
Barr Taylor 2003 SF-36, the Duke Activity Status Index for QoL, and the
BDI for depression
Little or no differences for any of the variables, but an
improved mood for both groups was found
Bruhn 2013 SF-12, HUI, CPG, and HADS-D No one measure was seen as the primary outcome. In
the prescribing arm there was a within-arm improve-
ment for CPG intensity and disability effect size sub-
scales and between arms on the intensity subscale but
not the disability subscale. There was a within-arm im-
provement in overall CPG in the prescribing and review
arms but not the TAU arm. The SF-12 and HADS-D
showed deterioration in the TAU arm. Compared with
baseline, patients had an improvedCPG in the prescrib-
ing and review arms but not the TAU arm. The SF-12
physical score difference showed no effect in prescribing
or review arms but improvement in the TAU arm. SF-
12 mental score showed no effect in prescribing or re-
view arms and deterioration in the TAU arm. HADS-D
scores within the prescribing arm showed improvement
for depression and anxiety which were also significant
between groups
Cohen 2011 SF-36 for Veterans Little or no change in quality of life scores over 6
months.
Finley 2003 The Brief Inventory for depressive symptoms andWork
and Social Disability Scale
Liitle or no difference at 6months between intervention
and control groups
Houweling 2009 SF-36 and the revised version of the Type 2 Diabetes
Symptom Checklist to measure the presence and per-
ceived burden of diabetes-related symptoms
Little or no differences over 12 months between groups
in either survey
Houweling 2011 SF-36 and the revised version of the Type 2 Diabetes
Symptom Checklist to measure the presence and per-
ceived burden of diabetes-related symptoms
In the control group there were little or no differences
between baseline and follow-up SF-36 measures, how-
ever in the practice nurse intervention group there were
differences in physical functioning, role physical, vital-
ity, and the physical component score. Little or no dif-
ferences were seen in the QoL results over time between
the two groups except for the physical component score
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Table 6. Secondary outcome - quality of life (Continued)
which was lower in the intervention group. After 14
months responses to the revised Type 2 Diabetes Symp-
tom Checklist revealed little or no differences between
groups
Hunt 2008 SF-36 Little or no difference except in the general health do-
main with scores higher in the control group
Jaber 1996 Health Status Questionnaire version 2 derived from the
SF-36
Little or no difference between or within groups.
Khunti 2007 SF-36, Seattle AnginaQuestionnaire andLVD-36ques-
tionnaire
Differences favouring the intervention group were
found in the SF-36 for physical functioning, general
health, vitality, social functioning, and mental health.
Seattle Angina Questionnaire scores in patients with
anginawere significantly better for intervention patients
compared to controls for exertional capacity and bor-
derline differences were found for angina frequency and
QoL. There was little or no difference in any of the SF-
36 health status domains or LVD-36 scores for patients
with a confirmed diagnosis of left ventricular diastolic
dysfunction
Litaker 2003 SF-12
Diabetes Quality of Life
Little or no difference between groups in either measure
at study end
McAlister 2014 Self-related health using a Likert scale
The EQ-5D as an index of health
Little or no difference between the pharmacist- and
nurse-led groups in participants overall self-related
health
Margolis 2013 SF-12 Little or no differences between groups.
Moher 2001 Dartmouth COOP charts EuroQol scores Little or no or clinically important differences between
groups for any dimension
Spitzer 1974 Not described Patients in the nurse practitioner and usual care groups
had similar values at baseline and study end for physical,
emotional, and social function
Taveira 2011 Change from baseline in depression symptoms by the
PHQ-9
Even though no pharmacologic treatments for depres-
sion symptoms were offered as part of the intervention,
the mean change in PHQ-9 scores was probably not
different for intervention and standard care participants
Vivian 2002 SF-36 Little or no significant differences either between or
within the two groups from baseline to study end, al-
though patients in the control group reported more
bodily pain
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BDI: Beck Depression Index
CPG: Chronic Pain Grade
EQ-5D: EuroQol five dimensions questionnaire
HADS-D: Hospital Anxiety and Depression Scale
HUI: Health Utilities Index
LVD-36: Left Ventricular Dysfunction
PHQ-9: Patient Health Questionnaire-9
QoL: quality of life
SF-12: Short-Form-12
SF-36: Short-Form-36
TAU: treatment as usual
Table 7. Secondary outcome - resource use
Medication and related therapy
Study Outcome
Ansari 2003 β-blocker use was higher in the nurse facilitator group with two-thirds of patients either initiated
or up-titrated on β-blockers versus fewer than one-third of patients in the other two study arms
(control provider education and provider/patient notification)
Chenella 1983 Little or no difference in amount of anticoagulant drugs prescribed by pharmacists compared to
a physician
Cohen 2011 More patients in the pharmacist prescribing arm were prescribed diuretics and sulphonylureas
compared to usual care. Overall there was an increase in the number of medications prescribed
by pharmacists for hypertension, diabetes, and cholesterol from baseline to six months, but little
or no change in the usual care arm
Denver 2003 In nurse-led clinic for hypertension management in diabetics at six months there were increased
changes in the proportions of patients receiving new prescriptions for calcium channel blockers
and thiazide diuretics as intensification therapy. The median number of drugs per patient in-
creased in the intervention group compared to conventional primary care
Einhorn 1978 In a familymedicine clinic inBogota, nurseswere less likely thanphysicians to provide intrauterine
devices, prescribe oral contraceptives, and sterilisation on the patient’s first visit. Nurses were
more likely than physicians to provide temporary prescriptions and defer intrauterine devices
and contraceptive measures if the patient on their first visit was not menstruating or believed to
be pregnant
Heisler 2012 Observational cohort results taken six months following the quarter start date showed interven-
tion patients had more blood pressure medication changes
Hirsch 2014 Pharmacists identified at least one hypertension drug therapy problem in 33/73 (45.2%) patients
at baseline requiring additional therapy in 14/33 (42.4%) and dosage increases in 11/33 (33.
3%)
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Table 7. Secondary outcome - resource use (Continued)
Houweling 2009 The nurse specialist in diabetes prescribed significantly more antihypertensive agents and the
internist (doctor control) prescribed more cholesterol-lowering agents
Hunt 2008 Themeannumber of antihypertensivemedications per patient anduse of generic antihypertensive
agents was higher in the intervention group
Logan 1979 Patients in the nurse-managed group were more likely to be put on antihypertensive medications,
prescribed more than two pills per day, and to be on more than one antihypertensive medication
MacMahon Tone 2009 There were more intervention intensive group patients on three or more antihypertensive drugs
(at the study beginning more patients in the standard care group were on three or more anti-
hypertensive agents). At the end of the study more patients with dyslipidaemia in the intensive
group were receiving statin therapy. More patients in the intervention group were on aspirin
antiplatelet therapy at the end of the study
McAlister 2014 The median number of antihypertensive medications taken at six months was probably not
different in the pharmacist- and nurse-led groups. There was a difference favouring pharmacists
in maximal dosing of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
at six months, but not the percentage of patients using these drugs
Magid 2013 In patients completing the six-month visit, there were more intervention patients that had an
antihypertensive medication added to their regimen and a dose increased for existing medication,
than usual care patients. There was an increase in the usage of specific antihypertensive drugs
Margolis 2013 There were increases in the mean number of antihypertensive medication classes at 6, 12, and
18 months in the intervention group compared to baseline and compared to usual care
Moher 2001 There was minimal change in prescribing antihypertensive drugs in the three groups. All groups
increased prescribing of lipid-lowering drugs but there was little or no difference between groups.
There was an increase of 10% more patients’ prescribed antiplatelet treatment in the nurse recall
group versus the audit group and 8%more in the nurse recall group versus the general practitioner
recall group
Pagaiya 2005 In examining the effects of training and guidelines on prescribing by nurses, the mean change
in antibiotic prescribing for all patients showed little or no difference. The mean change for
antibiotic prescribing for respiratory infections in children (0 to 5 years) fell. No change was
detected in prescribing antibiotics for diarrhoea. There was a mean fall in diazepam prescribing
in the intervention group
Rudd 2004 In the nurse management patient group at six months there was an increased number and variety
of antihypertensive medications and an increased number of medication changes than in the
usual care group
Taveira 2010 The intervention arm group (VA-MEDIC) had greater dose titrations of antihypertensive med-
ications, insulin, statins, and niacin compared to the usual care arm
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Table 7. Secondary outcome - resource use (Continued)
Taveira 2011 Intervention arm participants (VA-MEDIC-D) had more dose increases or initiation of any
antihypertensive agents andmore dose increases or initiation of antihyperglycaemic agents. There
was little or no difference in the initiation or dose titration of any antihyperlipidaemic agent or
antidepressants
Thompson 1984 The average number of drugs prescribed per patient was lower in the pharmacist group compared
to the physician group. The number of drugs was reduced by an average of 2.2 drugs per patient
from the pre-study to the study year. The practice of clinical pharmacists prescribing drug therapy
under physician supervision has the potential to save the healthcare system USD 70,000 per 100
skilled nursing facility beds
Tsuyuki 2015 In the pharmacist prescribing arm proportionally more new antihypertensive agents were initi-
ated, more dose changes occurred, more antihypertensives were discontinued, and more patients
were prescribed low-dose aspirin and a statin than in the usual care group
Vivian 2002 There was little or no difference in the type of antihypertensives prescribed to intervention and
control patients during the study
Wallymahmed 2011 Compared with baseline there were more patients in both groups taking antihypertensive medi-
cations but this difference was probably only important in the nurse-led intervention group
Healthcare visits, health resources, and associated costs
Ansari 2003 There was no difference in hospitalisations and emergency room visits between the three groups
of control (provider education), nurse facilitator, and provider/patient notification
Aubert 1998 Hospital admissions were rare and did not differ between the intervention and usual care groups.
ED visits did not differ between groups or from baseline. No hospital or ED visits were related
to diabetes. The average number of outpatient visits during the study was similar. The nurse
managed a case load of 71 patients, but it was estimated that a 300 patient case load could be
managed
Barr Taylor 2003 There was no change in health utilisation (physician visits, ED visits, days of hospitalisation) for
the year before and after the intervention and between groups
Choe 2005 In reporting process measures for the clinical pharmacist’s case management of patients there
was a difference between pharmacist intervention and control in the frequency of low-density
lipoprotein measurements, retinal examinations, and monofilament foot examinations but not
glycated haemoglobin measurement or urine albumin screen
Cohen 2011 Over six months there were a higher number of primary care visits in the usual care arm; an
average 1.65 visits per patient versus 1.56 in the intervention arm. It was suggested the difference
in the higher number of primary care visits may offset the intervention cost
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Table 7. Secondary outcome - resource use (Continued)
DeBusk 1994 The nursing time spent in the year after myocardial infarction was nine hours per patient; a per
patient cost of USD 500 which included the nurse salary, office costs, and other associated costs.
This compared with cardiac rehabilitation programmes in the San Francisco Bay area costing
USD 1800 to USD 2700 to participate for three months
Ellis 2000 In investigating the impact of clinical pharmacist interventions in patients with dyslipidaemia
there was little or no difference in physician or nurse visits between control and the intervention
patients at 12 months. At 12 months the intervention group had more pharmacist visits than
the control group. There were little or no difference in costs for hospitalisations, clinic visits,
laboratory costs, drug costs, and costs of lipid therapy between groups. The intervention group
had a USD 370 greater difference per patient in total costs which was probably not important
and approximately 5% of total costs
Fairall 2008 In the cohort of patients not yet receiving antiretroviral therapy there was little or no difference
in clinic visits with a nurse but clinic visits with a doctor were probably higher in the intervention
group
In the cohort of patients who had already received at least six months of antiretroviral therapy
clinic visits with a nurse probably higher in the intervention group. Economic data from the
study is the subject of further analysis by Barton 2013 (see Studies awaiting classification).
Finley 2003 Although the collaborative care model experienced a decrease in the total number of primary
care visits, the between-group difference was probably not important. ED visits increased more
in the usual care group but this was probably not important and neither was the difference in
utilisation of psychiatric services. The institutional cost of drugs, the cost of antidepressants and
the cost of psychotropic drugs overall was higher in the intervention group, but this was not
important
Fischer 2012 Hospital admissions (while trending to fewer admissions) in the nurse intervention group showed
little or no difference to the control group. Nurse case management was not associated with a
significant difference in the number of outpatient or ED visits. There was a decrease in total costs
in the nurse telephone intervention group comparing the period before and after randomisation.
In contrast, there was an increase for the same comparison in the control group. Similar results
were seen with hospitalisation and ED costs which were lower in the intervention group. There
was probably not an intervention effect on outpatient costs. The difference in average per patient
cost between the intervention group (USD 6600) and control group (USD 9033) of USD
2433 was important. The control group had higher baseline hospitalisation rates and total costs
cautioning interpretation of the result
Heisler 2012 Little or no difference in health services utilisation (hospitalisations, primary care visits, ED visits)
between intervention and control patients during the 14-month study of blood pressure control
through a clinical pharmacist outreach programme in diabetic patients
Hirsch 2014 The pharmacist collaborative group (PharmD-PCP MTM) had fewer primary care physician
visits during the intervention period than did the usual care group. The mean total combined
visits of primary care physician and pharmacist was not greater in the PharmD-PCPMTM group
than in usual care
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Table 7. Secondary outcome - resource use (Continued)
Houweling 2009 There was a lower number of visits in theNSD group compared with standard care but not in the
duration of visits. Significantly more patients were referred back to their GP by the NSD when
meeting treatment goals. Personnel and laboratory costs were lower in the intervention group
than the control group. The average per month increase in medication costs between the groups
was probably not important apart from the cholesterol-lowering medications. The average time
saving per internist was 61.4 minutes (meaning the internist could supervise 11 patients with
the NSD in the time he/she could treat one patient)
Houweling 2011 The mean number of visits and duration of visits was higher in the practice nurse intervention
group than the control group
Hunt 2008 The total number of clinic visits (physician plus pharmacist) was higher in the intervention arm
compared to the control arm. The number of physician visits was lower in the intervention arm
Ishani 2011 Little or no difference in the hospitalisation rate between intervention and control groups
Kuethe 2011 In testing the non-inferiority of asthma care in children with stable asthma provided by a hospital-
based specialised asthma nurse versus a GP or paediatrician, there was little or no differences
between the groups for medication, school absence or parental work absence after two years.
There was little or no difference in unplanned visits and no hospital admissions during the study
Litaker 2003 Mediumnumber of outpatient visits were higher for the teambased intervention patients. Average
personnel costs for one year’s treatment were significantly higher in the intervention group (USD
134.68 vs USD 93.70, P < 0.001)
Magid 2013 There was little or no difference in the mean number of outpatient clinic visits, total number of
ED visits, and hospitalisations between the two groups. The intervention group probably had a
higher number of email and telephone encounters
Margolis 2013 Over 12 months in the telemonitoring intervention group all 228 patients used a mean of 11.
4 ± 3.9 pharmacist visits lasting a mean of 34.2 minutes and 217 used telemonitoring services
with a mean of 9.8 ± 2.5 months of use. It was estimated direct programme costs would total
USD 1350 per patient
Spitzer 1974 A reported five per cent drop in gross practice revenue was explained by the absence of billing for
services provided by the nurse practitioner. Billing for unsupervised practice was not permitted
in Ontario at the time of the study. During the trial year the services rendered by the nurse
practitioner were worth approximately USD 16,000 of which almost 50% was for unsupervised
practice
Taveira 2011 There was little or no differences in primary carer visits, use of ED services for all cause visits,
diabetes-related ED visits or hospital admission rates
Thompson 1984 There was little or no difference in the average length of stay or hospitalisations although the
latter trended lower in the pharmacist group. Differences favouring the pharmacist group were
found in the rate of discharge to home or to a lower level of care
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Vivian 2002 Little or no differences between intervention and control groups in appointments with the
primary care provider during the 6 months of the study
ED: emergency department
GP: general practitioner
NSD: nurse specialised in diabetes
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The interventions in acute and secondary care were combined, as were interventions in chronic and primary care.
The fixed-effect model for meta-analyses was compared to the random-effects model.
Secondary outcomes: Deleted: ’Differential effects across advantaged and disadvantaged populations based on place of residence or
socio-economic status’.
Secondary outcomes: ’Patient-reported outcomes’ replaced the term ’humanistic outcomes’ and appears before resource use.
Dealing with missing data: Added: ’Imputing missing data was only considered when continuous outcomes were reported without
measures of variance’.
Assessment of heterogeneity: Added: ’We determined that heterogeneity might not be important between 0% and 40%, 30% to 60%
represented moderate heterogeneity, 50% to 90% substantial heterogeneity, and 75% to 100% considerable heterogeneity’.
Measures of treatment effect: Deleted: ’For ITS studies, we will report regression analysis with time trends before and after the
intervention. If possible we will re-analyse data for ITS studies where there is inappropriate analysis or reporting of results using the
methods described in Ramsay 2003’.
Unit of analysis issues: Deleted: ’We will re-analyse inappropriately designed ITS studies using time-series regression and report a
statistical comparison of time trends with a minimum of three data points before and after the intervention’.
We revised the database list to reflect current availability and coverage of the resources available at the time of update. The search
methods meet the current MECIR criteria.
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